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Background: Pharmacovigilance pertains to activities aimed at monitoring medicines for 
related safety concerns, thereby ensuring patient safety and wellbeing. The primary method 
of pharmacovigilance is spontaneous reporting of adverse drug reactions (ADRs). ADRs have 
a socio-economic impact when they are not reported and mitigated appropriately. This impact 
is even more apparent in low-to-middle income countries (LMICs), an economic category 
encompassing all African countries. The World Health Organisation (WHO) has developed a 
global pharmacovigilance database (Vigibase®) for countries which are members of the 
Programme for International Drug Monitoring (PIDM), which includes many African 
countries. ADR reporting levels however remains low across Africa. This is also true for 
South Africa, despite being the first African country to become a member of the PIDM in 
1992.  
 
Therefore, this research study was conducted to investigate the knowledge, attitudes, and 
practices of pharmacovigilance among medical doctors and pharmacists in South Africa. The 
aim of this study is to investigate the factors influencing the low adverse drug reporting levels 
by healthcare professionals in South Africa. 
 
Methodology: A cross-sectional survey was conducted in the form of a knowledge, attitudes, 
and practices (KAP) study design. The targeted sample population was 384 study 
participants. The questionnaire consisted of closed-ended questions, designed to assess the 
demographics, knowledge, attitudes, practices of healthcare professionals nationally. The 
survey also served to obtain suggestions from healthcare professionals to improve ADR 
reporting in SA. An online survey was created in the survey platform, SurveyMonkey® and 
the e-link to the survey was shared with the South African Medical Association (SAMA) and 
the South African Clinical Research Association (SACRA), two professional associations 
hosting memberships of registered medical doctors and pharmacists in South Africa. Both 
associations distributed the e-link to their members via email. The obtained data was analysed 
using IBM SPSS® Statistics version 27. 
 
Results: A total of 325 responses were received, accounting for 85% of the target sample 
population. Most (252; 77.5%) of the study participants on this study received an average 




28%) of training. Most of the respondents (269; 82.8%,) thought that awareness regarding 
pharmacovigilance in their professional environment is inadequate. Although the majority 
(310; 95.4%) of respondents agreed that ADR reporting is their professional obligation, (119; 
36.6%) had never seen a reporting form and only (172; 52.9%) had ever participated in ADR 
reporting. The major factors discouraging respondents from participating in ADR reporting 
were lack of knowledge on the reporting process and lack of access to the ADR reporting 
form. The topmost suggestions selected by the respondents to improve ADR reporting in 
South Africa were to include pharmacovigilance training in the undergraduate curricula of 
South African universities (266; 81.8%) as well as implementation of on-line or telephonic 
reporting platforms (235; 72.3%). 
 
Conclusion: This study indicates that there is an average level of knowledge of 
pharmacovigilance amongst medical doctors and pharmacists in South Africa and that they 
mostly have a positive attitude towards pharmacovigilance. However, this does not translate 
into acceptable levels of participation in ADR reporting, most likely due to inadequate 
pharmacovigilance training provided to medical doctors and pharmacists in South Africa. 
 
KEYWORDS: Pharmacovigilance (PV); adverse drug reaction (ADR), knowledge, attitudes, 





Agtergrond: Farmakowaaksaamheid bestaan uit aktiwiteite wat daarop gemik is om 
medisyne te monitor vir veiligheidsprobleme wat daarmee verband hou ten einde die pasiënt 
se veiligheid en welstand te verseker. Die primêre metode van farmakowaaksaamheid is 
spontane aanmelding van nadelige medisyne reaksies (NMRs). NMRs het 'n sosio-
ekonomiese impak as dit nie aangemeld en verminder word nie. Hierdie impak is selfs meer 
uitgesproke in lae-tot-middel inkomste lande (LMILe), 'n kategorie waarin alle Afrikalande 
val. Die Wêreldgesondheidsorganisasie (WGO) het 'n wêreldwye farmakowaaksaamheid 
databasis (Vigibase®) ontwikkel vir lande wat lede is van die Program vir Internasionale 
Geneesmiddelmonitering (PIGM); hierdie program sluit ook lede uit vele Afrikalande in. Die 
NMR verslagdoeningsvlakke uit Afrikalande, bly egter laag. Dit blyk ook die geval vir Suid-
Afrika te wees, ten spyte van die feit dat Suid-Afrika die eerste Afrikaland was wat in 1992 
reeds lid van die PIGM geword het. 
 
Die doel van hierdie studie is dus om die kennis, standpunte en praktyke ten opsigte van 
farmakowaaksaamheid onder mediese praktisyns en aptekers in Suid-Afrika te ondersoek. 
Die doel is om die faktore wat die lae vlakke van aanmelding van nadelige medisyne reaksies 
(NMRs) deur gesondheidswerkers in Suid-Afrika beinvloed, te ontleed.  
 
Metodiek: 'n Dwarsdeursneë-opname is gedoen in die vorm van 'n kennis-, standpunte-, en 
praktyk-ontwerp (KSP) navorsingstudie. Die geteikende steekproefpopulasie was 384 
deelnemers. Die KSP-vraelys het bestaan uit geslote-end vrae, ontwerp om landwyd die 
demografie, kennis, standpunte en praktyke van gesondheidwerkers te ondersoek. Die vraelys 
het ook gepoog om voorstelle van gesondheidwerkers  te bekom ten einde NMR 
verslaggewing in Suid-Afrika te verbeter. 'n Aanlynopname is in die SurveyMonkey®-
platform opgestel en die e-skakel is deur die Suid-Afrikaanse Mediese Vereniging (SAMV) 
en die Suid-Afrikaanse Kliniese Navorsingsvereninging (SAKNV) aan hul lede versprei. Die 
SAMV en SAKNV is beide professionele vereningings met mediese praktisyns en aptekers as 
lede. Beide verenigings het die e-skakel per e-pos aan hul lede versprei. Die data wat bekom 
is, is geanaliseer met behulp van die IBM SPSS® Statistics, weergawe 27. 
 
Resultate: Altesaam 325 response is ontvang, wat 85% van die teiken monsterpopulasie 




telling vir kennis oor farmakowaaksaamheid behaal, ondanks 'n lae vlak van opleiding op die 
gebied (91; 28%). Die meeste van die respondente (269; 82,8%,) het gedink dat die 
bewustheid van farmakowaaksaamheid in hul professionele omgewing onvoldoende is. 
Alhoewel die meerderheid (310; 95,4%) van die respondente saamstem dat NMR 
rapportering  hul professionele verpligting is, het (119; 36,6%) nog nooit 'n verslagvorm 
gesien nie en slegs (172; 52,9%) het al voorheen aan NMR verslaggewing deelgeneem. Die 
belangrikste faktore wat respondente ontmoedig om deel te neem aan NMR verslaggewing, 
was gebrek aan kennis oor die verslagdoeningsproses en gebrek aan toegang tot die NMR 
verslagvorms. Voorstelle wat die respondente gekies het om NMR verslagdoening in Suid-
Afrika te verbeter, wat die meeste uitgestaan het, was om farmakowaaksaamheid-opleiding in 
die voorgraadse kursusmateriaal van universiteite (266; 81,8%) sowel as die implementering 
van aanlyn- of telefoniese verslaggewing (235; 72,3%) in te sluit. 
 
Samevatting: Hierdie studie dui daarop dat daar 'n gemiddelde vlak van kennis oor 
farmakowaaksaamheid onder mediese praktisyns en aptekers in Suid-Afrika is, maar dat hulle 
grootliks ‘n baie positiewe standpunt oor die onderwerp toon. Die waarneming strook egter 
nie met die lae vlakke van NMR rapportering nie; heel moontlik weens onvoldoende 
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Introduction and project overview 
1.1 Brief chapter overview  
This chapter provides the background and rationale of the study. It describes the aims and 
objectives, significance, limitations, assumptions, a brief overview of the methodology as 
well as an outline of the thesis. 
1.2 Background to research problem 
In a small north England town of Winlaton, in January of 1848 15-year-old Hannah Greener, 
died while undergoing removal of an ingrowing toenail. Prior to the procedure, Physician Dr 
Thomas Nathaniel Meggison administered an anaesthetic, containing chloroform (Paul, 2002). 
The anaesthetic effects of chloroform had just been discovered less than a year prior by Dr 
James Simpson, professor of midwifery at Edinburgh (Routledge, 1998) (Fornasier, 2018). Due to the 
continuing concerns of the public and profession about the safety of anaesthesia, The 
Lancet journal set up a commission, which invited doctors in Britain and its colonies to report 
anaesthesia-related deaths. The findings were subsequently published in the journal in 1893 
(Lancet, 1893). They concluded that death under chloroform anaesthesia was 8.7 times more 
likely than death under ether anaesthesia (Lancet, 1893). The real cause of Hannah’s death was 
debated, and theories formed among physicians in the anaesthesiology field to date, with 
lethal arrhythmia and pulmonary aspiration appearing to be equally valid hypotheses (Paul, 
2002). Approximately 100 year later in 1954, Henry K. Beecher, the Professor of Anaesthesia 
at Harvard University, entered the historical debate. Using a well-designed and executed 
survey was reported by Beecher and associates, they collected data on 600 000 patients from 
10 university hospitals over a 5-year period. The report caused considerable controversy; in 
that it reported a considerably higher mortality in patients that had received the newly 
introduced muscle relaxant drugs compared with those that did not (Jones, 2001). 
The story of Hannah Greener initiated the basic principles of a spontaneous reporting system 
for suspected adverse drug reactions (ADRs). The US Federal Food and Drug Act was 
formed on June 30, 1906, and it established that drugs must be pure and free of any 
contamination and the presence and amount of eleven dangerous ingredients, including 
alcohol, heroin, and cocaine, had to be listed (FDA, 2019).  
In 1937, there were 107 deaths in the USA, because of the use of sulphanilamide elixir, 
containing diethyl glycol (DEG) as the solvent, which was considered the cause of these 
deaths (Ballentine, 1981). DEG is a colourless, practically odourless, poisonous, and hygroscopic 
liquid with a sweetish taste, widely used in manufacturing as a solvent for nitrocellulose, 
resins, dyes, oils, and other organic compounds (Ballentine, 1981). Sulphanilamide, a drug used to 
treat streptococcal infections, had been shown to have dramatic curative effects and had been 
used safely for some time in tablet and powder form. In June 1937, however, a salesman for 
the manufacturing company reported a demand for the drug in liquid form. The company's 
chief chemist and pharmacist, Harold Cole Watkins, experimented and found that 
sulphanilamide would dissolve in diethylene glycol and the mixture was only tested for 




(Ballentine, 1981). At the time the food and drugs law did not require that safety studies be done 
on new drugs. The incident hastened final enactment in 1938 of the Federal Food, Drug, and 
Cosmetic Act, the statute that today remains the basis for FDA regulation of these products 
(FDA, 2018). 
In December 1961, Dr William Griffith McBride published a letter in The Lancet, a weekly 
peer-reviewed general medical journal, reporting a notable number of babies being born with 
malformations of the arms and legs (phocomelia), specifically in children of patients who 
were exposed to thalidomide (Fornasier, 2018) (Kim JH, 2011 ). He noted that he had observed that 
the incidence of congenital malformations of babies (1.5%) had increased up to 20% in new-
borns of women who had taken thalidomide during pregnancy (McBride, 1961). Thalidomide was 
initially marketed as a sedative and rapidly became popular as it was perceived to be efficient 
and without toxic effects (Kim JH, 2011 ). The product was subsequently also prescribed for 
nausea in pregnant women and was advertised as being completely safe, even during 
pregnancy, until it was later established that approximately 10 000 babies were seriously 
affected by congenital abnormalities caused by this drug (Kim JH, 2011 ). Thalidomide caused 
serious damage to the unborn child when taken during the first trimester and depending on 
the timing and level of ingestion, the birth defects referred to as thalidomide embryopathy or 
thalidomide syndrome (Kim JH, 2011 ). The thalidomide tragedy marked the start of many 
processes globally, to improve regulations and attention to the safety of medicines (Fornasier, 
2018). This tragedy’s impact was an improvement in pharmacovigilance as the spontaneous 
reporting of adverse drug reactions became systematic, organized, and regulated.  
In the United States of America (USA), 1962, the Kefauver-Harris amendment US Food and 
Drug Administration (FDA) was enacted, requiring safety and efficacy data of drugs before 
premarketing submission, was approved required that manufacturers prove the effectiveness 
of drug products before they go on the market, that evidence of effectiveness be based on 
adequate and well-controlled clinical studies conducted by qualified experts and afterwards, 
serious side effects are reported and study participants would be required to give their 
informed consent (FDA, 2012). 
In 1964, the yellow card was implemented in the United Kingdom (UK) to compile a 
spontaneous report of drug toxicity (MHRA, 2021). In Europe (1965), the disaster of thalidomide 
stimulated the development of a European legislation with the EC Directive 65/65 (Directive, 
1965).  
Efforts to define and strengthen pharmacovigilance structures ultimately led to the 
establishment of the World Health Organisation (WHO) Pharmacovigilance pilot programme 
in 1968 as a resolution from the World Health Assembly in 1963 (Lessa, 2016).   
In 1995, the European Medicines Agency (EMA) was set up (EMA, 2015) and improved with 





The figure below depicts a timeline of historical events that have shaped pharmacovigilance: 
 
 
Figure 1-1: Timeline of the historical evolution of Pharmacovigilance. *ASA: acetylsalicylic acid; **WHO: World Health 
Organisation; ***EMA: European Medicines Agency (Fornasier, 2018)  
1.3 The need for pharmacovigilance 
Pharmacovigilance plays a key role in identifying long-term safety information which could 
not be picked up due to the nature of clinical trials. Once medicines are available on the 
market, they can be accessed by wider population groups, some of which are usually 
excluded from clinical trials, due to their vulnerability (e.g., geriatrics, paediatrics, pregnant 
women, etc.) and some medications are used chronically as well as in combination with other 
medicines and food (Onakpoya, 2016). Under these diverse circumstances, adverse drug reactions 
may occur, with differing severities and consequences.  
Adverse drug reactions can lead to dire consequences such as complications requiring 
hospitalization, permanent disability, and death. In the European Union (EU) an estimated 
197 000 deaths and 5% of hospital admissions annually can be attributed to ADRs, 
amounting to an annual cost of €79 billion (EMA, 2017 ). Pharmacovigilance therefore plays a 
pivotal role in collecting ongoing post-marketing Drug Safety information.  
Regulatory Authorities (RA), healthcare professionals (HCP) and patients each have a role to 
play in the safety surveillance of medicines. RA must, on an ongoing basis, monitor and 
ensure the safety, efficacy and quality of registered medicines, and the benefit/risk ratio and 
rational use of medicines (EMA, 2019).  
From the perspective of the HCP, therapeutic tools are ever evolving; and it is, therefore, 
important to remain abreast of new developments. The HCP must open communication lines 
with patients, sharing the latest relevant treatment information with the patients and 
collecting information from patients about their experiences with those medicines. This form 
of open communication is the basis for spontaneous ADR reporting (Kasliwal, 2012). In 
principle, a patient’s experiences of an undesirable reactions to the medicine, is 




between the reaction and exposure to the medicine., and this suspicion is reported to the 
pharmacovigilance centre. In most countries spontaneous ADR reporting is the most common 
method of pharmacovigilance and allows for the collection and systematic analysis of adverse 
drug reaction reports (Ampadu, et al., 2016). Many medications have been withdrawn from the 
market by RA or additional safety information was added to the Summaries of Product 
Characteristics (SmPC) in the form of black box warnings, additional contra-indications, 
side-effects, or drug interactions, due to the occurrence and reporting of ADRs, not detected 
during the development of the product.   
In 1968, the WHO established the Programme for International Drug Monitoring (PIDM) 
(PIDM, 2020), with the purpose of developing a central database for collection of 
information regarding adverse drug reactions from as many sources as possible and affecting 
a wide variety of population groups. The system ensures communication of changes in 
risk/benefit balance to member countries with a view of promoting patient safety, including 
rational and safe use of prescription medicines, including complementary medicines, 
biologicals, and vaccines. The pilot project was launched in ten countries and from 1968 to 
2017, 156 countries globally have gained full membership to the programme and now report 
individual case reports (ICSR’s) into Vigibase® (Juhlin et al , 2015). Vigibase® is the WHO 
global database of ICSR’s.  
The WHO requires that PIDM member countries have their own National Pharmacovigilance 
Centre, which manages reports of potential ADRs as received through their National 
Pharmacovigilance (PV) system (WHO-UMC, 2020). The information gathered within each 
national PV system then feeds into the WHO PV system known as Vigibase®. The aim of a 
well-functioning PV system is to improve the quality and safety of medication prescribed, 
administered, and used by patients. This can be achieved by collaboration among a wide 
range of local and international partners, organisations, governments, and society at large 
(Juhlin, 2015).  
As the work of the PIDM progressed, it became clear to the WHO that the sharing of 
information within the PIDM would allow for proactive prevention of future tragedies like 
those outlined in section 1.2 of this chapter. To carry forward the work of the PIDM, The 
Uppsala Monitoring Centre (UMC) an independent, non-profit foundation and a centre for 
international service and scientific research, was established in Uppsala, Sweden in 1978 as 
the WHO Collaborating Centre for International Drug Monitoring ((UMC), 2020). The UMC 
provides services and support to national centres worldwide and produces lexicons or 
nomenclature for the harmonized classifications of medicines and adverse drug reactions, 
e.g., the WHO Drug Dictionary, the WHO Herbal Dictionary and the WHO Adverse 
Reaction Terminology. The UMC also provides services to the global pharmaceutical 
industry, clinical research agencies and academia as partners in the Drug Safety arena. The 
UMC database, Vigibase®, reflects the world’s combined effort in adverse drug reaction 
reporting. Vigibase® has proven to be an effective tool, containing more than 8 million 
reports by 2013, dating back since the inception of the PIDM back in 1968 (Uppsala Report 61, 
2013) and approximately 15 million reports from 131 countries by 2018 (Watson, 2019). The 
WHO provides minimum requirements for a functional PV system to assist member countries 
in setting up national PV systems (WHO-UMC, 2020) and the UMC conducts training to the 




1.4.  Under-reporting of ADRs in South Africa and other low-middle 
income countries 
As a continent, Africa has delayed in joining the WHO PIDM; the magnitude of the clinical 
and economic impact is yet to be established. Published information from Europe indicates 
that over 1 million ADR reports were submitted in 2013 alone and in total, over 20% between 
2008 and 2013 (Uppsala Report 61, 2013). Under-reporting remains low even in Europe, where, 
unlike in LMICs, more activities are underway to increase awareness and promote 
pharmacovigilance. A study by Watson and colleagues (Watson, 2019) analysed data collected 
within Vigibase®, between 1967 to January 2018 and reported a reporting rate of 24,2% for 
Europe, compared to 49,8% from North America.  Table 1-1 below provides a breakdown of 
ADR reports in Vigibase® per geographical region between 1967 and 2018 (Watson, 2019).  
Table 1-1: ADR reports in Vigibase® per geographical region between 1967-2 January 2018 (Watson, 2019). 
Geographical region Number of reports 
per region  
Proportion of reports 
per region  
Africa 140,059 0,9% 
Asia 3,022,513 20% 
Europe 3,648,727 24,2% 
Latin America and the Caribbean 312,279 2% 
North America 7,501,871 49,8% 
Oceania 427,310 2,8% 
Total 15,056,524 100% 
 
In 1992 South Africa was the first African country to gain WHO PIDM membership and by 
2000, only five African countries were members. By 2015 there were still 21 African 
countries which had not yet become members of the programme (Ampadu, 2016).  The WHO 
reported that by September 2016, 35 African countries had become members of the PIDM 
and at that point collectively submitted 103 499 ICSRs into Vigibase®, which amounts to 
less than 1% (0.88%) of the total number of global reports (Ampadu, et al., 2016).  The Watson 
study reported that Africa’s ADR contribution was 0,93% by 2018 (Watson, 2019). Studies on 
this topic have identified obstacles to PV growth in Africa, including weak overall national 
health infrastructure and systems, poor understanding of PV, lack of PV in the formal tertiary 
education curricula and low levels of interest from healthcare professionals (Olsson S, 2015). 
Although South Africa established a national PV system in 1987 and joined the WHO PIDM 
in 1992, under-reporting still a challenge in the country. By 2018 of the 140,059 ICSRs from 
all African member countries, 39,881 (28%) (Watson, 2019) were received from South Africa, a 
slight improvement from 24% in 2013 (Ampadu, et al., 2016). Inadequate formal training on ADR 
reporting processes in South Africa is suspected to be one of the major contributors towards 
the low levels of ADR reporting (Mouton JP et al, 2014). 
1.5 Research Question 
This project seeks to address the following research question: 
“What is the level of knowledge, attitudes and current practices of pharmacovigilance 




1.6 Problem statement  
Although medical doctors and pharmacists in South Africa are familiar with the concept of 
pharmacovigilance, they are not well trained on the process of reporting adverse drug 
reactions and when they do report, theirs is no feedback received from the national PV unit.  
Due to their limited knowledge on how to report DRs, medical doctors and pharmacists in 
South Africa are not always able to identify potential ADRs and thus not motivated to report. 
Lack of feedback gives a feeling of reporting into a black hole, thus giving the perception that 
reporting is a futile exercise. Strengthening of the national PV system (to be well-funded and 
resourced), which is capacitated to perform signal detection and communicate such signals, 
incorporation of ADR reporting training into undergraduate curricula, as well as ongoing 
training of healthcare professionals are some interventions that will be effective in promoting 
ADR reporting in South Africa.  
1.7 Research aims and objectives 
The aim of this study is to investigate the factors influencing the low ADR levels in South 
Africa. The results of this study will be used to make recommendations on how to promote 
post-marketing surveillance of medicines in South Africa. 
1. The primary objective of this study is to determine the knowledge on PV among 
medical doctors and pharmacists in South Africa. 
2. To determine the attitude towards practicing PV among medical doctors and 
pharmacists in South Africa. 
3. To determine the current practices of PV, among medical doctors and pharmacists in 
South Africa. 
1.8 Significance of research 
This study investigated whether medical doctors and pharmacists are aware of PV and 
whether they understand the reporting of ADRs to be their professional obligation.  This 
study also investigated the factors contributing to the low rate of ADR reporting among 
medical doctors and pharmacists. Although nurses were not included in this study, they 
contribute significantly to patient care and commonly the first to receive patient reports of 
potential side effects from medication that they themselves administered on the patients.  The 
table below provides a summary of ADR reports submitted globally to Vigibase® per 
reporter type, since inception in 1967 to 1998 (Watson, 2019). Suggestions will be made on 
practical methods that could be implemented to promote awareness, enhance reporting rates, 
and increase communication among all stakeholders.  
Table 1-2: ADR reports submitted globally to Vigibase® per reporter type, since inception in 1967 to 1998  (Watson, 2019) 




reports vs total 
reports received 
Physician 5,212,044 34,6% 
Pharmacist 979,580 6,5% 
Other HCP 1,648,294 10,9% 





Questionnaires are a common and useful method to collect data from a large sample of 
human study participants. Distributing questionnaires electronically as a link to an online 
survey allows for distribution to a larger sample population compared to using hard copies. 
Although the link to the survey was distributed to over 7,000 SAMA members and to 
approximately 650 medical doctors and pharmacists the SACRA database, there was no 
guarantee that all recipients would indeed have received the email containing the link and if 
they did receive it, that they would have opened and read it. Having a large database of 
potential participants and sending of the survey link multiple times increased the chances of 
receiving responses to meet the targeted sample size of 384.  
Laxton (Laxton, 2004) outlines some limitations of administering questionnaires. The biggest 
challenge is low response rate on questionnaires distributed by email. In addition, 
respondents may choose not to respond to some of the questions and emailed questionnaires 
may even allow participants to manipulate the responses as is the case with knowledge 
related questions, for example. With the latter it is impossible to validate the authenticity and 
potential source, of responses. Furthermore, and unlike with personal interviews, the context 
of responses to emailed questionnaires cannot be established and questions can be open to 
interpretation. Emailed questionnaires may also exclude participants who would potentially 
provide valuable information but are too busy or uninterested in completing surveys. Such 
questionnaires may also end up being limited to research-minded participants or to those in 
favour of the issue.  
Medical and pharmaceutical associations were approached to distribute the survey via email 
to their members; these include SAAHIP (South African Association of Hospital and 
Institutional Pharmacists), SAAPI (South African Association of Pharmacists in Industry), 
ICPA (Independent Community Pharmacy Association), South African Medical Association 
(SAMA) and the South African Clinical Research Association (SACRA), among others.  
Approval was only received from SAMA and SACRA, while other associations declined the 
request, citing that they do not distribute surveys for academic purposes. Medical doctors and 
pharmacists who are not members of SAMA and SACRA and those who do not have access 
to email, fell outside the scope of this study.  
The potential for sampling bias was reduced by including all possible sub-groups of the 
sample population. Participants of all genders, professional levels, all racial groups, working 
across all facility types in South Africa, having achieved an undergraduate qualification from 
any university globally, were provided with an opportunity in this study, on provision that 
they had a membership with SAMA and SACRA. 
Due to the participant sources only being SAMA and SACRA membership databases, it was 
likely that the largest number of respondents would be medical doctors than pharmacists. It is 
important though, to collect data from both these groups as the HCPs who prescribe and 
dispense medications to patients. Pharmacists are well positioned to educate patients about 
medication that is being dispensed in terms of the correct use of the medicines, common side 
effects and any notable contra-indications (e.g., use of antibiotics while on hormonal 
contraceptives). A Portugal study reviewing 36% of the ADR reports submitted to a regional 
PV centre over a 10-year period, broke down ADRs reported by doctors as 54%, pharmacists 
31%, and nurses 15% (Marques, 2013). No local study could be found providing a breakdown of 





This study assumed that only the intended participants would complete the survey and each 
respondent would only complete it once. Some of the answers for the questions related to 
knowledge of PV could be found on internet search engines. To avoid this, some of the 
questions were phrased in a complex manner and verified by doing a quick internet search, to 
ensure that the answers are not readily available. It is assumed that the study participants 
would find it too time-consuming to search for answers on the internet, especially when the 
search leads to documents that must first be read to get the required information. It was 
assumed that the study participants would respond truthfully to the survey questions. This 
study assumed that responses would be received from both medical doctors and pharmacist, 
even though the ratio would be unequal.  
1.11 Overview of the methodological approach and ethics 
The research method applied on this study was quantitative data collection by means of an 
electronic questionnaire. The study population were medical doctors and pharmacists 
working in South Africa. The sample size was 384 medical doctors and pharmacists 
combined. There was no allocated ratio of medical doctors to pharmacists to complete the 
survey.   
The study protocol, informed consent form and questionnaire were approved by the 
Stellenbosch University Health Research Ethics Committee (SU-HREC) on 11 Feb 2019 
[HREC Ref # S18/10/231]. Medical and pharmaceutical associations were approached with a 
request to distribute the questionnaire via email to their members. Approval was received 
from SAMA and SACRA The questionnaire was entered into SurveyMonkey® online portal 
and the link was sent to SAMA and SACRA for distribution. SAMA distributed the survey 
link via email to 17,500 members (doctors) and SACRA sent the link to 650 email 
respondents (doctors and pharmacists).  
1.12 Thesis structure 
This thesis consists of six chapters.  
1. Chapter 1 is an introductory chapter, providing the background and rationale of the 
study. The significance of the study together with its limitations are also outlined. A 
brief overview of the research methodology used in this study is also included. 
2.  Chapter 2 is the literature review, which starts by outlining the drug development 
process, the events leading to the development of the WHO-UMC, defining 
pharmacovigilance, its scope, and common methods. The process of ADR reporting 
and management by the WHO-UMC is also outlined, as well as consideration for other 
types of medications such as vaccines, traditional medicines, etc. The chapter ends off 
by exploring global PV developments as well as developments on the African continent 
and in South Africa.  
3. Chapter 3 discusses the research methodology used in this study. It elaborates on the 
selected study population, development of the questionnaire used, data collection and 
analysis. Ethical considerations and limitations are also discussed.  
4. Chapter 4 presents the results of the study in a descriptive format, followed by, 
5. Chapter 5 discusses the results in a narrative.  
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  CHAPTER 2  
Review of Literature 
2.1 Introduction 
This chapter provides an overview of the review conducted on available published literature. 
To establish a theoretical and contextual foundation for this research study, a general search 
was initially conducted to assess the extent of published literature available. Search engines 
and databases such as PubMed®, Science Direct®, Scopus® and Cochrane Library® were 
used.  The focus was mainly on published journal articles, textbooks, websites, and other 
official publications such as reports, conference proceedings, training presentations, 
guidelines, and regulations, published by organizations such as the WHO, WHO-UMC, 
USA- FDA, EMA, the SAHPRA, and others. Themes and key words used in the online 
search included pharmacovigilance (PV), adverse drug reaction (ADR), knowledge, 
attitudes, and practices (KAP), ADR reporting, PV in South Africa, PV in LMICs, 
spontaneous reporting, quantitative research methods, causality assessment, signal detection, 
vaccine safety, AEFI reporting, PV training, PV awareness, PV funding, among others. A 
literature review matrix was utilised to screen and summarize the selected literature in a 
manner that facilitated the synthesis and narrative of the literature. The matrix arranged the 
literature in terms of study objectives, study design, geographical location of study, type of 
healthcare facility, sample population, and main findings. Through this process, key opinion 
leaders in the field of study were identified and additional searches were conducted for 
additional literature, lectures and other works published by them.  
The chapter begins with the background into the drug development process, and the historical 
events leading to the development of the WHO-UMC. Pharmacovigilance processes 
employed by the WHO-UMC are explored, including the dynamic scope and methods of PV, 
the tools used for ADR reporting and the management of ADRs received from WHO-PIDM 
member countries. Special considerations and PV for vaccines are also outlined. The chapter 
furthermore explores global PV activities as well as the efforts of the WHO-UMC to mentor 
and support the development of fully functional PV systems in African countries as well as 
other similar studies to the current study, conducted in other African countries. Finally, the 
chapter concludes with PV activities currently underway in South Africa, inter alia outlining 
gaps and challenges that were reported by other researchers.  
2.2 Drug Development  
A pharmaceutical drug, also called a medication, medicine, or medicinal product, is a 
chemical substance used to mitigate, treat, cure, prevent, or diagnose a disease or to promote 
well-being. The development processes typically consist of a drug discovery phase followed 
by a drug development phase. The development process consists of pre-clinical (in-vivo and 
in-vitro) testing, formulation, and clinical trials (phase I to III). Over the years it has become 
apparent that the life cycle of a drug continues beyond phase III clinical trials; this has led to 






Figure 2-1: Drug Development Process (FDA, 2021) 
2.3 Risk-Benefit Assessment 
Medicines may under most circumstances be effective and beneficial to human lives; 
however, they also present a risk of side effects. Throughout the life cycle of a drug, it is 
important for regulators to continuously monitor the benefit-risk balance to ensure the 
protection of the rights and wellbeing of people exposed to the drug. The benefit-risk 
assessment aims to measure the usefulness of a medicine, administered for a certain 
indication, at a certain dose, in a specific population. This assessment supports the approval 
of a drug to enter the pharmaceutical market after completion of phase III clinical trials and 
on a continuous basis afterwards, it supports the decision for the drug to remain on the 
market, or not. At each point of the assessment, the reliance is on the currently available 
information. For instance, once the drug is available on the market and available to more 
people, there may be newly found side effects which may lower the benefit-risk balance. 
Alternatively, there could be favourable data from phase IV trials, showing that the drug is 
more effective than shown in phase III trials, this brings the benefit-risk balance up. An 
external factor can be the availability of safer, more effective alternatives becoming available 
on the market; this may dramatically drop the benefit-risk balance of a drug (Caster, 2017).  
2.4 Adverse Drug Reactions 
2.4.1 Definition 
The WHO defines an adverse drug reaction as a response to a drug which is noxious and 
unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis, or 
therapy of disease, or for the modification of physiological function (Health, 2007). A side effect 
is defined as any unintended effect of a pharmaceutical product occurring at doses normally 
used in humans which is related to the pharmacological properties of the medicine. Such 
effect may be either positive or negative. Such effects may be well-known and even expected 
and may require little or no change in patient management (Health, 2007). An adverse drug 
event, otherwise known as an adverse event refers to any untoward medical occurrence that 




relationship with this treatment, that is, an adverse outcome that occurs while the patient is 
taking the medicine but is not, or not necessarily, attributable to it (Health, 2007). Post-
marketing monitoring plays a critical role in identifying rare ADRs which could not have 
been identified during clinical trials.  
2.4.2 Classification of ADRs 
Adverse drug reactions were originally classified by the WHO into types A and B. It was, 
however, noted that not all ADRs fit into these two categories and additional categories were 
therefore developed. About 80% of ADRs in the hospital setting or causing admission to a 
hospital are type A (Pirmohamed, 1998). These ADRs are potentially avoidable and often 
predictable. 
 
Table 2-1: ADR Classification (Pirmohamed, 1998) (Health, 2007) 
ADR Type Description 
A Dose-dependent and predictable from the known pharmacology of the drug, e.g., 
orthostatic hypotension with antihypertensive medications 
B Uncommon and unpredictable, depending on the known pharmacology of the 
drug; they are independent of dose and affect a small population. e.g., 
hypersensitivity (allergic) reactions to drugs 
C Chronic reactions, which relates to both dose and time  
D Delayed reactions 
E End of use / withdrawal reactions 
F Unexpected failure of therapy  
 
2.5 Pharmacovigilance 
2.5.1 History and Development of WHO-UMC 
The thalidomide tragedy demonstrated the danger of marketing drugs that had not been put 
through a development programme of rigorous testing for efficacy and safety. It also 
highlighted the importance of careful post-marketing monitoring of medicines.   This led to 
the establishment of the Programme for International Drug Monitoring (PIDM) by the WHO 
in 1968. By 1978, all operational responsibilities of the PIDM were transferred to the Uppsala 
Monitoring Centre (UMC). The WHO-UMC manages the global ADR database 
(VigiBase®), which is at the centre of the continuous research conducted on signal detection. 
The UMC undertakes multiple activities to promote PV, including the support and 
mentorship of PIDM member countries in the development of functional PV systems (WHO, 
1999). The process of post-marketing surveillance starts with ADR reports being submitted to 
the national PV centre. The PV centre then performs data entry, coding, assessment, signal 
detection. If a signal is detected, the PV centre is responsible for informing the stakeholders 
of the potential ADR. Confirmation of signals can lead to several regulatory implications, 
such as the mandatory adding of additional safety measures for the medicine (change in 






2.5.2  Scope of pharmacovigilance 
According to the WHO, Pharmacovigilance is “the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other possible 
drug-related problems” (WHO, 1999). The scope of pharmacovigilance is ever evolving, and an 
extended scope has developed to include the following. See Figure 2-2 below: 
• Types of medicines: regular medicines, vaccines, traditional/herbal remedies, 
biologicals 
• Substandard/spurious/falsely labelled/falsified/counterfeit (SSFFC) 
• When assessing adverse effects, a consideration of the properties of the drug 
ingredients and the characteristics of the patient. 
• Unexpected lack of efficacy, due to product quality (inadequate GCP, distribution, 
storage, counterfeiting, etc.). 
• Inappropriate use (medication errors, dependence and abuse, poisoning). 
• Safety challenges of mass treatment campaigns, e.g., rumours and stigma 
(immunization and public health programmes). 
 
 
Figure 2-2: Scope of pharmacovigilance (WHO, 2006) 
 
Pharmacovigilance activities include collecting individual case report forms, analysis of data 
to identify new signals and communication of those signals to stakeholders (Fornasier, 2018). 
These activities are important for promoting rational use of medicines and ensuring public 
confidence. Before medicines are put on the market, safety information is gathered through 
animal studies (pre-clinical) and clinical trials, conducted in humans. Animal studies are key 
in understanding the potential toxic effects that medicines can cause. Types of animal studies 
include acute toxicity, carcinogenicity, metabolism, organ damage, dose dependence, 
teratogenicity, kinetics, mutagenicity, etc. (WHO, 2006). Data gathered through these studies is 
critical for the next phase of the drug development process. The products under consideration 
go beyond conventional medicines, and include herbal medicines, other traditional and 


















Figure 2-3: Types of medicines included in PV practices (WHO, 2006) 
 
2.5.3 Pharmacovigilance Methods  
Studies conducted at post-marketing phase can be descriptive or analytical. Descriptive 
studies include spontaneous reporting systems (SRS) and intensive monitoring studies. These 
are useful in generating hypotheses, which are then tested through analytical studies. 
Analytical studies include cohort and case-control studies (WHO, 2006).  
2.5.3.1 Spontaneous Reporting System (SRS) 
Spontaneous reporting is a system to monitor the safety of all medicines on the 
market, throughout the entire lifecycle of the medicine. It covers the global 
population and detects signals of new, rare, and serious ADRs. This is the most 
common PV method, consisting of voluntary ADR reporting by HCPs, 
pharmaceutical companies and in some countries, including patients. An 
Individual Case Safety Report (ICSR) is the tool used for this method of PV and 
this is submitted to the national PV centre. Although country requirements may 
vary, reporting is generally expected for serious ADRs, new medicines (less than 
5 years on the market), unknows reactions (even if not serious/severe) and ADRs 
occurring in vulnerable groups (children, pregnant women, and elderly patients) 
(Hazell , 2006). The WHO definition of a serious adverse reaction is: “disability or 
any untoward medical occurrence that at any dose; results in death, life 
threatening, requires inpatient hospitalisation/prolongation of existing 
hospitalisation or results in persistent of significant incapacity” (WHO, 2012). The 
main criticism of this system is its voluntary nature which can easily lead to under 
reporting. A systemic review of ADR reporting in 2006 identified that more than 
94% of all ADRs remained unreported (Hazell , 2006). Another limitation of SRS is 
that it does not allow for assessment of incidence rates and risk factors of ADRs. 




compliant in reporting suspected ADRs to the relevant PV centres. A study of the 
signals discussed by the Pharmacovigilance Risk Assessment Committee (PRAC) 
at the European Medicines Agency (EMA) found that in 62% of the cases where 
regulatory decisions were made, the basis of those decisions was data from 
spontaneous reports (Clarke, 2006). Evidence from data collected through SRS led to 
the withdrawal of 11 medicines from US and UK markets between 1999 and 2001 
(Clarke, 2006). A systematic review of 18 medicines which were withdrawn or 
suspended in the EU between June 2012 and December 2016, found that the 
decision affecting 17 of those medicines, was based on evidence from 
spontaneous ADR reports. A spontaneous reporting system is the easiest PV 
system to implement, the least labour intensive and relatively inexpensive to 
maintain, making it a good starting point for most countries.  
2.5.3.2 Intensified ADR Reporting 
The aim of intensified monitoring is to gather additional information about ADRs, 
such as risk factors, type, frequency, time course and the impact of those ADRs on 
the quality of life of patients for medicines at early post-marketing phase. 
Intensified monitoring is like spontaneous reporting; however, HCPs are prompted 
to collect additional information from patients. The United Kingdom (UK) 
Medicines and Healthcare products Regulatory Agency (MHRA) introduced a 
concept of additional monitoring by placing a black triangle on label of new 
medication on the market, to prompt HCPs to be more alert when prescribing and 
dispensing those medicines. The EMA maintains an extensive list of medicines 
that require additional monitoring on their website, making it available not only to 
HCPs but to the public as well (EMA, 2021).   
Additional monitoring status is always applied to a medicine in the following 
cases (EMA, 2021): 
• it contains a new active substance authorized in the EU after 1 January 
2011. 
• it is a biological medicine, such as a vaccine or a medicine derived from 
plasma (blood), authorized in the EU after 1 January 2011. 
• it has been given a conditional approval (where the company that markets 
the medicine must provide more data about it) or approved 
under exceptional circumstances (where there are specific reasons why the 
company cannot provide a comprehensive set of data). 
• the company that markets the medicine is required to carry out additional 
studies, for instance, to provide more data on long-term use of the 
medicine or on a rare side effect seen during clinical trials. 
• it is authorized with specific obligations on the 
recording of suspected adverse drug reactions. 
• Other medicines can also be placed under additional monitoring, based on 






2.5.3.3 Targeted Spontaneous Reporting (TSR) 
TSR is an ideal PV method for collecting ADR data for targeted population 
groups such as children, pregnant women, specific clinics, ADRs and/or 
medicines (e.g., National Tuberculosis (TB) programmes, monitoring the safety of 
bedaquiline, as it is relatively new on the market) (WHO, 2006).  In Uganda, the 
National PV Centre, in collaboration with the HIV control programme 
implemented a TSR of suspected renal toxicity at two government facilities, 
monitoring tenofovir-based regimens from April 2012 to March 2014. It was 
found that the reporting rate for suspected ADRs had increased five-fold during 
the period of the TSR; with the incidence of renal toxicity occurring in 1:200 
patients. It was also found that with a treatment period of over 4 years, an increase 
was noted in creatinine levels (Ndagije, 2015). The benefit of TSR is that it can use 
already developed infrastructure, it targets specific medicines or interest, and it 
captures all useful information. The limitation is that reports are focused on 
specific ADRs and some ADRs can be missed.  
 
2.5.3.4 Cohort event monitoring (CEM) 
The aim of cohort event monitoring is to gather additional information about a 
medicine at early post-marketing phase; also referred to as Phase IV observational 
trials. The benefit of CEM is that all adverse events are recorded, whether related 
to the medicine or not, and not just suspected ADRs. CEM also identifies 
interactions when the medicine in question is taken along with other medicines 
(WHO, 2006).  
2.5.3.5 Electronic health records (EHR) mining 
Analysis of existing health records available in a database, to identify potential 
ADRs. This allows collection of all ADRs and all medicines. The UK established 
the General Practice Research Database (GPRD), which captures useful data 
including patient demographics, medical histories, hospital referrals, drug-
dispensing, vaccination records and lab results. Analysis of such databases can 
support the development of hypotheses, which are then tested in case-control and 
cohort studies. A study conducted to review the UK’s GPRD found that this data 
also contributes towards research studies conducted within other science 
disciplines including pharmacoepidemiology (56%), epidemiology (30%) (Gelfand, 
2005).  
2.5.3.6 Record Linkage 
This is a concept of linking available databases and registries for the purposes of 
data analysis. In the Netherlands, the PHARMO Database Network, a population-
based network of electronic healthcare databases, was established to link 
community pharmacy and hospital data. It contains information of more than 4 
million (25%) residents of a well-defined population in the Netherlands for an 
average of ten years. Over the years, the system has been linked to other databases 




pathology, mortality, perinatal, laboratory and genetic data, cancer, and accident 
registries, etc. Through linkages with various healthcare databases, a complete 
profile of an individual’s medical history throughout life can be created. This 
linkage makes the system useful in case-control studies, epidemiology, and 
analytical studies (Leufkens, 2005).  
2.6 ADR Reporting and Processing  
2.6.1 Individual Case Report Forms (ICSRs) 
A one-size-fits-all approach is not appropriate in creating a standard ADR reporting form 
which is able to accommodate the wide scope of reports required to be received by a national 
PV centre; however, there is standard information that is required in all cases. Standard 
information includes patient demographics, drug use, event, reporter (in case additional 
information is required). For patient demographics, no personal identifying information is 
collected, only age, gender, ethnicity, medical history. For drug use, it is good to have the 
suspected drug, indication, dosage, action taken, concomitant medications, how was 
suspected ADR treated. At times, a medicine may cause an undesired reaction if taken for the 
incorrect indication or at the incorrect dose. Concomitant medication may also reveal 
comorbidities. For the event, it is good to have information on the type of event, start and 
stop dates, treatment, circumstances (to be able to detect possible medication errors, 
counterfeit medicines, etc.). ADRs can be reported by a wide variety of stakeholders. In some 
countries, the HCPs who are required to report include physicians, pharmacists, nurses, etc. 
and patients themselves. ICSR’s can be available in paper (NDoH, 2021) or web-based (MHRA, 
2021) format. For vaccines, even telephonic reporting is possible. An advantage of a web-based 
format can be to allow for attachments to be uploaded into the web portal. For example, the 
easiest way for a physician in a busy hospital to submit a suspected ADR may be to submit a 
scanned copy of the anonymised hospital records with all the notes directly as they are 
written. The national PV centre would then have to enter that information into the ICSR 
format in the database, but this addresses the concern that ADR reporting is time-consuming 
(WHO, 2006). Web-based forms can be linked to the national PV centre’s database, thus 
avoiding the need for manual data entry. The designing process for the web-based form is 
costly; however, afterwards the costs to maintain it are low as there is a saving on printing 
costs. Web-based forms can be formatted such that for events where additional information is 
required, the reporter can be prompted to provide such information. Reporters can also pre-
populate their information (such as name, practice number, hospital, etc.) to save time by not 
needing to enter this each time they submit a report. The layout and design of the form is also 
important to consider when designing an ICSR. The form must be user-friendly and not use 
jargon, especially in countries where patients also report ADRs. It is also important to remain 
abreast with new developments, technology advances and continuously improve the ICSRs 
on a regular basis (WHO, 2020).  
2.6.2 Identification of ADRs 
Adverse drug reactions present the same way and follow the same course as natural disease; 
therefore, the diagnostic methods applied are the same. The only difference is that ADRs are 
drug induced. The drug classes most commonly responsible for ADRs in adults are adrenal 
corticosteroids, antibiotics, anticoagulants, antineoplastic and immunosuppressive drugs, 




most prevalent drug classes for ADRs are anti-infective drugs, respiratory drugs, and 
vaccines (Kongkaew, 2008). The following sub-headings outline examples of the type of drug 
induced ADRs that have been identified.  
2.6.2.1 Hepatotoxicity 
Hepatotoxicity is a potential reaction for all medicines, due to the multiple 
functions of the liver, including drug metabolism, excretion, and protein synthesis. 
Hepatotoxicity is the cause for premature termination of approximately 30% of 
clinical trials (Friedman, 1999). Researchers reported hepatotoxicity as the leading 
cause of medicines being withdrawn from the market between 1975 and 2005 
(Friedman, 1999). Hepatotoxicity also referred to as drug-induced liver injury (DILI) 
is classified as hepatocellular liver injury (ALT ≥ 2 ULN), cholestatic liver injury 
(AP ≥ 2 ULN) or mixed liver injury (ALT/AP) between 2 and 5 ULN) (CIOMS, 
1999). Medicines affect the liver in different ways, by identifying which type of 
injury occurs most frequently with the use of a particular medicine, it can facilitate 
the causality assessment.  
Example: Hepatic Steatosis (Fatty Liver)  
This occurs when fatty acids accumulate in the liver due to the impairment of 
oxidation processes in the mitochondria. Medicines that have been found to cause 
this include steroids, methotrexate, tetracyclines, perhexiline and amiodarone. 
2.6.2.2 Allergic reactions  
Allergic reactions make up 5-10% of all reported ADRs (American Academy of Allergy, 
2013). Drug-induced allergic reactions are triggered by any one of the four types (I 
– IV) of hypersensitivity immune response to the medication, causing symptoms 
in the nose, lungs, throat, sinuses, ears, mucosal lining and/or skin. Time to onset 
can range from immediate or up to two weeks after taking the medicine.  
Anaphylaxis is the most severe form of allergic reaction, with the onset usually 
being immediate or within one hour of taking the medicine and it can result in 
death. Clinical features of anaphylaxis include hives, facial or throat swelling, 
wheezing, light-headedness, vomiting and shock. Suspected medications for 
anaphylactic reactions include monoclonal antibodies, antibiotics, and 
chemotherapy medication.  
The most frequently drug-targeted organ is the skin; most commonly presenting 
as benign drug eruptions, which can be mild, severe, and sometimes even life-
threatening or fatal. Rash is the most common type of drug eruption, with a 
higher risk with antibiotics, antiepileptics and allopurinol. It usually starts from 
the trunk and spreads to lower extremities and responds well to conservative 
treatment. It usually occurs within 4-14 days of drug intake, sometimes even after 
discontinuation. The time to onset can be a challenge in assessing the causality of 
the rash, because if it commonly starts after the medicine has been stopped and is 
therefore not easily attributable to that medicine. Unintentional re-challenge often 
occurs when the rash could not be attributed to the drug initially until the patient 
is given the same drug again and it causes an even more severe reaction, thereby 




Example: Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis 
(TEN)  
Rare but severe skin reaction (blistering and detachment), 70% of cases are drug 
induced, although it can occur naturally (Raujeau, 1995). SJS and TEN are both life-
threatening, with a 10% mortality rate for SJS and 30% for TEN (Raujeau, 1995). The 
symptoms of SJS and TEN may include high fever and usually mucosal 
involvement (eyes, mouth, and digestive tract). Hepatic and pulmonary 
involvement is also possible. Time to onset is less than 4 weeks; usually between 
week 3 and 4 of treatment. Commonly associated drugs include allopurinol, 
anticonvulsants, sulphonamides, oxicams and pyrazolone non-steroidal anti-
inflammatory drugs (NSAIDs) (Raujeau, 1995). 
2.6.2.3 Nephrotoxicity 
Drug-associated nephrotoxicity is any injury to the kidney which is directly or 
indirectly caused by medication. Drug-associated acute kidney injury (AKI) 
accounts for 18 – 27% of acute kidney failure cases in USA hospitals (Taber, 2008). 
Haemodynamic renal failure may result from drugs that reduce renal 
prostaglandins and hence renal blood flow and glomerular filtration rate 
commonly associated with nonsteroidal anti-inflammatories (NSAIDs) and the 
relatively newer group cyclooxygenase-2 selective inhibitors (Coxibs) (Taber, 2008). 
Drug-induced tubulointerstitial nephritis and acute tubular necrosis are also 
frequent causes of AKI, often caused by antibiotics and less frequently by 
NSAIDs. Drug-induced glomerular and renal vascular disease is relatively rare. 
Direct renal tubular toxicity has also been described with medications with 
unique effects on the epithelial cells of the kidney, including the antiviral agents 
cidofovir, adefovir, and tenofovir as well as the bisphosphonate pamidronate (Raujeau, 
1995) (Taber, 2008). Additionally, crystal deposition in the kidney may promote the 
development of renal failure. Several different drugs have been described to 
induce crystal nephropathy, including the antiparasitic drug sulfadiazine, the 
antiviral agent acyclovir, and the protease inhibitor indinavir (Raujeau, 1995). 
Finally, an unusual form of renal failure characterized by swollen, vacuolated 
proximal tubular cells can develop from hyperosmolar substances, such as 
antibacterial drugs, antifungal agents, antimalaria agents’ antivirals, NSAIDs and 
anticancer drugs (Raujeau, 1995). Knowing the high-risk populations is essential for 
the prevention and early diagnosis of nephrotoxicity. The main risk factors are 
related to the reduction of the renal functional reserve (glomeruli without the 
ability to increase the filtration rate), a larger concentration of drugs on the 
tubules, and synergistic injury mechanisms (Raujeau, 1995). Some examples are 
drugs with vasoconstrictor effect associated with diuretics and drugs that compete 
for the transporter responsible for tubular secretion, increasing the cytoplasm 
concentration, such as in the combination of cisplatin and aminoglycoside (Raujeau, 
1995). 
2.6.2.4 Hematological 
Myelosuppression occurs when the production and maturation of bone marrow is 
affected, causing anaemia, leucopoenia, granulocytopoenia, low platelet count. 




For example, most oncology drugs act on fast replicating cells and if blood cells 
or the gut mucosa are exposed to such a drug, that same drug can cause 
pancytopenia or oral ulcers by affecting the bone marrow or oral mucosa, 
respectively. This is a predictable adverse effect explicable by the known 
pharmacology of the drug, they are dose dependent and common; therefore, the 
ADR classification is type A. With type B reactions, there is a genetic 
predisposition for some reactions with the use of drugs such as methotrexate, 6-
mercaptopurine, clozapine, or chloramphenicol (Parchment, 1998).  
Example: Aplastic anaemia and agranulocytosis 
Aplastic anaemia can occur naturally, but it may also be associated with use of 
medicines, exposure to chemicals, radiation, infections, and auto-immune 
disorders. A bone marrow examination may be needed to confirm the diagnosis 
aplastic anaemia characterised a sparsity of cells produced, across all cell lines 
(red blood cells, platelets, and white blood cells, including neutrophil 
granulocytes). Medicines classically associated with aplastic anaemia and 
agranulocytosis include anticonvulsants (phenytoin, carbamazepine), 
antimicrobials (sulphonamides, mebendazole, zidovudine), antirheumatics 
(phenylbutazone, piroxicam, indomethacin), ACE-inhibitors (captopril) and 
immunomodulators (alpha-interferon) (Parchment, 1998). Agranulocytosis is in 
addition, also strongly associated with clozapine and antithyroid medicines. It 
should be noted that anticonvulsants and sulphonamides are also often associated 
with SJS and TEN (Parchment, 1998).  
2.6.3 Causality assessment of suspected ADRs  
Causality assessment aims to provide answers as to whether a specific drug exposure caused 
the ADR and ultimately whether the implied drug increases the risk of the observed ADR 
(User manual for the revised WHO classification, 2018). The assessment of whether a drug 
has caused a particular ADR is not always straight forward; however, causality assessment 
can classify the relationship between suspected ADR and drug, using available evidence. 
Assessing causality on individual cases is limiting, due to challenges such as inadequate 
information, selection bias and lack of knowledge.  A case series of suspected ADRs may 
supply additional information and confirmatory evidence.  
Several methods for assessing causality of ADRs have been developed; however, no system 
has been able to direct assessors to a definite conclusion of causality. The available systems 
are, however, useful guides and with accumulating evidence available and continuous 
analysis of available data, a strong suggestion of likelihood can be made with greater 
confidence.   
A. WHO-UMC Causality Assessment System 
The WHO-UMC has developed a causality assessment system in consultation with WHO-
PIDM member countries. This system is used to assess case reports and it considers the 
quality of the data reported as well as the clinical-pharmacological aspects of the case history. 





Table 2-2: WHO-UMC Causality Assessment Categories (WHO-UMC, 2013) 
Category Description Comment 
Certain A clinical event, including 
laboratory test abnormality, 
occurring in a plausible time 
relationship to drug 
administration, and which 
cannot be explained by 
concurrent disease or other 
drugs or chemicals. The 
response to withdrawal of the 
drug (de-challenge) should be 
clinically plausible. The event 
must be definitive 
pharmacologically or 
phenomenologically, using a 
satisfactory re-challenge 
procedure if necessary. 
It is recognized that this stringent definition will 
lead to very few reports meeting the criteria, but 
this is useful because of the special value of such 
reports. It is considered that time relationships 
between drug administration and the onset and 
course of the adverse event are important in 
causality analysis. So also, is the consideration of 
confounding features, but due weight must be 
placed on the known pharmacological and other 
characteristics of the drug product being 
considered. Sometimes the clinical phenomena 
described will also be sufficiently specific to 
allow a confident causality assessment in the 
absence of confounding features and with 




A clinical event, including 
laboratory test abnormality, 
with a reasonable time sequence 
to administration of the drug, 
unlikely to be attributed to 
concurrent disease or other 
drugs or chemicals, and which 
follows a clinically reasonable 
response on withdrawal (de-
challenge). Re-challenge 
information is not required to 
fulfil this definition. 
This definition has less stringent wording 
than for "certain" and does not necessitate 
prior knowledge of drug characteristics or 
clinical adverse reaction phenomena. As 
stated no re-challenge information is 
needed, but confounding drug 
administration underlying disease must be 
absent. 
Possible A clinical event, including 
laboratory test abnormality, 
with a reasonable time 
sequence to administration of 
the drug, but which could 
also be explained by 
concurrent disease or other 
drugs or chemicals. 
Information on drug 
withdrawal may be lacking or 
unclear. 
This is the definition to be used when drug 
causality is one of other possible causes for 
the described clinical event. 
Unlikely A clinical event, including 
laboratory test abnormality, 
with a temporal relationship 
to drug administration which 
makes a causal relationship 
improbable, and in which 
other drugs, chemicals or 
underlying disease provides 
plausible explanations. 
This definition is intended to be used when 
the exclusion of drug causality of a clinical 
event seems most plausible. 
Conditional/ 
Unclassified 
A clinical event, including 
laboratory test abnormality, 
reported as an adverse 





data is essential for a proper 
assessment or the additional 
data are under examination. 
Unassessable 
/Unclassifiable 
A report suggesting an 
adverse reaction which 
cannot be judged because 
information is insufficient or 
contradictory, and which 




B. Naranjo Algorithm 
In addition to systems, there are algorithms that can be used to assess causality. These include 
the Jones algorithm (Jones, 1982), Kramer algorithm (Kramer, 1979), the Begaud algorithm (Bégaud, 
1985), among others. The most common algorithm is the Naranjo ADR probability scale. It 
consists of ten questions about the ADR; a numeric score is assigned as presented in Table 2-
3 (Naranjo, 1981). This is often used in clinical trials. 
Table 2-3: Naranjo ADR Probability Scale (Naranjo, 1981) 
Question Yes No No not 
known 
1. Are there previous conclusive reports on this reaction? +1 0 0 
2. Did the adverse event appear after the suspected drug was given? +2 -1 0 
3. Did the adverse reaction improve when the drug was discontinued, or a 
specific antagonist was given? 
+1 0 0 
4. Did the adverse reaction appear when the drug was re-administered? +2 -1 0 
5. Are there alternative causes that could have caused the reaction? -1 +2 0 
6. Did the reaction reappear when a placebo was given? -1 +1 0 
7. Was the drug detected in any body fluid in toxic concentrations? +1 0 0 
8. Was the reaction more severe when the dose was increased, or less severe 
when the dose was decreased? 
+1 0 0 
9. Did the patient have a similar reaction to the same or similar drugs in any 
previous exposure? 
+1 0 0 
10. Was the adverse event confirmed by any objective evidence? +1 0 0 
Scoring  
• > 9 = definite ADR 
• 5-8 = probable ADR  
• 1-4 = possible ADR  
• 0 = doubtful ADR 
 
C. Bradford Hill Criteria  
The Bradford Hill criteria developed by Sir Austin Bradford Hill for the assessment of 
causality in a case series are summarised depicted in Table 2-4. (Robyn, 2005).  
Table 2-4: Bradford Hill Criteria (Robyn, 2005) 
Criteria Description 
Strength of association Qualitative (disproportionality) measure of the association between a 




Specificity of event - There are many common ADRs that can be caused by multiple 
drugs, e.g., headache, nausea, renal failure, abdominal pain. 
Generally affecting physical systems that are responsible for 
metabolism and excretion of the drug. At the same time, these are 
common symptoms of a wide range of diseases across multiple 
severities. 
- Considering the pharmacokinetics (PK) and Pharmacodynamics 
(PD) of the drugs, it is easier to narrow down the suspected drug out 
of all that the patient has been exposed to within a reasonable time to 
onset. The less the number of drugs, the more likely the association.  
Temporal relationship Reasonable time to onset of ADR, post drug administration 
Dose response - ADR occurs above a certain dose and not for lower doses 
- Presence of risk factors, e.g., rhabdomyolysis with statins  
- Must compare dosage in reports with dosage on package insert 
Consistency of reporting - Reports received from a range of countries with similar 
observations. 
- Multiple risk factors e.g., Rhabdomyolysis with statins (age, dose, 
interacting drugs, hyperkalaemia, renal/hepatic/thyroid dysfunction) 
- Case series can establish if a reaction also occurs in the absence of 
other risk factors or combination of common risk factors 
- Clustered reporting (one type of clinic, research study, etc.) creates 
selection bias, which is challenging for signal detection 
- Geographical consistency, e.g., reports from two or more countries  
Biological Plausibility Fits with what is known about the drug’s actions 
Experimental Evidence Supporting evidence found by other researchers, e.g., prolonged QTc 
interval 
Coherence Fits with existing knowledge, e.g., drugs that are not absorbed are 
likely to cause organ damage 
Analogy Common reactions observed within the same Anatomical 
Therapeutic Chemical (ATC) group of drugs, e.g., combined oral 
contraceptives containing oestrogen and venous thrombosis 
 
Example: Causality assessment of omeprazole and acute renal failure as conducted by 
the New Zealand PV Centre in 1996 (User manual for the revised WHO classification, 2018) 
Omeprazole came into the market in 1988. By 1996, the New Zealand (NZ) National PV 
centre had received 3 reports of acute renal failure with omeprazole as the suspected cause, 
the first report was received in 1994.  
Gender: 2 male, 1 female 
Age: 67-78 years 
Outcome: One death, no evidence of rheumatoid vasculitis which could cause a possible 
effect on kidneys, other not yet recovered and the other was unknown. 
Step 1: Search all NZ reports for omeprazole in the urinary tract: 
• Abnormal renal function – search result 0 
• Interstitial Nephritis – search result 2 
- Males 2, Age 59-72 years, omeprazole suspect cause in both 
- Time to onset 8 months and 4 months 





Step 2: Search for Evidence  
• Literature – published case reports of interstitial nephritis and omeprazole since 1992 
• National database and VigiBase® search principles 
- Use substance name to search for a drug e.g., omeprazole instead of Losec. 
Prilosec, etc. 
• UMC-VigiBase® search 
- 15 reports found  
- 5 males and 9 females 
- Age range 51-87 
- Indication treated with Omeprazole: gastrointestinal disorders; no co-morbidities 
- Omeprazole was the sole suspect medicine in 12 of the reports  
- Time to onset: 14 days to 42 months; mostly between 1-7 months – information 
only available for 10 of the 15 reports 
- Concomitant or co-suspect drugs: 4 patients were taking 5 medicines that can 
cause interstitial nephritis (diclofenac, azathioprine, dicloxacillin, bendrofluazide 
and indomethacin). Two patients recovered when Omeprazole was stopped, while 
the other medicines continued.  
- Reported outcomes on de-challenge: 7 recovered, 1 recovered with sequelae, 3 
not yet recovered, 4 unknowns  
 
Step 3: Application of Bradford Hill Criteria: 
# Bradford Hill Criteria Case Series Assessment 
1. Strength of association Statistically disproportionate 
2 Consistent time to onset Time to onset mostly between 1 to 7 months of starting 
treatment 
3.  Specificity of event No comorbidities and concomitant medicines that could 
have been an alternative cause. Omeprazole was the sole 
suspect in most of the reports 
4.  Reasonable time to recovery Recoveries on de-challenge 
5.  Biological plausibility Interstitial nephritis is a typical ADR 
6.  Consistency of reporting Reports from 7 countries 
 
2.6.4 Signal Detection  
The WHO defines a signal as “a hypothesis of a risk with a medicine with data and 
arguments that support it, derived from data from one or more of many possible sources” 
(WHO-UMC, 2021). As new developments occur in pharmacovigilance, this definition has also 
evolved. A definition presented at the 1991 meeting of national centres participating in the 
WHO Programme for International Drug Monitoring was “Reported information on a 
possible causal relationship between an adverse event and a drug, the relationship being 
unknown or incompletely documented previously. Usually more than a single report is 
required to generate a signal, depending on the seriousness of the event and the quality of the 
information” (WHO-UMC, 2021). In their systematic review, Hauben and Aronson (Hauben, 2009).  
recommended this definition: “information that arises from one or multiple sources 
(including observations and experiments), which suggests a new potentially causal 
association, or a new aspect of a known association, between an intervention and an event or 




or clinical attention, and is judged to be of sufficient likelihood to justify verificatory and, 
when necessary, remedial actions” From all these definitions, it can be deduced that a signal 
is basically information that arises from one or multiple sources, which suggests a new 
potential causal association or a new aspect of a known association between an intervention 
(e.g., administration of a medicine) and an event. 
The primary global tool used for signal detection is disproportionality analysis. 
Disproportionality calculations can be viewed through the VigiLyze® system.  It can be 
applied to small databases such as national and regional PV centres as well as large databases 
such as VigiBase®. This analysis generates a hypothesis on possible drug-ADR associations. 
The hypotheses are further investigated with a clinical assessment of each ICSR. In their 
study, Caster et al. (Caster, 2020) suggested that there is no increased risk of generating large 
numbers of false-positive associations when applying disproportionality analysis to small 
databases. They further emphasized that this does not suggest that this analysis will be 
equally effective across all database sizes as well as the importance of manual clinical review 
of ICSRs.  
The WHO-UMC regularly screens ICSRs reported into VigiBase® by performing 
disproportionality analysis using VigiLyze®, until 2014 when they developed a statistical 
signal detection system, VigiRank® (Caster, 2020). VigiRank® routinely adds additional 
selection criteria such as the reports must be from two or more countries, quality of data 
available in the ICSRs, serious ADRs, specific groups of medicines or populations of interest. 
The selected reports are then assessed by members of a multi-disciplinary team, consisting of 
physicians, pharmacists, nurses, statisticians, and data scientists. The initial assessment 
includes whether the reported ADR is already listed in the medicine’s package insert and 
review of the case series to rule out any other possible causes. This is followed by an in-depth 
assessment of drug-ADR associations which have been selected for further review. The UMC 
Signal Review Panel reviews the individual report together with scientific literature for 
additional evidence. A decision is made as to the strength of the available evidence to suggest 
that a signal should be formulated and communicated.  
 
Figure 2-4: Flow of ICSRs in the WHO-UMC PV systems (Caster, 2020) 
 
VigiLyze & VigiRank
National PV centres can use the systems to perform signal detection on local, regional and 
global ADR reports
Vigibase
Data from Vigiflow is transmitted to the global ICSR database
Vigiflow
The Vigiflow system is available free of charge to all WHO PIDM member countries. 




2.6.5 Signal Communication  
One of the advantages of being a PIDM member country is access to VigiLyze® where the 
signal is made available as a summary report (WHO, 2020). Signals are also published in the 
WHO Pharmaceuticals Newsletter, which is available to the public on the WHO website. The 
global research fraternity also refers to published signals and conduct further scientific 
research into them.  
A survey was conducted with 71 countries participating in the WHO Programme. The 
recipients were asked about the usefulness of the signals published in 26 WHO 
Pharmaceutical newsletters. Responses were received from 45 out of 71 countries (63%) 
(WHO-UMC, 2021). The content of newsletters in general was always or often useful in 63.5% of 
the respondents. In 2001, 17 countries took actions on at least one signal. Actions were rarely 
taken without considering the published signals. This shows that signal detection and 
communication plays an important role and has a direct impact on Drug Safety issues handled 
by members of the WHO Programme for International Drug Monitoring (WHO-UMC, 2021). 
2.7 Special Considerations 
Additional considerations must be accounted for when identifying and reporting ADRs as not 
all ADRs are of a pharmacokinetic or pharmacodynamic nature.  
2.7.1 Medication Errors 
Ferner and Aronson proposed that a medication error is defined as “a failure in the treatment 
process that leads to, or has potential to lead to, harm to the patient” (Ferner, 2006). In May 
2016, stakeholders, and experts in the field of pharmacology engaged on the issue of 
medication errors and made a recommendation to include the word “unintended” before the 
word failure, to emphasize the non-intentional aspect of medication errors. It was further 
agreed that the word “failure” in the definition indicates that the intended process fell below 
expectation and the word “treatment” clarifies that all forms of treatment, not only medicines. 
“Treatment process” includes manufacturing of the medicine and all the activities that occur 
until treatment monitoring (Ferner, 2006).  
The global cost related to medication errors is estimated at $42 billion annually. This equates 
to approximately 1% of total global health expenditure (WHO , 2016). It is believed that the 
impact of unsafe medication practices in low-and middle-income countries is grossly 
underestimated due to lack of research in this area. To address this global concern, in 2016, 
the WHO launched the Global Patient Safety Challenge, consisting of 5 working groups. The 
objectives of the challenge include the development of guidelines, tools and promote 
collaboration among stakeholders to improve medication safety (WHO , 2016).  
The realization that some ICSRs contain evidence of medication errors which are sometimes 
reported as ADRs has led to the widening of the scope of PV as well as the WHO updating 
their definition of pharmacovigilance to include the terms: “any other drug-related problem” 
[41]. The definition for adverse drug reactions has been updated to include not only medical 
products at normal doses, but also medication errors, off-label use, misuse, and abuse of the 




Latent Factors: Aronson describes factors that are outside the control of HCPs which can 
affect them and cause them to make mistakes. These factors include exhaustion from being 
overworked, inadequate work resources/tools, management, or human resource (HR) related 
issues (Aronson, 2009). Errors that occur because of these factors can be prevented with good 
induction and training as well as improved working conditions.  
Active Factors: Aronson associates an error with the intention to perform an action, but the 
action is not performed (Aronson, 2009). He further distinguishes between errors resulting from 
pure mistakes, meaning the error was made at planning phase and errors which are skill-
based, which means the plan was correct, but the error occurred with execution (Aronson, 2009).  
1. Mistakes  
• Knowledge-based errors: occurring due to a lack of knowledge, for instance 
prescribing antibiotics without establishing if the patient is currently using hormonal 
contraceptives. These errors can be avoided with improved drug knowledge, the 
patient being treated and clear communication among HCPs who are involved in 
treating the patient.  
• Rule-based errors: occurring due to deviations from procedural practices, e.g., 
wrong dose preparation. This can be prevented with proper training and automated 
reminders when certain medications are dispensed.  
 
2. Skill-based 
• Action-based errors: also referred to as slips and they occur due to inadequate 
attention or distractions, e.g., picking up clarithromycin from the shelf when intending 
on picking up ciprofloxacin. This can be avoided by avoiding distractions and by 
implementing a QC process.  
• Memory-based errors: also referred to as lapses and occur due to the inability to 
recall important information which is known. E.g., forgetting to inform a patient to 
take the full course of antibiotics. These can be prevented by implementing a QC 
process and with automated alerts during dispensing.  
 
Reporting of Medication Errors 
Spontaneous reporting is the primary method of collecting data on medication errors. The 
ICSR must be improved to optimize detection of medication errors by soliciting reports on 
medication errors that cause harm (ADR) and those that do not cause harm. Those that do not 
cause harm often to remain unreported as they may not be considered to pose any risk. At the 
same time, there is a hesitation to report those that cause harm as well, due to fear of getting 
into potential trouble or getting blamed. Education is a key element for preventing medication 
errors. Some hospitals perform an analysis of medication errors occurring within the facility 
and provide feedback to the reporter either on a case-by-case basis or in the case of recurrent 
errors, correspondence and training are across all HCPs within the hospital. National PV 
centres disseminate alerts resulting from reported medical errors though Dear Doctor letters. 
Medication errors that cause harm are essentially ADRs; therefore, can result in the same 






Analysis of Medication Errors 
A quantitative analysis of the ICSRs containing medication errors is performed where the 
medical reports requiring action are summarised and prioritized. Followed by a qualitative 
analysis, consisting of a root cause analysis, to identify the underlying causes of the error and 
establishment of a corrective action, preventative action (CAPA) plan.  During quantitative 
analysis at the WHO-UMC (see Figure 2.5), medication errors in VigiBase® are analysed 
according to their level of achievement, the stage in the treatment process, type of medication 
error or seriousness. Medication error terms are also included in the UMC medical terms 
dictionary MedDRA (WHO, 2014).  
 
Figure 2-5: WHO-UMC assessment of medication errors (WHO, 2014) 
 
Qualitative analysis is performed to improve systems to reduce the likelihood of medication 
errors. Root cause analyses are for medication errors which have caused or have the potential 
to cause serious harm. The James Reason concept states “we cannot change the human 
condition, but we can change the conditions under which humans work” (Reason, 2000). This 
concept propelled a move from the individual approach, which focused on the errors caused 
by humans to a systemic approach, focusing on the circumstances under which humans 
operate. The James Reason model distinguishes between latent errors (e.g., healthcare system 
errors) and active errors (e.g., frontline healthcare providers). To identify underlying causes 
and contributing factors that lead to medication errors, the Ishikawa diagram is used. Finally, 
risk minimization actions (RMAs) or CAPA are implemented and followed up. Public health 
RMAs can include educational tools such as awareness and training programs. The WHO-
UMC can collaborate with national regulatory authorities and pharmaceutical industry to 
implement RMAs including changes in the medicine’s package insert, labelling, controlled 
distribution, etc.  
As a result of pilot projects conducted by the WHO-UMC in collaboration with national PV 
centres, guidelines were published with title: reporting and learning systems for medication 




for national PV centres, but also for medication and patient safety organizations to provide 
guidance on the identification and analysis of medical errors. Another lesson learned from the 
pilot studies is the need to improve ICSR’s to optimize detection of medication errors. The 
items proposed for improvement include patient weight, current medical conditions, previous 
history of allergy, suspected and concomitant medications (drug-drug interactions), relevant 
laboratory test results, narrative describing the circumstances. The guidelines also promote 
stakeholder collaboration between four levels of partnerships to create a synergistic result for 
the early detection and prevention of medication errors.  
Level 1: PV centres, poison control centres, patient safety organizations 
Level 2: Academia, media, professional associations, consumer organizations 
Level 3: Patients, HCPs 
Level 4: Regulatory Authorities, pharmaceutical industry, hospitals 
 
Examples of Medication Errors 
• Medication errors that have resulted Dear Doctor Letters 
Methotrexate: Incorrect frequency of administration 
Methotrexate must be taken once per week, but reports received of patients taking it once 
every day and experiencing ADRs due to this. A part of the WHO-UMC risk minimization 
actions, recommendations were outlined in the “Dear Doctor letters” to avoid future 
occurrences. Recommendations include providing patients with clear handwritten dosing 
instructions on the drug label. Also, specifying the day of the week when medication should 
be taken and avoid “Monday” as it can be confused with “morning” (Grissinger, 2018 ). 
• Medication errors that have resulted in amendment of public health program 
Multiple reports of nephrocalcinosis in infants, including two deaths received by the 
Moroccan national PV centre because of vitamin D supplements given to infants as part of 
the national program for preventing rickets. Two doses of vitamin D were given at 600 000 
IU at birth and at 6 months. Investigations of the reports concluded that the dose was 
inappropriate for infants; therefore, it was reduced to 200 00IU and a special paediatric 
formulation was introduced at this dose (Porter, 2006 ).  
2.7.2 Counterfeit Medicines 
The WHO defines counterfeit medicines as “one which is deliberately, and fraudulently 
mislabelled with respect to identity and/or source. Counterfeiting can apply to both branded 
and generic products and counterfeit products may include products with the correct 
ingredients or with the wrong ingredients, without active ingredients, with insufficient 
(inadequate quantities) of active ingredient(s) or with fake packaging” (WHO, 2017). A term that 
was collectively used for substandard and counterfeit products is ‘SSFFCs’ 
(substandard/spurious/falsely labelled/falsified/counterfeit medical products). On 29 May 
2017 at the Seventieth World Health Assembly, it was agreed to replace the use of 
“substandard/spurious/falsely labelled/falsified/counterfeit medical products” (SSFFC) with 
“substandard and falsified medical products” (SF), as the term to be used and in all future 




Counterfeit medications are a public health problem globally and have caused more than 100 
000 deaths to date. It is estimated that 10% of medicines worldwide are counterfeit (Berkrot, 
2012). The WHO estimates that counterfeit medicines make up 30% of all medicines sold in 
Asia, Africa, and Latin America, with China being the main culprit as a source of counterfeits 
(Berkrot, 2012). In 2010 worldwide sales of counterfeit medicines were estimated at $75 billion 
(WHO, 2010).  In 2011, 64% of antimalaria medicines sold in Nigeria were found to be 
counterfeit (Anon., 2012). In 2013 an estimated 122 350 (3.75%) deaths in children under 5 
years old across sub-Saharan Africa were attributed to poor quality antimalaria medicines 
(Renschler, 2015). The health impact of counterfeit medicines depends on the ingredients that are 
used in making the counterfeit medicine. At times, the medicine contains no active 
ingredients and does not cause any direct harm; however, the medicine does not provide a 
health benefit to the patient, which can ultimately harm the patient. In the case of antibiotics, 
this can result in antibiotic resistance. In other cases, the counterfeit medicine may contain 
harmful ingredients, including bacteria-laced water, antifreeze, dye, and boric acid (Rentz, 008). 
Counterfeit paediatric cough syrup which was found to contain diethylene glycol (DEG), a 
substance commonly used in commercial products such as resins, antifreeze, inks, and glues, 
has resulted in the deaths of more than 500 children worldwide (Rentz, 008). In 2012, the FDA 
distributed warning letters to physicians to alert them about a counterfeit version of their anti-
cancer drug Avastin (bevacizumab), in which the active ingredient was replaced with starch 
and salt (Mackey, 2015).  Falsified artemether-lumefantrine has also been described across 
central and west Africa (WHO, 2017). Such products will inevitably cause increased morbidity, 
mortality, and transmission, and can create the impression that artemisinin resistance has 
developed. Additionally, modelling strongly suggests that underdosing is an important 
contributor to resistance. Therefore, if patients consume co-circulating falsified and 
substandard medicines, so that underdosing persists, the risks of patients developing 
resistance to the drug are high.  
In high income countries, the primary source of counterfeit medicines are online pharmacies, 
which are mostly not registered in any country and operate under false pretence (e.g., 
claiming to be registered in a neighbouring country). Most people purchase drugs online 
because they are not aware of the potential dangers. At a global level, counterfeit medicines 
can enter the market through legitimate supply chain processes, from the supply of 
counterfeit ingredients at manufacturing, to subsequent stages including storage, 
transportation, and distribution. Factors which promote the entry of counterfeit medicines 
into the supply chain process include shortages of medicines in the country as well as 
corruption. In their survey conducted in Nigeria, Garuba et al. found that Nigeria’s 
pharmaceutical industry is vulnerable to corruption, particularly at points of entry and drug 
registration into the country (Garuba, 2009). Cohen et al. support this analogy with their 
argument that direct government involvement in drug registration, procurement and 
inspection processes creates opportunities for corrupt practices (Cohen, 2007).   
A global reporting system for counterfeit medicines is yet to be developed; however, in 2011 
the WHO-UMC constructed an algorithm that allows for the identification of substandard 
products from ICSRs in VigiBase®. The counterfeit medicines identified through this method 
are likely to be those that have caused harm and end up being reported as suspected ADRs. A 
similar algorithm was used by the Monitoring Medicines project which ran from 2009 to 
2013. One key challenge encountered on both occasions is inadequate information in the 
ICSRs, which led to inconclusive findings. Both algorithms did lead to the identification of 8 
confirmed, and 12 potential counterfeit medicines. This is evidence of the effectiveness of 




reports submitted into VigiBase®. An awareness must be created to ADR reporters to 
provide their contact details in case of any queries and not to discard the suspected 
counterfeit medicine in case testing of the medicines is required (Juhlin, 2015) (Pal, 2015). 
(Erwin, 2014) and (Hamilton, 2016), in their systematic reviews agree on the following strategies to 
combat the scourge of counterfeit medicines: 
A. Cooperation among stakeholders 
In 2006, IMPACT (International Medical Products Anti-Counterfeit Taskforce) was 
established, with the mandate to promote collaboration stakeholders including national 
medicines regulatory authorities, INTERPOL, NGOs, pharmaceutical companies, etc. (WHO, 
2016).   
The 65th WHO World Health Assembly (WHA) in 2012 established the Member State 
Mechanism (MSM) on SSFFCs, to promote collaboration and information sharing among 
WHO member countries (Garuba, 2009).  
B. Increase public awareness 
The FDA launched an awareness campaign titled “Be Safe; Know your online pharmacy” to 
educate customers about the dangers of buying medicines online (US, FDA, 2021).  
C. Strengthen criminal justice systems 
There have been calls for stringent consequences to be applied to punish those involved in the 
counterfeit medicine (Newton, 2014. ) (Nayyar, 2015) (Attaran, 2015). In the United States, the penalties 
for crimes related to counterfeit medicines are regulated by the Federal Food, Drug and 
Cosmetics Act; however, the penalties have remained the same since the initial promulgation 
of the act in 1938. For example, one person involved in the Avastin case was only penalised 
to 6 months house arrest and 5 years’ probation (Mackey, 2015).  
D. Improve Management of Supply Chain 
A good example for low-to-middle income countries is the successful implementation of 
stringent regulations for tackling counterfeit anti-TB drugs is Rwanda. Rwanda’s strategy 
includes the distribution of reporting forms to patients and HCPs to report suspected 
counterfeit medicines to the national PV centre. They also conduct quality control testing at 
ports of entry, regular sampling and testing of anti-malaria and anti-TB drugs, which are the 
most counterfeited medicines in the country (Binagwaho, 2013).  
Taylor suggests the application of product identifiers to the packaging of the medicine, which 
may be difficult to falsify (Taylor, 2014. ). These include 2D barcodes and radio frequency 
identification (RFID). These can be used to manage the inventory by tracking and tracing 
batches of correctly manufactured batches.  
Latest technologies such as GPHF-MinilabTM can be used at ports of entry. The usefulness of 
this equipment was demonstrated in the detection of 1.4 million counterfeit artemether-
lumefantrine, mebendazole and anthelminthic which arrived in Angola from China. This also 
evidence of the ability of this equipment to screen large batches of medicines. A checklist of 
Medicine Quality Assessment Reporting Guidelines (MEDQUARG) proposed by Newton et 




South Africa, Algeria, Kenya, Uganda, and Zimbabwe house the six WHO prequalified 
Medicine Quality Control Labs (MQCL), meeting the standards as set out by the WHO for 
testing of medicines. The high-tech equipment available at these labs can be used to test 
specific medicines which are commonly counterfeited or those that are suspected to be 
counterfeit through initial screening with GPHF-MinilabTM (WHO, 2015). 
E. Increase diligence of HCPs 
• Regular training and remaining abreast with latest developments in Drug Safety alerts 
• Purchase medicines from reputable sources and confirm registration with the national 
regulatory authority 
• Use WHO checklist to examine product packaging 
• Report suspicious medicines to the national PV centre 
• Educate patients when dispensing medication to them 
F. Point of purchase verification 
• The WHO checklist can also be used by consumers, in addition to HCPs 
• Mobile Authentication Services (MAS) – a scratch code is affixed on the medicine 
packaging. When the consumer buys the medication, they scratch the packaging to 
reveal the barcode and they SMS it to a secure hotline. The consumer then receives a 
confirmation SMS, verifying the authenticity of the medicine. Examples of this 
technology include mPedigree GoldKeys, Sproxil and Pharmacure. Currently in 
Africa, Kenya, Ghana, and Nigeria are embracing this technology (PREVENT, 2016).   
 
2.7.3. Misuse of prescribed drugs - U.S.A 
Opioids are analgesics, commonly used when other pain medications do not provide 
sufficient pain relief or other medications cannot be used due to safety concerns. In 2016 
alone, more than 60 million patients in the USA had at least one prescription for opioid 
analgesics filled or refilled (Dowell, 2016). Examples include prescription medicines such as 
codeine, morphine, oxycodone, hydrocodone, etc. Careful management due to serious risks, 
which can extend to others who came to contact with them is crucial in the management of 
the safety of such products. Misuse of prescription opioids occurs when they are not used as 
directed at the correct dose, frequency, duration, and administration method; whereas abuse 
occurs when opioids are used for non-therapeutic reasons or for known psychological effects 
(e.g., euphoria) (Harding, 2019).  
Opioid-use disorder (OUD) is the medical term used for the abuse of opioids and the 
consequences thereof, such as addiction and dependence. Symptoms of OUD include a strong 
desire for opioids, the inability to control or reduce use, continued use despite interference 
with major obligations or social functioning, the use of larger amounts over time, and a great 
deal of time spent obtaining and using opioids. Since the 1990s, the use of cough syrup 
(containing codeine) to create a recreational drink popularly referred to as ‘Lean’, ‘sizzurp’, 
‘purple drank’, was popularized by American hip hop musicians.  By 2016, 11.5 million 
Americans were misusing prescription opioids, 2.1 million had opioid use disorder (OUD), 
and more than 64,000 died from overdosing on opioids. In October 2017, the US Department 
of Health and Human Services declared the opioid crisis a public health emergency (HHS, 




the beginning of the Covid-19 pandemic, although it is too soon to get definitive data (HHS, 
2017). In general, the effects of the pandemic include anxiety, grief, isolation, economical and 
health changes as well as decreased access to medical treatment (HHS, 2017).  
Professional organizations, states, and federal agencies (e.g., the American Pain 
Society/American Academy of Pain Medicine, 2009; the Washington Agency Medical 
Directors Group, 2015; and the U.S. Department of Veterans Affairs/Department of Defense, 
2010) have developed guidelines for opioid prescribing. Existing guidelines share some 
common elements, including dosing thresholds, cautious titration, and risk mitigation 
strategies such as using risk assessment tools, treatment agreements, and urine drug testing  
(Dowell, 2016).  
The FDA has developed a strategy to combat opioid abuse, by focusing on 4 main domains 
(FDA , 2021): 
• Decreasing public / patient exposure to opioids 
• Stopping and treating those with OUD 
• Promoting the development of other types of pain medications, to reduce the need for 
opioid use 
• Acting against illegal sale of opioids 
 
Actions implemented by the FDA include the following: 
• Promulgation of the SUPPORT for Patients and Communities Act, also known as 
Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment 
for Patients and Communities Act took place in 2018. This act allows for the 
implementation of the strategies outlined above (Dept of Health and Human Services, 2020).  
• In June 2020, the FDA and the Department of Commerce started to collaborate with 
Internet Domain Name Registries to combat online sale of opioids  (FDA , 2021):  
• In July 2020, the FDA informed opioid manufacturers and manufacturers of 
medicines used to treat opioid overdose to update their package inserts to include 
warning information regarding naloxone. Nalaxone is indicated for the complete or 
partial reversal of opioid-associated adverse effects caused by both natural and 
synthetic opioids (RXList, 2020). The updates will be effective as of 2021.  They also 
mandate prescribers to discuss carefully assess the patient’s risk factors and the need 
for opioid treatment, considering available alternatives.  
2.8 Vaccine Pharmacovigilance  
Based on the emerging success of the smallpox programme, in 1974, the World Health 
Organization (WHO) launched the Expanded Programme on Immunization (EPI). The initial 
EPI goals were to ensure that every child received protection against six childhood diseases 
(i.e., tuberculosis, polio, diphtheria, pertussis, tetanus, and measles) by the time they were 
one year of age and to give tetanus toxoid vaccinations. When given to women of 
childbearing age, vaccines that contain tetanus toxoid (TT or Td) not only protect women 
against tetanus, but also prevent neonatal tetanus in their new-born infants. By 1990, 
vaccination was protecting over 80% of the world's children from the six main EPI diseases, 




countries. In 1999, the Global Alliance for Vaccines and Immunization (GAVI) was created 
to extend the reach of the EPI and to help the poorest countries introduce new and under-used 
life-saving vaccines into their national programmes (WHO, 2020). 
Each year, vaccines prevent more than 2.5 million child deaths globally. Between 2000 and 
2008, vaccination reduced global deaths from measles by 78% (from 750 000 deaths to 164 
000 deaths per year) (WHO, 2008). This shows the important health contribution made by 
vaccines; however, they are not completely risk-free. A recent example of the influenza 
vaccine, Pandemrix highlighted vaccine safety and pharmacovigilance (Doshi, 2018).  
An AEFI is defined as “any untoward medical occurrence which follows immunization, and 
which does not necessarily have a causal relationship with the usage of the vaccine” (WHO, 
2012). Typically, AEFIs are those adverse events which are injection-process related and a 
direct effect of the vaccine component, but also include patient or host genetics.  Adverse 
vaccine reactions (AVRs) are those for which causality has been determined to be associated 
with the vaccine. AVRs can result in local reactions, systemic reactions and may include 
allergic reactions. Local reactions occur at the injection site, including pain, erythema, 
induration, etc. Fever is the most common systemic reaction. Allergic reactions include 
wheezing, generalized urticaria, swelling of the mouth and throat, difficulty breathing and in 
severe cases, anaphylaxis (WHO, 2012).  
2.8.1 Adverse Events Following Immunization (AEFIs) 
The WHO classifies AEFIs into five categories as listed and described below (WHO, 2020): 
A. Vaccine quality defect induced (WHO, 2020): 
• Based on factors such as the manufacturing process, adjuvants, preservatives, 
concomitant vaccines administered. 
• Example: Influenza vaccine administered in children in Australia during 2010-2011. It 
was observed that children ˂ 5 years had an increased risk of fever and febrile 
seizures. Investigations concluded that the cause was from the manufacturing process 
(Wood, 2012).  
 
B. Injection process (WHO, 2020): 
• Reactogenicity (bleeding, redness, swelling, pain, etc.) 
• Inappropriate diluents used; shoulder injury related to vaccine administration 
(SIVRA) 
• Contamination on the surface of the vial 
• Errors occurring during administration, e.g., lymphadenitis from the BCG vaccine, 
• The routes of administration of vaccines (oral, intramuscular, subcutaneous, 
intradermal, intranasal) contribute to the occurrence of AEFIs. For example, Bell’s 
palsy (facial muscle paralysis) was noted after some intranasal immunization with the 
influenza vaccine, resulting in a change in the vaccine route of administration.  
 




• Resulting from anxiety about the immunization, e.g., syncope before or after 
vaccination. 
 
D. Coincidental events (WHO, 2020): 
• AEFI caused by an underlying condition and not by the vaccine itself or the injection 
process, e.g., fever occurs at the time of vaccination can easily be associated with the 
vaccine but when confirming patient’s comorbidities, it might be caused by another 
illness such as onset of malaria.  
 
E. Vaccine product induced (WHO, 2020) 
• An AEFI resulting from inherent properties of the vaccine product. Example: 
Vaccine-acquired rotavirus in infants with severe combined immunodeficiency 
(SCID). Attenuated vaccines are typically contraindicated in patients with known 
severe immunodeficiency; however, the rotavirus-vaccine series is recommended at 2 
months of age. At this age, SCID cannot yet be identified in infants with no family 
history of immunodeficiency. Administration of the rotavirus vaccine is what revealed 
the immunodeficiency. A case series of five infants was reported with these findings 
[91]. This occurrence gave rise to the hypothesis that ADRs might not be random but 
rather be genetically predetermined. This phenomenon is referred to as adversomics; 
which is an emerging field of study of immunogenetics and immunogenomics of 
vaccine adverse events at the individual and population level, respectively (Poland, 2009). 
Further studies in adversomics may reveal the need for population-based vaccination 
programmes to be adapted to incorporate exclusion of certain individuals based on 
genetic profiles.  
 
• Examples of genetically predetermined AEFIs: 
o Adjuvanted influenza-H1N1 vaccine causing age-dependent myeloid and 
lymphoid cellular responses (Sobolev, 2016). 
o MMR vaccine causing febrile seizures – children with AEFI found to have similar 
genetic presentations (Svanström, 2014 ). 
o Smallpox vaccine causing reactogenicity at injection site due genetic 
polymorphisms in genes expressing an immunological transcription factor (Reif, 
2008). 
o Live vaccines cause infections and is therefore contra-indicated in immunocompromised 
patients or patients receiving immunosuppressive agents such as methotrexate for the 
treatment of tumours or auto-immune diseases such as rheumatoid arthritis or psoriasis 







2.8.2 Types of Vaccines (CDC, 2019) (Pardi, 2018) 
A. Live attenuated vaccines, e.g., Tuberculosis [Bacillus Calmette-Guérin (BCG) 
vaccine], oral polio, measles, rotavirus, yellow fever 
• Live form of the pathogen, which causes a mild form of the disease; thereby 
stimulating the body’s own immune response.  
• There is a potential to revert to the fully pathogenic form of the microorganism and 
cause the disease.  
• Immunocompromised patients at high risk for developing the pathogenic form of the 
disease.  
• Risk of contamination during manufacturing and cold chain processes 
• Increased risk for immunization errors (e.g., during reconstitution)  
o Examples of known AEFIs: 
- BCG vaccine: Disseminated BCG 
- Oral Polio vaccine: vaccine-associated paralytic poliomyelitis 
- Measles vaccine: febrile seizures, anaphylaxis 
- Yellow fever vaccine: hypersensitivity reactions 
B. Inactivated whole cell vaccines (killed antigen), e.g., whole cell pertussis 
• Made from pathogens which have been killed through physical or chemical processes 
and cannot cause disease; may be considered safer than live attenuated vaccines. 
• Vaccine may be ineffective, or the immune response may be short lived. Booster dose 
might be necessary. 
• Examples of known AEFIs: 
• Pertussis vaccines: seizures, hypotonic-hyporesponsive episode 
 
C. Subunit vaccines (purified antigen), e.g., Hep B, HPV, Meningococcal vaccine 
• Contain only the antigenic parts (proteins or polysaccharides) of the pathogen which 
are necessary to causes an immune response. 
• Conjugate vaccines incorporate polysaccharides to a carrier protein. 
o Examples of known AEFIs: 
- Hepatitis B vaccine: anaphylaxis 
- Conjugated meningococcal vaccines (e.g., MenAfriVac): fever, urticaria 
and bronchospasm. 
 
D. Toxoid vaccines (inactivated toxins), e.g., Tetanus, diphtheria toxoid 
• Made from a non-pathogenic form of a bacterial toxin which are harmless, called 
toxoids. 
• This requires an adjuvant to enhance the immune response and booster doses are 
necessary.  
o Examples of known AEFIs: 






E. RNA Vaccines, e.g., Covid-19 messenger (mRNA) vaccine candidates developed by 
Pfizer and AstraZeneca pharmaceutical companies (Pardi, 2018) 
• Novel vaccines developed as a response of the global Covid-19 pandemic. 
• Works by introducing a sequence which is coded for a disease-specific antigen.  
• The antigen is the recognized by the immune system. 
• In the case of the Covid-19 vaccine candidates, the mRNA instructs the production of 
harmless spike proteins on the cell surfaces.  
• The immune system detects the spike protein as being foreign to the body and 
develops an immune response by developing antibodies against the spike proteins.  
• The same antibodies are effective against Covid-19 infection. 
2.8.3 Vaccines Ingredients (WHO, 2020): 
Listed below are some of the components, both active- and inactive ingredients of vaccines. 
AEFIs may result from any of these ingredients and not necessarily from the active ingredient 
or vaccine itself.  
• Pathogen, antigen, or epitope – the pathogen or a component of the pathogen  
• Stabilizers - ensures vaccine effectiveness during storage, e.g., lactose-sorbitol, 
sorbitol-gelatine. 
• Adjuvants - stimulate production of antibodies against the antigen when only a part of 
the pathogen is used in the vaccine, e.g., aluminium (most used), monophosphoryl 
lipid A, AS03 (used in Pandemrix vaccine), Freud’s adjuvant. 
• Antibiotics - often used during manufacturing of live attenuated vaccines to prevent 
bacterial contamination of tissue culture cells in which vaccines are produced. 
neomycin is commonly used; however, it has a risk of allergies 
• Preservatives - used in multidose vials during manufacturing to prevent 
contamination, e.g., phenol derivatives, formaldehyde, thiomersal (contains ethyl 
mercury) 
 
Vaccines’ safety cannot be managed according to the same algorithms as other medicines as 
they are administered to healthy individuals, mostly children and to exponentially large 
populations, most often to prevent disease or alleviate symptoms of disease. The benefit/risk 
profile of a vaccine changes with circumstances and across different regions and countries. 
For example, a vaccine for Ebola Virus would be more beneficial in West African countries 
than in many other parts of the world; whereas, currently in 2020, a vaccine for the SARS-
CoV-2 virus is required and will be beneficial worldwide (WHO, 2020).  
They are often given concomitantly with other vaccines, which makes it difficult to 
investigate causality. Vaccines are complex biological compounds, usually consisting of a 
mixture of multiple antigens or live organisms, adjuvants, and preservatives. Due to their 
biological nature, vaccine storage, handling and administration are extremely specific; 
particularly the live attenuated vaccines and if not adhered to, can result in AEFIs  (WHO, 2020).  
The WHO defines vaccine pharmacovigilance as “the science and activities relating to the 
detection, assessment, understanding, prevention and communication of AEFIs (adverse 





Spontaneous reporting is the primary PV method of AEFI reporting globally. The WHO 
recommends that AEFI surveillance must be tightly integrated with the public health system 
coordinating the delivery of vaccines on a national level. This requires a collaboration 
between the National Immunization Programme (NIP) and the National Regulatory Authority 
(NRA).  
Historically, vaccines have been made available to LMICs after years of use in US, Europe, 
and other EU countries. Lately, there has been a need for introduction of newly developed 
vaccines directly to LMICs (e.g., MenAfriVac®, Dengvaxia®) (Trotter, 2017). This puts the 
responsibility of safety surveillance of these vaccines from early post-marketing phase, 
squarely on the LMIC’s regulatory authorities and NIP’s. 
 With the current global Covid-19 pandemic, multiple vaccine candidates are undergoing 
concurrent clinical trials and it remains unknown which of these will successfully enter the 
market (Wellcome, 2021). Most likely, more than one vaccine candidate will be introduced into 
the global healthcare system at the same time, due to the presence of different viral variants 
as well as known scale up and manufacturing constraints. Due to the novel nature of the 
various Covid-19 vaccines, the importance of robust pharmacovigilance cannot be 
emphasized enough. The risk of AEFIs occurring and not being detected and reported is 
remarkably high in most LMICs.  
The WHO has created a reporting form specifically for AEFIs, with a set of “core variables” 
to collect essential information to facilitate for safety review. For serious AEFIs, there is an 
AEFI investigation form, which contains information to be collected to facilitate the 
investigation of causality. This includes, among other data, information about the patient’s 
family, other patients who received the same vaccine. Other WHO forms to be completed 
during the investigation include the laboratory request form for collection of specimens from 
the patient, vaccine, syringe, and needle used during the vaccination. Finally, there is also a 
causality assessment form for performing an individual level causality assessment 
(brightoncollaboration, 2021).  
Brighton collaboration is a group of scientists who have come together with the joint effort to 
harmonise definitions of events or clinical syndromes which are often reported in association 
with vaccines (brightoncollaboration, 2021). When performing the individual level causality 
assessment according to the WHO method, the clinical diagnosis of the adverse event is 
defined according to the Brighton collaboration. This can be a challenge for national PV 
centres where AEFI reports are received but they only contain one symptom, such as 
vomiting or weakness, which are general and can be associated with multiple diagnoses.  
The WHO process and forms required to be completed by PV centres at a national level, have 
been criticised for being cumbersome and challenging; particularly in LMIC due to resource 
and staff limitations. The number of forms and information to be gathered for investigation of 
reported AEFIs can be time consuming when there are issues of inadequate staff, lack of 
electronic health records, inadequate knowledge/training of reporters regarding information 
to be included when submitting an AEFI report to the national PV centre, etc.  
At times it can be difficult for the national PV centre to confirm a certain diagnosis which is 
suspected by the reporter due to resource limitation, for example, a report is received with 
meningitis as the AEFI. As part of the investigation, the reporter is contacted for additional 
information on how the diagnosis was confirmed and the reported notes that this was based 




These are common LMIC challenges which must be taken into consideration when national 
PV centres construct their PV framework. Another time and resource demanding task are 
literature search for similar AEFIs reported elsewhere or available data on the vaccine. This 
is typically done at a later stage with regular medicines, but with vaccines, it is part of early 
investigations to see how commonly it occurs, typical triggers and assess any similarities with 
known data.  
Figure 2-6 depicts the surveillance cycle followed by Figure 2-7, which illustrates the WHO-
UMC upon investigation of an individual AEFI and the algorithm recommended by WHO-
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Observed vs expected analysis is a comparison of how many cases of common reactions are 
expected to be identified vs those identified post-vaccination. The estimates are typically 
based on data from pre- and post-marketing clinical trials as well as clinical practice. For 
instance, if an NPI normally receives one case of fever during seasonal influenza 
vaccinations, but suddenly they receive five cases in a season, this is a trigger for further 
investigation. In some countries, prior to introducing a new vaccine into the national 
vaccination programme, an estimate the expected frequency of common vaccine related 
effects and compare that to the effects observed during the vaccination programme, to see if 
the observed frequency is higher than the expected. This was done with the influenza virus 
vaccine during the 2009 novel H1N1 pandemic and it was an effective method to distinguish 
events that are temporarily associated with, but not caused by, vaccination from those caused 
by vaccination in mass immunization (Wang, 2013). Countries can learn from this and 
implement the same strategy for the upcoming SARS-CoV-2 vaccine.  
For AEFI case series, like regular ADRs, the WHO-UMC applies the Bradford Hill criteria 
for the causality assessment. The signal detection at the WHO-UMC involves the 
identification of patterns across multiple case reports, received from multiple countries. The 
patterns include similarities in patients, clinical presentations, time to onset, outcomes, etc 
(WHO, 2013). The WHO-UMC communicates potential signals in their Signal publication, 
which is distributed to PIDM member countries. This is not necessarily done to confirm that 
causality is established; however, it is mostly to alert national PV centres and HCPs to look 
out for similar occurrences and to submit them into VigiBase® for further analysis as well as 
to minimize the risks, where possible.  
2.9 Global Pharmacovigilance Awareness 
Global efforts to promote health education are undertaken by the WHO and other 
stakeholders. The WHO-UMC provides methods, tools and training that empowers 
stakeholders, including patients, healthcare professionals, researchers, WHO PIDM member 
countries, etc. with the aim of strengthening PV communication and awareness (UMC, 2021).  
The WHO-UMC uses the following platforms for this purpose: 
A. Website (UMC, 2021) 
In the first year of the website’s implementation in 2017, the website had attracted over 
82 000 users. On the website, users are directed to other awareness projects such as the 
following: 
• Online Magazine (Uppsala Reports that contains latest PV-related news and activities 
of the WHO PIDM (UMC, 2021).  
• Podcast (Drug Safety Matters) on latest trends and challenges in medicines safety 
(UMC, 2020). 
• Patient-centred communication, translated into multiple languages. 
- Take & Tell with theme music and brochures targeted at educating patients 




- Annie & Mac’s Adventures using a comic book which teaches children 
about medicine e.g., special campaign package for world antibiotic 
resistance week. 
- Drugs and Bugs, an academic book for young readers. 
-  
B. Social Media – active accounts on Twitter, LinkedIn, Facebook, and YouTube 
The MHRA collaborated with the WHO-UMC to pilot the Scope campaign, the first EU-wide 
PV awareness campaign (Jadeja, 2016).  EU member states participated in the campaign to 
increase awareness of their national level ADR reporting system for spontaneous reporting. 
This requirement is included in the updated EV PV legislation Directive 2010/84 – Article 
102 which states “The Member States shall take all appropriate measures to encourage 
patients, doctors, pharmacists and other healthcare professionals to report suspected adverse 
reactions to the national competent authority; for these tasks, organisations representing 
consumers, patients and healthcare professionals may be involved as appropriate” (Union, 2010). 
The entire project timeline from planning to reporting phase took place between February 
2014 and April 2017; however, the campaign itself was ran for 5 days (form the 7th to the 11th 
of Nov 2016).  
The strategy employed by the Scope campaign was to make ADR reporting easy and 
accessible, raise an understanding of the value of reporting, encouraging patients to 
participate in reporting and to develop communication strategies for ongoing promotion. 
Animations (MHRAgovuk, 2016) and infographics (MHRA, 2021), were distributed, using social 
media platforms to the public and 165 relevant stakeholder groups (patient organizations, 
advocacy groups, etc.). The campaign reached 2,562,071 people, mostly through stakeholders 
disseminating to their networks. As a result of the campaign, there was a 13% increase in 
suspected ADR reporting (1,056 reports) between 15 NCAs in the campaign week (Jadeja, 2016). 
With this campaign having run for a week, the recommendations resulting from the campaign 
include the consideration of more frequent social media use and further collaboration 
between NCAs and stakeholders to make this an annual ADR awareness week at a global 
level.  
As a result, toolkits containing good practices, together with the infographics and animations, 
have been made available for adaptation, translation, and future implementation. A 
CPD/CME accredited e-learning course has also been launched, targeting HCPs at any stage 
of their careers and it can be part of a curriculum for students.  
2.10. Global Pharmacovigilance activities during the Covid-19 pandemic 
The International Society of Pharmacovigilance (ISoP) is a global, professional, independent, 
not-for-profit society founded in 1992, aiming to promote pharmacovigilance globally (ISoP, 
1992). ISoP has coverage in more than 60 countries. A key initiative for Africa is the 
establishment of ASop, the African subsidiary of ISoP, launched in November 2010 at the 
10th ISoP Annual Meeting in Accra, Ghana to play an educational role with the objective to 
develop and foster pharmacovigilance in African countries. ASoP’s objectives include 
regular exchange of information on pharmacovigilance by means of meetings, workshops, 
bulletins, trainings, and specifically organised congresses as well as seeking funds, and 
awarding grants, fellowships, and other contracts to promote pharmacovigilance in African 




The current novel Covid-19 pandemic provides a challenge with limited timelines within 
which solutions in terms of prevention and treatment protocols have had to be explored to 
combat the virus rapidly and effectively (WHO, 2020). Not only does the pandemic necessitate 
an extensive shortening of timelines for the conduct of clinical trials, but multiple phase II 
and III clinical trials are implemented in parallel and data analysis performed in a staggered 
manner as key clinical endpoints are achieved (WHO, 2020).  
Several recent vaccine related safety concerns which have received substantial public 
attention, viz Pandemrix® causing narcolepsy, Dengvaxia® causing severe dengue, have 
suggested the presence of patient specific risk factors associated with the occurrence of these 
adverse outcomes. In addition, a new study field of systems immunology has emerged to 
describe the complexity of the immune system which may allow us to further understand the 
pharmacodynamic principles of adverse events associated with vaccination and the 
subsequent process of developing immunity (WHO, 2020).   
Like with any other medication, the risk extends to safety matters arising from counterfeit 
vaccines as well as quality concerns throughout the life cycle of a vaccine, including 
formulation, manufacturing, packaging, storage conditions, handling, dispensing, and 
administration. Recent surveys have furthermore documented concerning decreases in public 
confidence in vaccine safety, further escalated by several rumours and stigma within specific 
communities and amongst different cultures and religions. In 2019, the WHO has declared 
vaccine hesitancy as one of the ten threats to global public health (WHO, 2020).  
The International Society of Pharmacovigilance (ISoP) and the WHO UMC have a common 
interest to promote scientific research and practice through the mutual exchange of 
information on adverse events and risks related to medicinal products. The 42nd Global 
Advisory Committee on Vaccine Safety (GACVS) held on 27–28 May 2020, addressed 
pharmacovigilance preparedness for the launch of the future Covid-19 vaccines (ISoP, 1992). In 
collaboration, the WHO global manual (WHO, 2020) was developed in 2020 to provide 
guidance on how the stakeholders could collaborate to ensure the efficient handling of Covid-
19 vaccine safety, surveillance, and pharmacovigilance. Prior to vaccine roll-out, each 
country should include safety surveillance as part of their preparedness plans.  For the 
successful and effective roll-out of Covid-19 vaccines, stakeholder collaboration must 
include national health departments, regulatory authorities, immunization programmes, 
pharmaceutical companies, and NGOs. The manual contains several chapters and modules 
spanning from safety considerations for different types of vaccines, resource-sharing at 
regional level and across industries, to establish adverse event following immunization 
(AEFI) & adverse event of special interest (AESI) reporting platforms, how to perform 
causality assessments using the Brighton Collaboration Benefit-Risk Assessment of Vaccines 
by Technology (BRAVATO) safety templates and provision of practical tools such the AEFI 
reporting and investigation forms (WHO, 2020).  
2.11. Region-specific Pharmacovigilance Developments 
2.11.1 FDA Pharmacovigilance Activities and Funding 
The United States (US) Food and Drug Administration (FDA) consists of the Office of the 




Products and Tobacco, Foods, Global Regulatory Operations and Policy, and Operations. 
(Ofir, 2017). 
The Centre for Drug Evaluation and Research (CDER) provides safety oversight on drugs 
within the authority of the FDA. The Drug Safety Oversight Board (DSB), created in 2005 
and mandated by law in the, advises the CDER Centre Director on the handling and 
communicating of important and often emerging Drug Safety issues. The DSB meets 
monthly and provides a forum for discussion and input about how to address potential Drug 
Safety issues (Ofir, 2017). 
The FDA's Human Drugs Program is responsible for ensuring the safety and efficacy of new, 
generic, and over the counter (OTC) medicines, monitoring marketed medicines to ensure 
patient safety, and monitoring medicine quality. The Centre for Drug Evaluation and 
Research (CDER) and the Office of Regulatory Affairs (ORA) field drugs program are the 
components of FDA’s Human Drugs Program, which operates with funding from budget 
authority and user fees. 
In 2007, the FDA introduced the FDA Amendments Act (FDAAA). As a response, the 
Sentinel Initiative was launched in 2008 (sentinelinitiative, 2016). Over time, Sentinel has 
developed the largest multisite distributed database in the world dedicated to medical product 
safety. It is constantly growing and improving from the pilot version to the version with 
advanced capabilities. In 2016, the full version of the Sentinel System was launched 
(sentinelinitiative, 2016). 
Other initiatives of the CDER include the FDA Adverse Event Reporting System (FAERS); a 
spontaneous reporting system for submitting ADRs, medication error reports and product 
quality complaints resulting in adverse events; to the FDA. Under 21 CFR 314.80 post-
marketing safety reports which are serious and unexpected adverse from all sources 
(domestic and foreign) must be submitted within 15 days (Ofir, 2017). The reports in FAERS 
are evaluated by clinical reviewers, in the Center for Drug Evaluation and Research (CDER) 
and the Center for Biologics Evaluation and Research (CBER), to monitor the safety of 
products after they are approved by FDA. The Good Pharmacovigilance Practices and 
Pharmacoepidemiologic Assessment Guidelines were published in March 2005 for the 
purpose of providing guidance to the pharmaceutical industry (CDER, 2005). 
If a potential safety concern is identified in FAERS, further evaluation is performed. Based 
on an evaluation of the potential safety concern, FDA may take regulatory action(s) to 
improve product safety and protect the public health, such as updating a product’s labelling 
information, restricting the use of the drug, communicating new safety information to the 
public, or, in rare cases, removing a product from the market. 
Healthcare professionals, consumers, and manufacturers submit reports to FAERS. FDA 
receives voluntary reports directly from healthcare professionals (such as physicians, 
pharmacists, nurses, and others) and consumers (such as patients, family members, lawyers, 
and others). Healthcare professionals and consumers may also report to the products’ 
manufacturers as depicted in Figure 7. If a manufacturer receives a report from a healthcare 
professional or consumer, it is required to send the report to FDA as specified by 
regulations.   Over 13 million reports have been submitted into FAERS since 1969, averaging 






Figure 2-8: FDA post-marketing safety data reporting process (Ofir, 2017). 
 
2.11.2 EMA Pharmacovigilance Activities and Funding 
The European Medicines Agency (EMA), the European Union (EU) Member States and the 
European Commission are responsible for implementing and operating much of the 
pharmacovigilance legislation. The Agency plays a key role in coordinating activities relating 
to the authorisation and supervision of medicines, including safety monitoring, across this 
network (EU, 2001). 
The Agency is working with a wide range of stakeholders including the European 
Commission, pharmaceutical companies, national medicines regulatory authorities, patients, 
and healthcare professionals to ensure effective implementation and operation of the 
pharmacovigilance legislation.  
It was noted that ADRs were the cause of 197 000 deaths per year in the EU. As a response to 
this concern, pharmacovigilance legislation was developed in the form of Directive 
2010/84/EU (EU, 2001) and Regulation (EU) No 1235/2010 (EU, 2010). This was accompanied by 
an implementing regulation: Commission Implementing Regulation No 520/2012 of 19 June 
2012 (EU, 2012).  
The pharmacovigilance legislation aims to reduce the number of ADRs in the EU. It aims to 
achieve this through (EU, 2012): 
• the collection of better data on medicines and their safety. 
• rapid and robust assessment of issues related to the safety of medicines. 
• effective regulatory action to deliver safe and effective use of medicines. 
• empowerment of patients through reporting and participation. 
• increased levels of transparency and better communication. 
 
This new legislation led to the establishment of the Pharmacovigilance Risk Assessment 
Committee (PRAC) at the EMA. The PRAC was formally established in July 2012 and its 
membership was completed in spring 2013 with the appointment of patient and health-care 
professional organization representatives as full voting members. The Committee includes 




detection, risk communication and vaccine vigilance. The main responsibility of the PRAC is 
assessing all aspects of the risk management of medicines for human use. This includes the 
detection, assessment, minimisation, and communication relating to the risk of adverse 
reactions, while taking the therapeutic effect of the medicine into account. It also has 
responsibility for the design and evaluation of post-authorisation safety studies and 
pharmacovigilance audits. The PRAC generally provides recommendations to the CHMP, the 
Coordination group for Mutual and Decentralized procedure- Human (CMDh), the EMA 
secretariat, Management Board and Ethics Committee, as applicable (Arlett, 2014). 
In just a year of being in existence, the PRAC achieved the following among many 
achievements (Arlett, 2014):  
• An increase of more than 9,000 in patient reports of suspected adverse drug reactions. 
• Product information changes because of assessment of signals of new or changing 
safety issues with certain medicines. 
• Initiation of major public-health reviews, including combined hormonal 
contraceptives and venous thromboembolism, medicines containing cyproterone 
acetate / ethinylestradiol and venous thromboembolism, and codeine-containing 
products used for pain relief and overdose in children. 
• Training thousands of individuals in pharmacovigilance. 
 
In the first 18 months of its operation, the PRAC has considered risk management plans for 
160 medicinal products. In this work the PRAC has focused on ensuring feasible, evidence-
based and risk-proportionate planning.  
The collection of individual reports of suspected adverse drug reactions (ADRs) is one of the 
foundations of drug surveillance, and the reporting rules have been strengthened. These now 
include the formal introduction of patient reporting in all EU member states (to enable patient 
engagement), the provision of instructions on reporting in drug leaflets for patients, as well as 
the labelling of new drugs and those under close safety surveillance with a black triangle 







Figure 2-9: Impact of the new European legislation on pharmacovigilance (Arlett, 2014).  
a | Number of cases of spontaneous reports of adverse drug reactions within the European Economic Area in the 12-month 
periods before or after  
 b | Number of safety signals evaluated by the Pharmacovigilance Risk Assessment Committee (PRAC) in its first 18 months 
and the outcomes of the finalized evaluations. 
 
In October 2012, the EU pharmacovigilance legislation was further amended following 
review of the withdrawal of the medicine Benfluorex, sold under the brand name Mediator®. 
Benfluorex was used as an add-on treatment in patients with diabetes who are overweight. 
Medicines containing benfluorex were first authorised in 1974. At the time of this review, 
they were available as tablets containing 150 mg benfluorex hydrochloride in France and 
Portugal. In 2007, a re-assessment of the benefit–risk balance led to the withdrawal of the 
indication for the use in patients with high blood levels of triglycerides. In November 2009, 
following several reports of cardiac valvulopathy (thickening of the heart valves) and 
pulmonary arterial hypertension (high blood pressure in the artery that leads from the heart to 
the lungs), the French medicines regulatory authority carried out a review of the safety of 
benfluorex and decided to suspend its marketing authorization. As a result, benfluorex-
containing medicines were taken off the market in France (Frachon, 2011). Shortly after, as a 
precautionary measure, the Portuguese medicines regulatory authority also decided to recall 
these medicines from the market. On 18 Dec 2009, the EMA issued a press release 
announcing its recommendation that the marketing authorisations for products containing 
benfluorex are to be withdrawn across the EU (EMA, 2009). 
Following this, the PV regulations were amended, to further strengthen the protection of 
patient health. Amended Regulation (EU) No 1027/2012 was effective as of 5 June 2013 and 
Directive 2012/26/EU was applicable since 28 October 2013 (EU, 2004) (EU, 2012). Practical 
measures to facilitate the performance of pharmacovigilance in accordance with the 
legislation are available in the guideline on Good Pharmacovigilance Practices (GVP) (EMA, 
2019). GVP apply to marketing-authorization holders (MAH), the EMA and medicines 
regulatory authorities in EU Member States, and cover medicines authorized centrally via the 
Agency as well as medicines authorized at national level. 
All MAH’s across the EU and the European Economic Area (EEA) must submit information 
to the EMA on authorized medicines and keep this information up to date. The aim of the 
submission of data is to establish a complete inventory of all medicines authorized for use in 
the EU and EEA, including medicines authorized centrally via the EMA and those authorized 




• Data analysis: 
o analysis of data in EudraVigilance and signal detection 
o reporting and coding of individual case safety reports 
• Regulatory activities: 
o maintenance of a repository of periodic safety update reports (PSURs) and 
literature monitoring 
o calculation of PV fees  
• Communication with stakeholders: 
o European medicines web portal 
o publishing a complete list of all medicines authorized in the EEA  
o exchanging data within the EU and internationally 
o supporting communication between PRAC and MAH’s 
 
Regulation 658/2014 of 15 May 2015 introduced a fee-based funding approach for PV 
services, paid by MAH’s, applicable as of 26 Aug 2014 (EU , 2014). The PV services charged 
for include Assessment of PSUR/PBRER, post-auth safety studies (PASS) and safety 
referrals. An annual fee was applicable as of 01 Jul 2015 for maintenance of the IT systems 
used for PV activities as well as for monitoring relevant scientific literature. Prior to the new 
2012 legislation, all MAH’s were mandated to remain abreast of all scientific literature 
containing safety information on their active ingredient. This included information published 
by manufacturers of generic products. As of 2012, the EMA decided that such monitoring 
would be done centrally for all EU member countries and MAH’s would then pay an annual 
fee as of July 2015. Fee reductions apply for SME’s and manufacturers of herbal and 
homeopathic medicines are exempt from paying. The annual fees are calculated per 
chargeable unit, which depends on the number of active substances, products on the market, 
pharmaceutical form, number of countries the products are sold in, see below Table 2-5. (EMA, 
2019).  
 
Table 2-5: Summary of EMA pharmacovigilance fees  (EMA, 2019) 
Type of 
procedure/service 























(conducted in more 
than one-member 
state) 
- EUR 43 000 per procedure to be paid in two 
instalments: 
1. EUR 17 200 assessment of draft protocol 
2. EUR 25 800 assessment of final study report 
Full fee / share of 
fee 
Assessment of PV 
referrals 
- EUR 179 000 if the referral concerns 1 or 2 
active substances and/or combinations 
- Fee increased by EUR 38 800 for every 
additional active substance/combination, up to 
max EUR 295 400 
Full fee 
Annual Service (PV 
information 
technology and 
monitoring of medical 
literature) 
- EUR 67 per chargeable unit 




80% of applicable 









2.12 Pharmacovigilance Developments in Africa 
2.12.1. Challenges of Pharmacovigilance in Africa 
Compared to Africa, the impact of ADRs can more readily be measured in places such as the 
USA and Europe, because ADRs are relatively well reported in those areas and the 
information is readily available. Africa is heavily ridden with diseases such as HIV/AIDS, 
tuberculosis (TB), and malaria. Investments to public health programmes in LMIC by global 
health initiatives such as PEPFAR, Global Fund (GF), Global Alliance for Vaccines and 
Immunizations (GAVI), Bill and Melinda Gates Foundation (BMGF) and others against 
HIV/AIDS, TB and Malaria has resulted in treatments and vaccines becoming rapidly 
available in many African countries, which also increases the occurrence of ADRs. Due to 
limited ADR reporting, their exact impact in this region cannot be measured. African drug 
regulators mainly depend on the FDA and EMA to share information regarding changes in 
the benefit-risk ratio of drugs registered in those regions as well.  It is no doubt that PV is in 
serious need in all countries, including LMICs and it is gaining traction as countries become 
aware of the need.   
Recent studies have identified several obstacles to PV growth in Africa, including lack of 
capacity for HCPs, weak overall national health infrastructure and systems, lack of 
communication/feedback from national PV centres, lack of PV training (Ampadu, 2016) (Olsson S, 
2015).  
Due to cultural and financial reasons, there is a wide use of traditional medicines; however, 
these are not well characterised as traditional healers are not willing to share their trade 
secrets, which are said to be sacred and spiritual. A good example of a non-African country 
with a wide use of traditional medicines but with well-established systems is China. Because 
their traditional medicines are well characterised, they can assess causality and identify 
traditional medicines associated with certain ADRs. A 2012 China Food and Drug 
Administration (CFDA) report estimated approximately 15-20% of reported ADRs to be 
associated with traditional medicines (China FDA, 2013). ADR forms are still widely available in 
paper format across Africa and logistically, the distribution and return of completed ADR 
forms to the national PV centre from all parts of the country can also pose a challenge. From 
the time that an ADR form is completed at a healthcare facility for instance, it probably gets 
filed until a certain time when there are enough reports to be returned to the national PV 
centre through the postal service. Meanwhile, at the national PV centres, paper ADR reports 
are received from multiple areas with varying quality of information included. These must be 
captured into a database by the limited staff available together with follow-up with reporters 
where key information is missing. In the end, there is a delay in the submission of ADRs to 
VigiBase® and the quality of the ADRs is not the best. These dynamics limit the activities at 
the national PV centres to data entry and leaves little time for essential activities such as 
causality assessments and signal detection (Olsson, 2015).  
2.12.2. Improving Pharmacovigilance in Africa 
Although the number of African countries establishing national PV systems and gaining 
membership into the WHO PIDM, only a few African countries (e.g., Nigeria and Eritrea) 
have well established national PV policies. Politicians and healthcare decision makers need to 
be convinced of the urgent need to implement legislation and policies that mandate the 




researchers must perform local studies providing evidence of the prevalence, harms, and 
financial impact of ADRs at country level. National drug regulations should make it 
mandatory for not only MAH’s to report ADRs, but also HCPs as well as patients. Among 
the HCPs, nurses and pharmacists should be empowered with adequate training, to complete 
ADR forms; however, the treating physician should remain the official reporter in case of any 
additional information required or queries. Awareness campaigns must be funded by 
governments to create a reporting culture within the country (Olsson, 2015).   
The international community has explored several strategies to support the African continent 
in developing structures for safety surveillance of marketed medicines. The WHO as well as 
the Uppsala Monitoring Centre (UMC) and the WHO Collaborating Centre for PV undertook 
a focused approach on PV capacity building in Africa, with the UMC alone training 100 
HCPs since 1993 in its annual PV course. Furthermore, the WHO has developed PV 
handbooks addressing specific needs for PV in HIV/AIDS, TB, and malaria, focusing on 
active PV methods such as targeted spontaneous reporting and of cohort event monitoring 
(WHO, 2013) (WHO, 2007) (WHO, 2012). Practical implementation of these methods has been 
successfully demonstrated in pilot studies conducted in Kenya, Tanzania, Ghana, Nigeria, 
Uganda, and Zimbabwe (Ndagije, 2015) (Bassi, 2013) (Dodoo, 2014) (Suku, 2015). The implementation 
itself was not without its challenges, considering the existing socio-economic challenges 
across Africa. The following are some of the common lessons learned from these CEM 
programmes, which can be expected when implementing similar programmes in other 
African countries (Suku, 2015): 
 
• The biggest and most common challenge was identified to be inadequate funding. 
Other challenges such as inadequate data entry staff and study resources (internet, cell 
phones, etc.) can be avoided with adequate funding being available.  
• Community engagement and sensitization starting prior to study commencement.   
• Understanding the local disease landscape to inform recruitment strategies and 
planning (e.g., recruiting for a malaria programme during the rainy season, when 
malaria is highly prevalent).  
• Adequate time and trained site staff to perform effective informed consent (IC), which 
includes explaining to participants, the purpose of the study. The CEM handbook 
warns that including these explanations in the IC process can be time consuming and 
have cost implications; however, also warning that a requirement for formal informed 
consent could lead to participants refusing to be enrolled. Ethically, however, there is 
no way around this. There is a high risk of exploitation to occur in study participants 
coming from poor populations, where participants provide consent but motivated by 
financial and/or other incentives. This risk is mitigated by national regulatory 
authorities recommending reimbursement fees for study participation. An additional 
mitigation is robust informed consent, to ensure that participants are fully aware what 
the study entails. Other challenges related to IC, which can be reduced with detailed, 
robust IC, included women requiring permission from their husbands, reluctance to 
participate and low literacy rates. 
• Adequate programme staff training, regular re-training, staff support and onsite 
monitoring visits and remuneration. This may also reduce issues of high staff 
turnover, which were found to be prevalent at all studied countries.  




• Strike action was another common challenge; however, this is usually due to local, 
socio-economic, and political issues and out of the researchers’ control. This can 
cause unforeseen delays in enrolment and study completion.  
In June 2009, the WHO-UMC established an African office (UMC–Africa) with dedicated 
funding, while the University of Ghana (October 2009) was designated as a WHO 
Collaborating Centre for Advocacy and Training in Pharmacovigilance (WHO–CC), working 
together with UMC–Africa. The African hub (WHO–CC, UMC–Africa) undertook advocacy, 
country visits, in-country training, and capacity building in several countries, culminating in 
most of them becoming full members of the PIDM (Olsson, 2015). Since its inception, the UMC-
Ghana has developed a PV Toolkit, among other PV tools (including disease-specific 
toolkits) intended to support the setting up on PV centres. The PV toolkit provides minimum 
requirements for a functional PV system, provides basic information regarding the WHO 
PIDM as well as key concepts on pharmacovigilance (WHO Collaborating Centre Ghana, 2012). 
2.12.3. Pharmacovigilance indicators to develop pharmacovigilance systems in 
African countries 
In general, indicators are objective measures that allow an evaluation of baseline situation 
and progress in healthcare services and interventions. The WHO-UMC uses 
pharmacovigilance indicators to measure the status of national PV systems within PIDM 
member countries to determine the extent of support required by that country as well as the 
measure the impact of the support provided. PV indicators facilitate the ability to identify 
strengths, weaknesses, achievements, growth, and impact and to assess the return on 
investment made into pharmacovigilance (WHO-UMC, 2015) (SPS Program, 2009). Effective 
indicators should be simple to understand, easy to measure and interpret, reproducible, 
sensitive to detect problems and applicable to any facility engaged in PV. There is also an 
assessment checklist to be used when performing an assessment of a PV system/program 
against the indicators (WHO-UMC, 2015). The idea of PV indicators arose during a 2007 meeting 
of PV consultants and staff from WHO, UMC and WHO African Regional Office in Ghana. 
The over-riding philosophy was to develop a set of indicators to measure the impact of 
interventions which are to be developed by the WHO-UMC to support the establishment of 
PV systems within African countries. The identification of candidate indicators and their 
categorization was carried out through questionnaires to national pharmacovigilance centres, 
the results presented and discussed at subsequent meetings of the African Pharmacovigilance 
Consultant Group and annual meetings of WHO PIDM member countries. The development 
process was continuously reviewed and finally validated by WHO Advisory Committee on 
Safety of Medicinal Products (ACSoMP) until publication in 2015. As part of field testing of 
the PV indicators prior to publication, the WHO-UMC collaborating centre in Ghana, used 
the indicators to assess the status of PV across African countries during their visits to those 
countries (WHO-UMC, 2015). Prior to using the pharmacovigilance indicators, it is 
necessary to obtain some background information covering the demographics, economics, the 
health-care system, and the pharmaceutical scenario. This will provide the denominator for 
calculating most of the indicator values. 
There is a total of 63 indicators, classified as structural, process and outcome/impact 
indicators and categorized into Core (27) and Complementary (36). Core indicators (C) are 
those considered to be highly relevant, important, and useful in characterizing 
pharmacovigilance, while Complementary indicators (T) are those additional measurements 




A. Structural indicators assess 
• Visibility and magnitude of the PV programme 
• Enabling environment 
• Legal framework 
• Sustenance – are there structures in place 
B. Process indicators assess 
• Extent of PV activities 
• Describe the mechanism of PV (i.e., collection, collation, analysis, and evaluation) 
• Extent to which the PV system is operating 
C. Outcome/Impact Indicators (core and complementary), to indicate the following 
• Effects and changes resulting from PV activities 
• Advocacy tool 
• Trends 
• Return on investment 
2.12.4. Core PV indicators 
There are 27 core pharmacovigilance indicators: 10 structural, 9 process and 8 outcome or 
impact indicators (WHO-UMC, 2015). 
2.12.4.1. Core Structural Indicators (10) check for the existence of (WHO-UMC, 
2015):  
1. A PV centre with a standard accommodation 
2. A statutory provision for PV? (legislation, policy) 
3. A drug regulatory authority 
4. Regular financial provision for the PV centre 
5. Human resources to carry out its functions properly 
6. A standard ADR reporting form 
7. A process in place for collection, recording and analysis of ADRs 
8. Is PV included in national curriculum of schools for healthcare professionals? 
9. A newsletter/information bulletin/website for dissemination of PV information 
10. A national PV advisory committee  
 
2.12.4.2. Core Process Indicators (9) check for the following (WHO-UMC, 2015): 
1. Total number of ADR reports received in the last calendar year (target 200 reports per 
million inhabitants per year) 
2. Total number of reports in national/local database 
3. Percentage of total annual reports acknowledged 
4. Percentage of reports subjected to causality assessment in the year 
5. Percentage of national reports satisfactorily completed and submitted to the national 




5.a) Submitted to WHO 
6. Percentage of reports on therapeutic ineffectiveness  
7. Percentage of reports on medication errors 
8. Percentage of registered pharmaceutical companies having functional PV systems 
9. Number of active surveillance activities initiated, ongoing or completed in the last 5 
years 
2.12.4.3. Core outcome/impact indicators (8) check for the following (WHO-UMC, 
2015): 
1. No. of signals identified by PV centre in the last 5 years 
2. No. of regulatory actions taken last year based on national data, not 
information/action taken by international RA’s.   
- label change 
- safety warning 
- medicine suspension/withdrawal/other restrictions 
3. No. of medicine related hospital admissions/1,000 admissions 
4. No. of medicine related deaths/1,000 persons served by hospital 
5. No. of medicine related deaths/100 000 in the population 
6. Average cost of treatment of medicine-related illness 
7. Average duration of extension of medicine-related hospital stay 
8. Average cost of medicine related hospitalization 
 
In addition, nine pharmacovigilance indicators cutting across the three classes were selected 
for Public Health Programmes (PHP) to enable the monitoring and evaluation of 
pharmacovigilance following the large-scale deployment of medicines in a PHP where many 
people are exposed to medicinal products: 
2.12.4.4. Core indicators for Public Health Programmes (PHP) (WHO-UMC, 2015): 
1. PV activities in place within the PHP 
2. All main treatment guidelines/protocols in use within the PHP systematically 
considers PV 
3. Existence of standard ADR reporting form in the PHP 
4. Total no. of ADR reports collected within the PHP in the previous year 
5. Total no. of ADR reports/1,000 individuals exposed to medicines in the PHP the 
previous year 
6. Total no of reports on therapeutic ineffectiveness in the previous year 
7. Percentage of completed reports submitted to the national PV centre in the previous 
year  
7.a) to WHO 
8. No. of medicine-related hospital admissions/1,000 individuals exposed to medicines 
in the PHP in the previous year 
9. No. of medicine-related deaths/1,000 individuals exposed to medicines in the PHP in 
the previous year 
2.12.5. Complementary Indicators (WHO-UMC, 2015): 





1. Existence of a dedicated computer for pharmacovigilance activities 
2. Existence of a source of data on consumption and prescription of medicines 
3. Existence of functioning and accessible communication facilities in the 
pharmacovigilance centre 
4. Existence of a library or other reference source for Drug Safety information 
5. Existence of a computerized case-report management system 
6. Existence of a programme (including a laboratory) for monitoring the quality 
of pharmaceutical products 
6.a) The programme (including a laboratory) for monitoring the quality of 
pharmaceutical products collaborates with the pharmacovigilance programme 
7. Existence of an essential medicines list which is in use 
8. Systematic consideration of pharmacovigilance data when developing the 
main standard treatment guidelines 
9. The pharmacovigilance centre organizes training courses 
9.a) for health professionals 
9.b) for the public 
10. Availability of web-based pharmacovigilance training tools 
10.a) for health professionals 
10.b) for the public 
11. Existence of requirements mandating market authorization holders to submit 
periodic safety update reports 
 
An older set of the PV indicators is called “Indicator-based Pharmacovigilance Assessment 
Tool (IPAT) (SPS Program, 2009). It was developed within the Strengthening Pharmaceutical 
Systems (SPS) and supported by USAID and published in Dec 2009 for conducting PV 
assessments in developing countries at a national, public health programs and health facility 
level. The indicators in this tool are remarkably like the WHO PV indicators; however, the 
outcome/impact indicators in the IPAT tool are not as elaborate. The tool was used in the 
assessment of PV systems and their performance in 46 African countries in 2010. The report 
was published in 2011 and the development of PV systems in many of those 46 countries 
remain inadequate to date (SPS Program, 2009). Such assessments should not be in isolation; after 
performing the analysis and knowing the status of the PV system, there should be 
interventions and plans on how to implement them. A follow-up assessment should also be 
performed after implementation, to measure the impact of the interventions.   
 
The IPAT tool measures performance in each of the following PV components (SPS Program, 
2009): 
1. Policy, law, and regulation 
2. System, structure, and stakeholder coordination 
3. Signal generation and data management 
4. Risk evaluation and assessment 
5. Risk communication and management 
 
A Masters research study conducted in Kenya, assessing the vaccine PV system using the 
IPAT tool reported that although Kenya had a PV system specifically for vaccines in place, 
there was no specific legislation guidelines and structural framework for this. Out of 100 %, 
indicators on law, policy and regulations scored 50%, structures, systems and stakeholder 




management and evaluation scoring 25% (Chepkemboi, 2016). These limitations result in poor 
coordination of vaccine PV activities and are part of the factors contributing to low ADR and 
AVR reporting.  
2.12.6. Pharmacovigilance in practice: lessons learned 
The PV indicators were used in a study conducted from July to Dec 2018, to assess the 
functionality and to identify the strengths and limitations of the national PV systems in four 
East African countries (Ethiopia, Kenya, Tanzania, Rwanda) (Barry, 2020). The study was 
conducted as part of the PROFORMA projects, which aims to strengthen the national 
pharmacovigilance infrastructure and post-marketing surveillance system involving mass 
drug administration and immunization programmes being deployed under public health 
programs in the selected East African countries. As a follow-up to the assessment, capacity-
building interventions to be carried out by the PROFORMA project. Below is a tabular 
presentation of the National Medicines Regulatory Authorities (NMRA) in each of the four 
countries as well as the year in which country joined the WHO PIDM and total number of 
ICSR’s submitted to VigiBase® since joining the PIDM to the time of assessment in 2018 
(Barry, 2020). 
Table 2-6: NRA name changes and year of joining WHO PIDM  (Barry, 2020) 







Tanzania Medicines and Medical Devices 
Authority (TMDA) 
Tanzania Food and Drugs Authority (TFDA) 1993 1,331 
Ethiopian Food and Drugs Authority 
(EFDA) 
Ethiopian Food, Medicine and Health Care 
Administration and Control Authority (FMHACA) 
2008 11,373 
Kenya Pharmacy and Poisons Board 
(PPB) 
Same 2010 30 
Rwanda Food and Drugs Authority 
(RFDA) 
Rwanda (Ministry of Health) 2013 1,899 
 
The East African Community (EAC) Harmonized Pharmacovigilance Indicators tool was 
used in this assessment. This tool was derived from the WHO pharmacovigilance indicators 
and the Indicator-Based Pharmacovigilance Assessment Tool (IPAT). 
 







Existence of a 


















Ethiopia 10 × ×   ×    
Kenya 5  × ×  × ª ×  
Rwanda 2 × × × × × × × × 
Tanzania 12  × ×  ×    
✓ present, X missing/not available, NMRA National Medicines Regulatory Authority, PPB Pharmacy and Poisons Board 





Table 2-8: Summary of data management structures within the national PV systems  (Barry, 2020) 











event reporting form 







and analysis of ADR 
reports 
Ethiopia   × ×  
Kenya   ×   
Rwanda  ª  × × × 
Tanzania      
✓ present, X missing/not available, ADR adverse drug reaction 
ª database was not in use 
 
 

















Ethiopia       ª 
Kenya    ×  ª ª 
Rwanda   × ×  ª  
Tanzania    ª  ª  
✓ present, X missing/not available, AEFI adverse events following immunization 
ª present in a separate form 
 
It was found that all four countries have policies and legal frameworks defined by laws and 
regulations and there are guidelines in place for the conduct of pharmacovigilance activities. 
All countries, excluding Rwanda have systems in place for the conduct of PV activities. All 
four national PV centres have not initiated any regulatory action based on local information 
regarding safety issues (Barry, 2020). Olsson and colleagues highlighted that the number of 
reports received from Africa are inadequate to identify significant safety issues (Olsson, et al., 
2015). African countries are therefore, encouraged to increase ADR reporting rates as 
information from other continents may not always be relevant for the African population. For 
a more efficient VigiBase® analysis, it is important for safety data from similar geographical, 
demographic, genetic and nutritional backgrounds to be available and this can only be 
achieved through ICSR’s received from national PV centres. Kenya and Tanzania have acted 
upon information received from the WHO or individual countries abroad, whereas, Ethiopia 
and Rwanda have not (Barry, 2020).  
Another common challenge at all four national PV centres is inadequate funding and human 
resources. Ethiopia and Rwanda both do not have a dedicated budget for PV activities. Kenya 
and Tanzania do have dedicated budgets; however, the budgets do not match the resource and 
workload requirements, therefore, an improvement is required (Barry, 2020).  
Although only Tanzania has adverse event reporting forms for the public, it is encouraging to 
see that Tanzania, Kenya and Ethiopia have communication plans in place, even if the 
communication plan in Kenya is not specifically for PV related matters. Only Ethiopia and 
Tanzania’s national PV centres have toll-free numbers. Ethiopia promotes the toll-free 




related to the safety of medicines across five television and radio stations, while Kenya also 
includes newspapers and roadshows (Barry, 2020).  
2.12.7. Pharmacovigilance Funding  
Historically, pharmacovigilance activities started as a voluntary initiative across different 
settings, with HCPs to address the growing concern around the risks of medicine use. The 
reason for spontaneous reporting being the primary method of PV widely used is that it can 
be done at a low cost. Cost estimates are illustrated in the PV toolkit (WHO Collaborating Centre 
Ghana, 2012). The costs associated with PV have been summarised in Table 2-10.  
 
Table 2-10: Example of budgetary items for a PV centre  (WHO Collaborating Centre Ghana, 2012) 
Fixed Costs Recurring Costs 
Infrastructure Salaries 
Equipment (Computers, software) Office costs (rent, electricity, etc.) 
Training (Baseline Induction) Stationery and other office supplies 
Research on pharmacovigilance Travel 
Website development and maintenance Training and Workshops 
 Communication (Advocacy and public 
sensitization using the media e.g., internet, 
radio, TV, and newspapers 
 
2.12.7.1. Source of PV funding: 
• Government (usually DoH) – structured budget allocated annually from fiscus 
• Regulatory Authority – fluctuating budget depending on other priorities 
• Fees charged to industry for PV services – revenues depend on activities 
• Donor funding – Donors generally do not fund national PV centres; however, they 
fund public health programmes. Primarily for the introduction of new medicines or 
vaccines in LMIC’s (e.g., WHO Global Vaccine Action Plan with Vaccine Safety 
Blueprint and Global Vaccine Safety Initiative [GVSI]). Funders for public health 
initiatives and related PV activities include Global Fund, UNITAID (through WHO), 
PEPFAR (HIV/AIDS), Bill and Melinda Gates Foundation (BMGF), GAVI 
(vaccines), USAID (SIAPS programme), EU (Horizon 2020, Monitoring Medicines 
Project) (Kovacs, 2017). 
 
A. Global Fund: 
Application to the global fund can be disease focused (e.g., HIV, TB, Malaria) or for general 
strengthening the health system (focusing on PV) or PV system implementation with the 
introduction of new medicines/vaccines. The application requires a description of PV 
activities already in place or planned as part of public health programmes (Xueref, 2013).  
B. Bill and Melinda Gates Foundation: 
The foundation hosted a series of international meetings throughout 2012 and afterwards 
published a report in 2014 titled “A report of the Safety and Surveillance Working Group”. 




between 2012-2015 and this was matched with an analysis of the PV capacity in of the 
countries where the products will be launched. The only African countries which had the 
highest capacity were Nigeria and Uganda. The BMGF then embarked on a predictable and 
sustainable funding model, where funding is shared among stakeholders (Donors, MAH, 
NMRA), but emphasis on local country ownership of the systems from the outset. Funding 
must be self-sustaining and long-term, and the system should not be product-specific, but 
rather allow for entry of other products with time. For this purpose, a trust fund was formed 
under the World Bank and technical support is sought from regional implementing partners 
and WHO with the use of indicator-based monitoring and evaluation (BMGF, 2013). 
 
2.12.7.2. Strategies to get funding: 
• Researchers must convince Government with research data that shows the burden of 
ADRs globally and locally  
• Apply for donor funding for public health programmes 
• Partnerships with Universities, healthcare facilities and WHO/collaboration centres 
• Publication of scientific literature on research conducted relating to PV 
 
2.13 Pharmacovigilance Developments in South Africa 
2.13.1 South African Pharmacovigilance Structures 
The Medicines and Related Substances Control Act 101 (Act 101) was promulgated in South 
Africa in 1965 (Govt, 2017). The Act mandated the establishment of the Medicines Control 
Council (MCC), currently called the South African Health Products Regulatory Authority 
(SAHPRA) and stipulates the standards by which medicines are to be regulated and 
monitored in South Africa. Regulation 40 of Act 101 stipulates that the holder/applicant of a 
certificate of registration for a medicine in terms of section 15 of the Act, or a holder of a 
licence in terms of section 22C(1)(b) must inform the Authority, in the manner and within the 
time frame as determined by the Authority, of any:  
 
• New or existing quality, safety or effectiveness concerns related to any medicine or 
scheduled substance, including but not limited to ADR, and risk management 
activities associated with the medicine (Govt, 2017). 
• A health care provider, veterinarian or any other person should inform the Authority, 
in the manner as determined by the Authority, of any suspected adverse drug 
reactions; or new or existing safety, quality or effectiveness concerns, occurring 
because of the use of any medicine or scheduled substance (Govt, 2017).  
 
In 1987 the MCC, in collaboration with the University of Cape Town, established the 
National Adverse Drug Event Monitoring Centre (NADEMC); a unit to collect and perform a 
causality assessment of ADRs received through spontaneous reporting. ADRs were then 
submitted from the NADEMC to the MCC. The ADRs were then reviewed by the PV 




status of medicines, including labelling changes or market withdrawal. The PV Advisory 
Committee consisted of a pharmacist and 6 external experts from various institutions. The 
small number of committee members and the fact that they are not full-time employed, 
created a limitation in the committee’s ability to perform robust causality assessments and 
signal detection. Committee members who were not full-time employed may also have had 
limited capacity to attend technical training and to stay abreast with latest international 
developments around Drug Safety and pharmacovigilance (SAHPRA, 2020).  
In 1992, South Africa became the first African country to gain membership into the WHO 
Programme for International Drug Monitoring. The Expanded Programme for Immunization 
(EPI) implemented a targeted spontaneous reporting (TSR) system in 1998, to collect adverse 
events following immunisation (AEFI). With the launch of the national antiretroviral (ARV) 
treatment programme in 2003, TSR systems were implemented at provincial level for the 
collection of ARV-related ADRs. TSR systems were expanded to include not only ARV’s but 
also TB-medicines in 2011, with the National Department of Health (NDoH) programmatic 
decentralised PV unit. As part of this initiative, provincial training was provided to HCPs and 
bulletins were published providing updates on national PV activities (Dheda, 2013). A 
concerning maternal and infant mortality rate in South Africa, resulting from HIV/AIDS 
(complicated by Tuberculosis and pneumonia), haemorrhage and hypertension led to the 
WHO 2013 recommendation of ARV treatment for pregnant women diagnosed with HIV 
during pregnancy being initiated immediately, regardless of CD4 cell count or clinical stage ( 
WHO, 2013). This recommendation led to the establishment of a pregnancy exposure registry 
and birth defects surveillance (PER/BDS) system the eThekwini District, KwaZulu-Natal 
(KZN) province (SA NDoH, 2015).  
 
Figure 2-10: Summary of PV activities in South Africa (Mehta, 2014) 
From the summary of the PV activities in South Africa (Figure 2-10), with growing access to 
medicines and vaccines, PV systems are evolving from passive to more active methods. 




passive spontaneous reporting to the NADEMC. Multiple efforts are undertaken; however, it 
appears that these are operated in parallel, which limits their effectiveness. This observation 
is in keeping with the August 2012 South Africa PV workshop, which resolved that there are 
multiple existing PV programmes and there is a need for coordination of all databases to feed 
into the national database (Mehta, 2014). There is a concern as to whether the reports collected 
through all the programmes in isolation end up making it into the WHO VigiBase® database. 
The same was acknowledged at the 2012 Africa Pharmacovigilance Meeting, where it was 
noted that the national database does not include data from all sources (Ouma, 2012). The focus 
area thus far appears to be on HIV and TB medicines, which is understandable as these are 
most widely used in this country. Attention also needs to include non-communicable diseases 
as well such as diabetes, hypertension, and cardiovascular medications as these are also 
widely used in the country. With the novel Covid-19 pandemic and resulting research into 
vaccine and treatment options, this further highlights the need to focus the safety of 
medicines across the board.  
In terms of the Act 101, the SAHPRA’s objectives are to provide for the monitoring, 
evaluation, regulation, investigation, inspection, registration, and control of medicines, 
scheduled substances, medical devices, radiation control, clinical trials, and related matters in 
the public interest (SAHPRA, 2020). To achieve its objectives, the SAHPRA must ensure that 
evidence of existing and new adverse events and reactions, interactions, and signals emerging 
from post-marketing surveillance and vigilance activities are investigated, monitored, 
analysed, and acted upon; and this is achieved through vigilance. ‘vigilance’ in relation to a 
medicine, medical device, means the continuous monitoring and evaluation of its safety, 
efficacy and performance profile and the management of any risk throughout its life cycle. 
Currently spontaneous reports can be sent to National Adverse Drug Event Monitoring 
Centre (Cape Town) or Pharmacovigilance Unit (SAHPRA). The PV teams at NADEMC and 
the SAHPRA PV unit then manually capture the ICSR into the WHO VigiFlow® system 
from which they are imported to the WHO VigiBase® database.  
In 2003, the MCC published guidelines for post-marketing ADR reporting; these have been 
updated numerous times with the latest version published by the SAHPRA in September 
2020 (SAHPRA, 2020). These guidelines place the obligation of ADR reporting squarely on the 
holder of the medicine certificate of registration (i.e., pharmaceutical company / marketing 
authorization). The guidelines stipulate that the company is to appoint a pharmacovigilance 
officer, who will serve as the main liaison with the NADEMC and the SAHPRA PV unit 
(SAHPRA, 2020). This is contrary to EMA and FDA regulations, which in addition, allow 
reporting by HCPs and consumers directly to the national PV centre. For reporting to include 
HCPs and consumers, online reporting is the most practical method. Currently in South 
Africa, only manual ADR reporting or CIOMS forms are available. ADR forms are available 
on the SAHPRA website or at their offices or at the back of the South African Medicines 
Formulary (SAMF). These can be completed in hard copy or electronically and submitted to 
the PV centre via email. The guidelines also stipulate those reports can also be submitted in 
the e2b format using an xml. file. In their survey conducted among HCPs (doctors, nurses, 
pharmacists, and pharmacist assistants) at a public sector hospital, Terblanche, and colleagues 
(Terblanche, 2017) found that the factors discouraging ADR reporting included not knowing how 
to report them (53.8%), lack of time (37.1%), additional workload (22.0%). Most of the 
respondents also reported that they had never received PV training (Mehta, 2014). Easy access to 




At minimum, the following information must be included in an individual ADR report 
/CIOMS form (SAHPRA, 2020): 
• An identifiable source (reporter) of the information. This should include the name or 
initials and address of the reporter and the reporter’s qualification (e.g., doctor, 
dentist, pharmacist, nurse, or lay person). 
• An identifiable patient. A patient may be identified by surname and forename(s) or 
initials of surname and forenames, or by a reference number, or by age or gender. 
• Suspected medicine(s); and 
• Suspected reaction(s) 
 
In latest version of the SAHPRA guidelines, the following items have been removed; 
however, ideally, the following relevant information must be included as much as possible to 
facilitate causality assessment. The initial analysis of the pilot National Department of Health 
(NDoH) programmatic decentralised TSR system revealed that 48% of the reports were 
unevaluable due to poor quality data (Dheda, 2013). As much as it is important to reduce the 
workload for reporters by defining the minimum reportable information, it is also important 
to collect as much information as possible for the data to be useful.  
 
• Treatment starts date and reaction onset date – temporal relation 
• Dose and dosing regimen 
• Indication 
• Concomitant medicines and comorbidities 
• Age and gender 
• Action taken – de-challenge/re-challenge and outcome 
• Other information that may be relevant 
• Discharge summaries, post-mortem reports, and relevant laboratory data  
 
The future of pharmacovigilance in South Africa is looking bright. In its Strategic Plan 2018-
19 to 2022-23, the SAHPRA has outlined plans to strengthen the existing vigilance 
framework. Among other things, the SAHPRA endeavours to develop Good Vigilance 
Practice, like those available for the EMA and FDA (SAHPRA, 2018). The SAHPRA board and 
leadership realizes the importance of communication in pharmacovigilance and thus plans to 
develop a framework for feedback and communication of vigilance-related matters to 
stakeholders. Considering the multiple decentralised PV programmes that have been 
implemented over the years in South Africa, there is a need to create linkages across all 
databases, to feed into the VigiFlow system (SAHPRA, 2018). Although these have been focusing 
on specific therapeutic areas (HIV, TB, malaria) and population groups (pregnant women, 
children), their contribution to policy decisions on treatment protocols are undoubted. For 
example, in 2012 the NDoH changed first-line ARV treatment in pregnant women from 
Nevirapine-based regimen to an Efavirenz-based one due to reported ADRs (Dheda, 2013).  
Additionally, the SAHPRA recognizes the need to strengthen the vigilance of 
complementary, veterinary medicines and medical devices with the improvement of 
regulatory framework. The strategic plan also mentions plans to move to online reporting 
ICSRs, replacing the current paper-based forms and to include HCPs as required ADR 
reporters (SAHPRA, 2018). The plan to include HCPs is not reflected on the SAHPRA guidelines 







The SAHPRA regulations require post-marketing ADR reporting up to six months after the 
expiry date of the last marketed batch (SAHPRA, 2020). Unlike the FDA and EMA, the 
SAHPRA does not charge pharmaceutical companies/license holders for the services 
provided by the PV unit and NADEMC, yet it has been established that the function of a 
national PV centre includes data entry into VigiFlow®, correspondence with reporters for 
queries ad feedback, causality assessment, signal detection as well as communication of 
signals and any other relevant information. National PV centres also need to work closely 
with other stakeholders locally and globally to learn and remain abreast with the latest 
developments. All these activities require funding both from industry and government. 
Medicines and Related Substances Amendment Act 72 of 2008, section 39 states that funds 
may be derived from sources including State funds received through the Department of 
Health; fees raised and interest on overdue fees; as well as money accruing to the RA from 
any other source (Govt, 2017). The WHO minimum requirements for a functional PV system 
emphasizes the need for guaranteed funding. A systematic and qualitative review of the PV 
systems in South Africa, India, and Uganda, reported that the key deficiencies in all three 
countries included lack of funding, poor coordination of activities, inadequate human 
resources and poor training for existing staff and HCPs. The study recommends that a PV 
specific budget must be allocated to address the reported deficiencies (Maigetter, 2015).  The fee-
based model for PV that has been introduced in the EU per Regulation 658/2014 of 15 May 
2015 in South Africa. However, it is important that the government also allocates dedicated 
funds for PV to ensure steady and sustainable support to PV in the country. Several public 
health programmes and clinical trials in South Africa are already funded by donors such as 
PEPFAR, Bill and Melinda Gates Foundation, etc. In the opinion of the author, it would, 
therefore, be fitting for the national PV centre, through the SAHPRA, to apply for donor 
funding from existing and other donors.  
2.13.3 Other studies on factors affecting ADR in reporting in South Africa 
Under-reporting of adverse drug reactions is a global concern and, although South Africa has 
shown an improvement over the years, reporting rates are still extremely low considering the 
time since South Africa became a member of the WHO PIDM in 1992. It is reported that 
since 1992, South Africa had submitted a total of 28, 609 reports into VigiBase® (Olsson, 2015). 
This amounts to approximately 27 reports per million inhabitants per year, compared to the 
expected 200 reports per million inhabitants as estimated by the WHO-UMC (SPS Program, 
2009).  
Several studies have been conducted across different sectors and HCPs in South Africa, to 
investigate the factors that contribute to low ADR reporting. Terblanche et al, Bogolubova et 
al, Gordhon and Padayachee as well as Joubert and Naidoo all found that most HCPs both in 
public and private hospitals believe that ADR reporting is important although they had 
previously not received PV training (Terblanche, 2017) (Bogolubova, 2018) (Joubert M, 2016) (Gordhon Y, 
2020).  Generally, the majority also agreed that they would report ADRs if they receive 
sufficient training, although in the study conducted by Gordhon and Padayachee in nurses, 
doctors, and pharmacists, 92% of the respondents noted that they believed that doctors should 
be responsible for reporting (Gordhon Y, 2020). Hanafi et al had a similar finding with 89% of 




(Hanafi, 2013). De Angelis et al. concluded that this lack of confidence seen in nurses is due to 
them not being fully aware of their role in ADR reporting (Angelis, 2016). On the other hand, an 
Australian study among doctors and nurses, found that both doctors and nurses (98.3%) were 
aware of their hospital’s PV system; however, nurses were more likely than doctors to know 
how to report (88.3% v 43.0%), and have reported previously (89.2% v 64.4%) (Evans, 2006 ).  
A study in several public health facilities in Tshwane Health District, Gauteng Province, 
among doctors, pharmacists and nurses found that 51.1% of all HCPs combined reported that 
their clinical knowledge is inadequate to equip them in identifying an ADR [83]. 
Approximately half of the respondents across all these studies reported that some of the 
barriers to reporting include lack of knowledge on how and where to report. Factors that 
discourage ADR reporting are lack of time, concerns that the ADR is wrong and lack of 
feedback from the national PV centre after reporting (Terblanche, 2017) (Bogolubova, 2018) (Joubert M, 
2016) (Gordhon Y, 2020). In the study conducted in 2016 and 2017 by Gordhon and Padayachee, 
pharmacists were the HCPs who were the most aware of how to report ADRs at 83%, 
compared to doctors and nurses 54% each group (Gordhon Y, 2020). It is encouraging to see a 
more recent study, conducted by Haines et al.in 2019, indicating higher mean knowledge 
scores at 91.4% for pharmacists, 82.8% for doctors and 84.0% for nurses. The study also 
reported that 92% of respondents believe that they should try to prevent ADRs when 
prescribing and dispensing medicines (Haines, 2020). It is evident that studies conducted in 
South Africa in recent years, relating to pharmacovigilance practices, has a positive impact 
on HCPs, by creating an awareness about the concept of PV. This does not; however, replace 
the impact that purposeful PV and ADR training can have. This only supplements by making 
HCPs aware of their obligation. To indicate this point, the same study reports that only 12% 
of the respondents knew where to find ADR forms within their facilities, although they are 
aware of the requirement to report (Haines, 2020). 
This is consistent with Bogolubova et al, who found that Pharmacists were more likely to 
have received training (p = 0.040685) (Bogolubova, 2018). In the study conducted by Joubert and 
Naidoo, 44.1% participants indicated that they had previously reported an ADR (Joubert M, 
2016). This is a relatively high reporting rate compared to other studies such as Gordhon and 
Padayachee with 17% and Bogolubova et al.at 18.9%. Regarding the relationship between 
work experience and likelihood of reporting, Gordhon and Padayachee and Bogolubova et al. 
found that respondents with less experience had little knowledge (23% of pharmacist and 
doctor interns) on ADR reporting than senior level HCPs (Bogolubova, 2018) (Gordhon Y, 2020). This 
is consistent with findings from a similar, older study conducted in Australia, where senior 
nurses reported to be more involved in PV activities than their junior counterparts (Evans, 2006 
).  
2.13.4. Pharmacovigilance in South Africa during the Covid-19 pandemic 
On 08 Feb 2021, the South African government announced the suspension of AstraZeneca 
vaccine roll-out, after receiving results of reduced efficacy of the vaccine against the 
circulating Covid-19 variant (B.1.351). By 17 Feb 2021, in collaboration with the South 
African Medical Research Council (SAMRC) and other stakeholders, the NDOH, initiated 
roll-out of the Johnson & Johnson vaccine (Ad26.COV2.S), aiming to vaccinate 500 000 
healthcare workers across South African. At that point, no regulatory authority had granted 
the J&J vaccine a marketing authorisation; it could hence not be procured for use in South 
Africa under a Section 21 application as per the Regulations to Act 101. An alternative option 




meaning “together” in Isizulu and Xhosa). At the time, the development of the functionality 
to report AEFIs into the EVDS was still underway and the SAHPRA Vigilance Unit was still 
developing the framework through which AEFI data will be collected in a suitable format to 
allow for timeous exporting to VigiBase®.  
The SAHPRA guidelines for safety reporting during clinical trials (SAHPRA, 2019), mandate 
safety reporting by the sponsor for unregistered medicines. To comply to the guidelines, the 
Sisonke study Protocol and Safety Team (PSRT) developed an online ADR reporting tool 
(Sisonke PSRT, 2021) using the REDCap® system, based on the paper-based NDoH AEFI 
case report form (NDoH, 2021) (CRF), which was updated on 28 Jan 2021 to include Covid-
19 vaccines. Figure 2.11 below displays a summary of the flow of AEFI reported data during 
the conduct of the Sisonke vaccine roll-out, from the study participant to the WHO 
VigiBase® database (Sisonke PSRT, 2021).  
The Sisonke project provides a great opportunity to serve a pilot initiative for the South 
African NDoH to identify challenges, lessons learned and good practices that can be utilised 
in the national roll-out of registered Covid-19 vaccines after completion of the Sisonke study  
(SAMRC, 2021). By 26 the end of the Sisonke study on 16 May 2021, over 10 000 AEFIs had 
been reported into the REDCap® system.  
On 22 April 2021, SAHPRA announced the launch of the Med Safety App, which is targeted 
at HCPs and patients, for reporting ADRs. This launch was just in time for the national 
Covid-19 vaccine roll-out which started on 17 May 2021. 
 






The reviewed literature provides evidence that ADRs pose a significant global public health 
threat. With further understanding of the shortfalls leading to Drug Safety issues, the scope of 
PV has evolved to include other types of medicines as well as issues of quality and 
falsification. The WHO, through the Uppsala Monitoring Centre, has developed several 
pharmacovigilance structures over the years and many countries have started actively 
participating in PV activities. The African continent remains behind with ADR reporting to 
the WHO VigiBase® database; however, with the support of the UMC together with 
collaborating partners, gradual improvements can be seen. Researchers are becoming more 
aware of the risks that come with a wider range of medicines becoming increasingly available 
in LMIC’s. The public health and cost implications are not yet well established in resource-
limited countries; however, the need for research in these areas is becoming increasingly 
apparent. Researchers need to produce evidence in terms of research data, to convince 
politicians of the importance of pharmacovigilance. It is critical for governments to 
implement legislative frameworks and provide funding for PV systems. National PV centres 
need to get to a point where they are well capacitated, HCPs need to be well trained and 
reporting mechanisms need to be functional, to allow for local and regional signal detection 
to occur. National Regulatory Authorities in Africa must get to a point where regulatory 
decisions (e.g., market withdrawal, package insert updates, etc.) are made based on local 
ADR reports instead of only relying on international agencies such as the FDA and EMA.  
A systemic review published by Onakpoya and colleagues in 2015 identified 407 medicines 
withdrawn from the market globally between 1957 and 2011. Of the 407, death was 
documented as the reason for withdrawal in 95 medicines. Only 27% of the medicines were 
withdrawn worldwide, whereas 40% were withdrawn in in more than one country. 
Surprisingly, 16 medicines remained on the market despite being withdrawn in at least two 
other countries. The longest interval between the first death reported and withdrawal of the 
attributed medicine was 56 years; this timeframe has not improved in over 60 years (Onakpoya, 
2016).  
The current Covid-19 pandemic has undoubtedly amplified the urgent need for robust PV 
systems to be developed. Funding must be directed towards post-marketing surveillance of 
vaccines and medicines which are being developed much quicker than the typical drug 
development processes. HCPs must be trained on PV requirements in time for the rolling out 
of SARS-Cov-2 vaccines and treatments, to notice any adverse effects that are highly likely 
to be missed during rapid clinical trials. The current pandemic has also created an opportunity 
for agility in addressing the crisis. Public: private partnerships have been strengthened 
between pharmaceutical companies, NGO’s, Academia, and government institutions; 
facilitating real-time data analysis and information sharing. The same spirit of agility can be 







  Chapter 3 
Research Methodology 
3.1 Introduction 
This chapter discusses the research methodological considerations and choices that have 
shaped the conduct of this study. The chapter explores the development of the survey that 
was used, considerations made during study sample selection as well as other aspects such as 
sample error and bias as well as data reliability and validity. Ethical aspects and methods of 
data analysis are also outlined.  
3.2 Research design 
This was a knowledge, attitudes, and practices (KAP) study design. A quantitative research 
method was adopted and involved the use of a questionnaire as a data collection tool. The 
study participants consisted of medical doctors who are affiliated with the South African 
Medical Association (SAMA) and a combination of medical doctors and pharmacists 


























Figure 3-1: Flow Diagram of study conduct  
1. Develop Research Question and Study Title 
3. SU-HREC 
 
2. Protocol & Questionnaire 
development 
4. Permission from SAMA & 
SACRA to distribute survey  
 




7. Thesis write-up by chapter 
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3.3 Questionnaire development 
The survey used in this study consisted of a brief description of the study, an informed 
consent and confidentiality statement, with the option to agree or decline participation, 
followed by the questionnaire. The informed consent section (Annexure A) of the survey 
stipulated the purpose of the research study, the size, benefits of participation, potential risks, 
withdrawal of participation, protection of data privacy and contact details of the researcher 
and supervisors. The questionnaire contained six (6) demographics-related questions, eight 
(8) questions to establish knowledge, five (5) attitude-related and five (5) practices-related 
questions (Annexure B).  
3.3.1. Content and face validity 
Pilot testing of questionnaires is essential in checking whether individuals from the same 
sample group as those who will be administered the questionnaire understand the contents 
of the questionnaire in the manner intended by the researcher (Taherdoost, 2016). Pilot testing 
is also useful in detecting layout and presentation problems that could contribute to the 
target group misunderstanding statements or questions and/ or being reluctant to complete 
the questionnaire. Pilot studies thus play an important role in proactively detecting and 
correcting errors and ambiguities in questionnaires, as described by Taherdoost (Taherdoost, 
2016), Laxton (Laxton, 2004) and others, which could adversely influence the quality of data 
that will be collected.  
To ensure that the questions would be correctly interpreted by the target population, the 
questionnaire was validated by a combination of ten selected medical doctors and 
pharmacists who fit the description of the target population. The participants of the pilot 
study were assured of the anonymity and confidentiality of their feedback and 
participation in the pilot study. Participants were asked how they interpreted the various 
questions and sections in the questionnaire, whether the questionnaire was clear and easy 
to understand, and whether the presentation and format were user-friendly and 
encouraged completion. Patients were also asked to comment on the appropriateness of 
questions, and whether they thought that additional questions should be included. The 
questionnaire was amended based on feedback received from the pilot study prior to 
initial ethics committee submission. In teams of ease of completing the survey, it was 
estimated that the study survey would take approximately 5-10 minutes to complete, and 
this was found to be acceptable for surveys typically used in KAP studies. 
3.3.2. Enhancing reliability of data 
Reliability refers to the consistency of a measure (whether the results can be reproduced 
under the same conditions) (Roberta Heale, 2015). To enhance the reliability of study data, 
sampling error and sampling bias must be minimised. Data may be highly precise and 
consistently reflect a certain response but may be inaccurate if the data-gathering tool has 
been incorrectly designed, as described (Taherdoost, 2016) (Laxton, 2004). To enhance the 
reliability of the data, a large sample size of 384 participants was selected and the 
questionnaire was distributed to more than 7,000 potential participants. The study was 
tailored for the target population which consists of medical doctors and pharmacists 
working in South Africa and thus the questions included in the questionnaire were 
relevant for the target group. To ensure this, the questionnaire was adapted from similar 




knowledge, attitudes, and practices of pharmacovigilance in different settings (Bharadwaj, 
2016) (Kumari, 2015) (Reddy, 2014).  
The questionnaire was distributed to medical doctors and pharmacists who work at public 
or private healthcare facilities and at all professional levels. This minimised sampling bias 
and thus improved reliability of the study data.  
3.3.3. Enhancing validity of data 
Although reliability contributes to data integrity, it does not necessarily always lead to 
validity (Roberta Heale, 2015). Validity reflects the accuracy of data obtained from a sample 
and can be classified into two types (Laxton, 2004): 
(i) Internal validity, which refers to the accuracy of a specific study’s findings 
and the clear illustration of cause-and-effect relationships (Laxton, 2004). 
Concerns related to internal validity could include whether each 
respondent had only completed one questionnaire and whether the survey 
was conducted in a manner that did not influence respondents to respond 
in a particular way.  
(ii) External validity reflects the extent to which the findings of a study can be 
extrapolated or applied to other situations (Laxton, 2004). External validity 
could be undermined by the nature of study participants, the time-period or 
place at which the study is conducted, which all have the potential to make 
the data obtained unrepresentative of the target population. 
 
Validity in this current study was improved by minimizing bias, with the increase of 
sample size and diverse population groups. Distributing the questionnaire in the form 
of an online survey enabled the distribution to a wide number of potential participants, 
thereby increasing the response rate as well.  
3.4 Sampling 
3.4.1. Selection of target population and sample size 
The healthcare professionals who typically assess and report ADRs in South Africa are 
medical doctors and pharmacists. Although nurses are likely the first care givers in a 
position to collect initial reports of new symptoms from hospitalized patients, the treating 
doctor, as the prescriber, remains ultimately responsible for ensuring the accuracy of such 
information prior to submitting a potential ADR report.  
Medical and pharmaceutical associations were approached to distribute the survey via 
email to their members; these include the South African Association of Hospital and 
Institutional Pharmacists (SAAHIP), the South African Association of Pharmacists in 
Industry (SAAPI), the Independent Community Pharmacy Association (ICPA), the South 
African Medical Association (SAMA) and the South African Clinical Research 




both associations have representation of HCPs working in private as well as public 
healthcare sectors across South Africa.  
3.4.2. Determining sample size 
A previous study conducted in a Ghana, in medical doctors across the country, similar to 
the current study, estimated the underlying rate of reporting of ADR to be about 59% 
respectively (Sabblah, 2014). OpenEpi®, a web-based, operating system-independent series 
of programs for use in epidemiology, biostatistics, public health, and medicine was used 
to calculate the sample size. A sample size of 334 healthcare professionals was 
established to be appropriate to estimate the ADR reporting rate, if ADR reporting rate is 
estimated at 59% with a desired precision of +-5.5%. The sample size was inflated by 
15% (from 334 to 38 4) to account for non-response.  
3.4.3. Sampling error and bias 
The potential for sampling bias was reduced by including all possible sub-groups of the 
sample population. Participants of all genders, professional levels, racial groups, and 
working in all categories of healthcare facilities in South Africa, having achieved an 
undergraduate qualification from any university in South Africa or abroad, were provided 
with an opportunity to participate in the study, on provision that they were SAMA and/or 
SACRA members. The size and diversity of the sample population also had a positive 
impact on the reliability and validity of the study data.  
3.5 Ethical clearance procedures 
Initial ethics approval was received from Stellenbosch Health Research Ethics Committee on 
11 Feb 2019 [HREC Ref # S18/10/231].  The initial protocol planned to conduct the study at 
all nine (9) Academic Hospitals in South Africa. Additional ethical clearance was sought 
from the Provincial Departments of Health (DoH) in all nine (9) provinces as well as from the 
Chief Operating Officer (CEO) or Superintendent from each Academic Hospital. After the 
declaration of a national lockdown, caused by the global Covid-19 pandemic in March 2020, 
the protocol was updated to change the format of the questionnaires from hard copy 
questionnaires delivered to the target facilities, to an online survey. Final SU-HREC approval 
of the amended protocol was obtained on 09 Jun 2020.  
Data confidentiality was maintained by not collecting participant identifiers. In the 
consenting phase of the survey, participants were informed that the purpose of this study is a 
component of the researcher’s master’s in science (MSc) degree and that the study was 
conducted under ethical approval by SU-HREC. Participants were given an option to decline 
participation without any explanation and consequences.  No coercion was used, no 
incentives were provided, and no reimbursements were offered to participation. 
3.6 Study conduct 
The survey was created in the SurveyMonkey® online survey system. The survey was shared 
with the relevant parties at SAMA and SACRA in the form of a Uniform Resource Locator 
(URL) link for distribution to their respective members. Data collection occurred over a 




3.7 Data analysis and reporting 
Data was downloaded from the SurveyMonkey® system in Microsoft Excel 2016 ™ format 
and manually coded. The raw dataset was cleaned, by grouping universities where 
respondents achieved their undergraduate qualifications into “local, low-to-middle income 
and European” and by categorising knowledge scored into “good, average, and low”. The 
data was then coded with numerical values. Once coded, descriptive data analysis was 
performed using IBM SPSS® Statistics version 27.  
Categorical variables were summarised as count (percent) and presented graphically as bar 
graphs. To determine factors associated with ADR reporting, a binomial regression was 
performed. Due to the outcome of ADR reporting being common (>50%) the appropriate 
measure of association was risk ratio, and this was estimated using a multivariate binomial 
regression model (Mancl, 2013). A univariate binomial regression was used to confirm if each 
variable is related to ADR reporting (Smith, 2018). A cut of p=value of p ˂ 0.1 was used to 
select variables to be included in the multivariate binomial regression model. This cut off 
point was selected to remain conservative in order not to exclude any variables early, that 
could be significant in the multivariate binomial regression model after adjusting for 
confounding. Such a cut-off is a standard and typically used when aiming to remain 
conservative.  Although the cut-off p-value was applied, some variables with p > 0.1 were 
also included if they are known to have a potential association with ADR reporting. in the 
multivariate binomial regression model, a p-value of p ˂ 0.05 was considered statistically 





CHAPTER 4  
Data analysis and results 
4.1 Introduction  
This chapter presents the results obtained from this study. Most of the results are presented in 
the form of frequencies and appear in either tabular or graphic form. Associations among 
variables were tested using a binomial regression model. Pearson chi-squared tests were 
performed to analyse the association between the knowledge category and the baseline 
characteristics; however, none of the results were significant; therefore, the data was not 
shown. 
4.2 Data collection process  
Over 7,000 surveys were emailed to members the South African Medical Association 
(SAMA) and the South African Clinical Research Association (SACRA), respectively. From 
these, 325 responses were received within a period of five (5) months, providing for a sample 
response rate of 85%. 
Table 4-1: Summary of data collection process 









4.3 Demographics  
The majority (164; 50.5%) of the respondents were male, whereas (161; 49.5%) were female, 
with a mean age of 48 years from 324 respondents who specified their age. The highest 
proportion of the respondents (157; 48.3%) were employed at private healthcare facilities, 
followed by public facilities (120; 36.9%), private-public facilities (20; 6.2%) and clinical 
research sites (16; 4.9%). A small portion of respondents (12; 3.7%) did not specify the type 
of healthcare facilities where they worked.  
The highest number (137; 42.2%) respondents consult less than 14 patients a day, followed 
by those who consult 15-19 patients (69; 21.2%), 20-25 (47; 14.5%), more than 35 patients 
(30; 9.2%). Those who consulted 25-35 patients a day ranged from 16-21 (4.9-6.5%). Some 
respondents did not specify the number of patients they consult per day (5; 1.5%).  
Most of the respondents were medical doctors (298; 91.7%), across several professional 




officers (126; 38.8%) and medical specialists (133; 40.9%). The total number of pharmacists 
were (24; 7.4%). Three (3; 0.9%) respondents did not indicate their profession.  Most 
respondents achieved their undergraduate qualifications at South African universities (298; 
91.7%).  Those who graduated from European universities were (12; 3.7%). Universities 
within low-to-middle income countries (LMIC’s) were grouped to exclude South African 
universities. Like those who graduated at European universities, a low (10; 3.1%) of 
respondents had graduated from LMIC universities. A small number (5; 1.5%) of respondents 
did not specify the university where they achieved their undergraduate qualifications.  
Table 4-2: Frequency distributions of demographic characteristics (N = 325) 
Demographic Characteristic Summary 
Gender, n (%)  
  Male 164 (50.5%) 
  Female 161 (49.5%) 
Age (n) 324 
Health facility, n (%) 
  Public  120 (36.9%) 
  Private 157 (48.3%) 
  Private and Public 20 (6.2%) 
  Research Site 16 (4.9%) 
  Not specified (NS) 12 (3.7%) 
Number of patients served per day n (%) 
  < 14 137 (42.2%) 
  15-19 69 (21.2%) 
  20-24 47 (14.5%) 
  25-29 21 (6.5%) 
  30-34 16 (4.9%) 
  > 35 30 (9.2%) 
 Not specified (NS) 5 (1.5%) 
Professional level, n (%) 
  Medical Intern  12 (3.7%) 
  General Practitioner 27 (8.3%) 
  Medical Officer 126 (38.8%) 
  Pharmacist 13 (4.0%) 
  Senior Pharmacist 11 (3.4%) 
  Medical Specialist 133 (40.9%) 
  Not specified (NS) 3 (0.9%) 
University of graduation, n (%) 
  Local University 298 (91.7%) 
  European Union University 12 (3.7%) 
  Low to Middle Income Country (LMIC) 
University, excluding South African Universities 
10 (3.1%) 






Table 4-3: Breakdown of number of patients seen per day by facility type 
Characteristic Facility 
Number of patients 











Site n (%) 
(n=16) 
NS n (%) 
(n=12) 
  < 14 47 (39.2%) 64 (40.8%) 9 (45%) 12 (75%) 5 (41.7%) 
  15-19 17 (14.2%) 42 (26.8%) 5 (25%) 1 (6.25%) 3 (25%) 
  20-24 23 (19.2%) 19 (12.1%) 5 (25%) 1 (6.25%) 0 
  25-29 9 (7.5%) 10 (6.4%) 0 1 (6.25%) 0 
  30-34 6 (5%) 10 (6.4%) 0 0 1 (8.3%) 
  > 35 16 (13.3%) 10 (6.4%) 1 (5%) 1 (6.25%) 2 (16.7%) 
 Not specified (NS) 2 (1.7%) 2 (1.3%) 0 0 1 (8.3%) 
 
Most respondents who consulted less than 14 patients a day were employed at clinical 
research sites (12; 75%).  There was a small difference in the proportion of healthcare 
practitioners (HCPs) consulting less than 14 patients a day, among those working at private, 
public or combination private-public facilities. Among HCPs consulting >35 patients a day, a 
slightly higher proportion (16; 13.3%) worked at public compared to those who worked at 
private healthcare facilities (10; 6.4%), respectively.  
4.4 Knowledge 
It was noted during data cleaning that knowledge question no. 7 (what document is used 
when for ADR reporting in South Africa?) was omitted from the survey erroneously. The 
knowledge scores ranged between 2-9, with a mean of 6.25. The good category was allocated 
to a score of 8-10, average was a score of 5-7 and poor was ≤4.  Most of the respondents 
scored average for knowledge (252; 77.5%), followed by good knowledge (45; 13.8%) and 
poor knowledge at (28; 8.6%). Most of the study participants (310; 95.4%) understood and 
knew the purpose of pharmacovigilance (PV).  
Table 4-4: Summary of knowledge categories 
Knowledge Category Summary n (%) 
 Good (8-10)  45 (13.8) 
 Average (5-7) 252 (77.5) 






Table 4-5: Knowledge-related questions and scores 
Knowledge Question Correct 
response, n (%) 
1. Select a definition of pharmacovigilance  90 (27.7%) 
2. The most important purpose of pharmacovigilance 278 (85.5%) 
3. Is it your professional obligation to report ADRs? 310 (95.4%) 
4. Where is the pharmacovigilance unit situated in South Africa? 189 (58.2%) 
5. What does NADEMC stand for? 232 (71.4%) 
6. What is the name of the international centre for ADR monitoring? 88 (27.1%) 
8a. Tick all the applicable minimum information required when reporting an 
ADR: An identifiable source (reporter) of the information. 
285 (87.7%) 
8b. Tick all the applicable minimum information required when reporting an 
ADR: An identifiable patient. 
245 (75.4%) 
8c. Tick all the applicable minimum information required when reporting an 
ADR: Suspected medicine(s). 
314 (96.6%) 
8d. Tick all the applicable minimum information required when reporting an 
ADR: Patient home address. 
244 (75.1%) 
 
Although very few respondents selected the correct definition for PV (90; 27.7%) and 
provided the correct name of the international centre for ADR monitoring (88; 27.1%), more 
respondents were familiar with the NADEMC. Over eighty percent (278; 85.5%) knew what 
the purpose of PV is and the highest proportion (310; 95.4%) agreed that ADR reporting was 
their professional obligation. Most of the participants were aware of the minimum 
information required when reporting a suspected ADR, ranging from 244-314 (75.1 – 
96.6%).  
 
Table 4-6: Background characteristics for knowledge 
Characteristic Knowledge, n (%) 
Poor (n=28) Average 
(n=252) 
Good (n=45) 
University of graduation, n (%) 
  Local university 28 (100%) 228 (90.5%) 42 (93.3%) 
  European Union (EU) 
University 
0 11 (4.4%) 1 (2.2%) 
  Low to Middle Income Country 
(LMIC) university 
0 9 (3.6%) 1 (2.2%) 
 Not specified (NS) 0 4 (1.6%) 1 (2.2%) 
 
Pearson chi-squared tests were performed to analyse the association between the knowledge 
category and the baseline characteristics summarised in table 4.2 was performed. None of the 
results were significant (data not shown). None (0; 0%) of the respondents who achieved 
their undergraduate qualifications at European and / or LMIC universities had poor 
knowledge. Poor knowledge occurred most frequently with respondents who qualified at 





Most respondents (320; 98.5%) agreed that reporting of adverse drug reactions is necessary. 
Above eighty percent (287; 88.3%) of the respondents admitted that they are concerned about 
the risks associated with medicines. Over half (193; 59.4%) of the respondents reported that 
they do have time to report suspected ADRs. A high proportion (231; 71.1%) of respondents 
admitted that it may be difficult to accurately detect whether an adverse drug reaction has 
occurred. Most of the respondents (269; 82.8%) thought that awareness regarding 
pharmacovigilance in their professional environment is inadequate.  
Table 4-7: Attitudes-related questions and scores 
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2 Do you have any concern about the risk(s) associated with 











4 Do you think it may be difficult to accurately detect 






5 Do you think there’s adequate awareness regarding 









Figure 4-1: Background characteristics of those who have time for ADR reporting 
From the (193; 59.4%) respondents who reported that they have enough time for ADR 
reporting, a slightly higher proportion were females (101; 52.3%). Of the 193 respondents, 
most are working at private healthcare facilities (91; 47.2%), closely followed by those 
working at public healthcare facilities (69; 35.8%). Those who consult less than 14 patients a 
































Do you think you have time to report suspected ADRs? 




time for ADR reporting, (75; 38.9%) were medical specialists, and (76; 33.4%) were medical 
officers, (123; 63.7%) had never received training on ADR reporting and (158; 81.9%) of 







Figure 4-2: Knowledge and training breakdown of those who noted that it was difficult to identify ADRs  
From the (230; 71%) respondents who agreed that it is difficult to detect whether an adverse 
drug reaction has occurred, the majority (160; 69.6%) had never received ADR reporting 
training, yet a high proportion of them (178; 77.4%) were found to have an average 
knowledge level.  
4.6 Practices 
Most of the respondents (266; 81.8%) have previously encountered an ADR in a patient. 
More than sixty percent (206; 63.4%) have seen an ADR reporting form before and (172; 
52.9%) have previously reported an ADR. Of the (152; 46.8%) who have not previously 
reported an ADR, (65; 20.0%) responded that they were not aware of the reporting procedure, 
(31; 9.5%) mentioned that the ADR reporting form was not available in the facilities of their 
employment, (26; 8.0%) have never been able to identify an ADR and (25; 7.7%) did not 
know that they were supposed to report ADRs. An extremely low (91; 28%) had been trained 
on ADR reporting previously and (229; 70.5%) had not been trained on ADR reporting 



























 Good  Average  Poor  Yes  No
Series1 14.30% 77.40% 8.30% 28.70% 69.60%
Do you think it may be difficult to detect 




Table 4-8: Practices-related questions and scores 









1. Have you ever encountered an adverse drug reaction in 




















4a If your answer to the above question was “no”, select 
the most appropriate reason(s) below:  
The reporting form was not available 
0 0 0 31 
(9.5%) 
4b If your answer to the above question was “no”, select 
the most appropriate reason(s) below:  
I have never been able to identify an adverse drug 
reaction 
0 0 0 26 
(8.0%) 
4c If your answer to the above question was “no”, select 
the most appropriate reason(s) below:  
I am/was unaware of the reporting procedure 
0 0 0 65 
(20.0%) 
4d If your answer to the above question was “no”, select 
the most appropriate reason(s) below:  
I did not know I was supposed to report 
0 0 0 25 
(7.7%) 
5. Have you ever been trained on how to report suspected 














































Of those respondents contributing to ADR reporting (172; 52.9%), a slightly higher 
proportion were females (96; 55.8%), work at private healthcare facilities (80; 46.5%) and 
consult less than 14 patients a day (80; 46.5%) respectively. Most (83; 48.3%) were medical 
specialists, followed by medical officers (61; 35.5%) and the majority (159; 92.4%) achieved 
their undergraduate qualifications at local South African universities. 
Table 4-9: Factors associated with ADR Reporting – Multivariate binomial regression. 
Baseline 
Characteristics 



















Gender, n (%)  
 Male  1 (Ref)   1 (Ref)   
 Female 1.29 0.02 1.05   1.59 1.26 0.001 1.10    1.44 
Professional level, n (%) 
 Medical Intern 1 (Ref)   1 (Ref)   
  General 
Practitioner 
1.48 0.48 .49   4.43 1.91 0.22 .68    5.35 
  Medical officer 1.94 0.19 .71     5.25 2.29 0.09 .88    5.95 
  Pharmacist 3.08 0.03 1.10    8.57 2.84 0.03 1.10    7.29 
  Senior Pharmacist 1.82 0.32 .56    5.88 1.50 0.49 .47    4.81 
  Medical Specialist 2.52 0.07 935    6.76 3.16 0.02 1.23    8.13 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Training, n (%) 
 No 1 (Ref)   1 (Ref)   
 Yes 1.78  <0.001 1.48   2.14 1.84  <0.001 1.57    2.15 
Knowledge Category, n (%) 
 Poor 1 (Ref)   1 (Ref)   
 Average 1.34 0.22 .97    2.70 1.08 <0.001 1.08    1.08 
 Good 1.62 0.07 .83    2.16 1.04 <0.001 1.04    1.04 
 
The prevalence of ADR reporting amongst the respondent was found to be common at 
52.9%. The appropriate regression approach to estimate the risk ratio of ADR reporting was a 
binomial regression model. A univariate binomial regression was initially performed to 
confirm which individual characteristics could be included in the multivariate binomial 
regression model. A significant probability of p = 0.1 was used as a cut-off point to select 
variables to be included in the multivariate regression model. This is a standard cut-off point 
commonly used in descriptive statistics, and it is used to remail conservative, thus avoiding 
exclusion of variables which could become significant when included into the multivariate 
regression model.  Variables which are known, through literature, to have a possible 
association with ADR reporting were included with p > 0.1 to ensure that they were included 
in case are significant when included in the multivariate binomial model, when adjusting for 
confounding. The variables selected were gender, professional level, ADR training, and level 




from the multivariate regression model due to p-values which were far greater than the cut off 
pint of p = 0.1. In the multivariate binomial regression, a p-value of p ˂ 0.05 was considered 
statistically significant. 
 The multivariate regression results showed that females were 26% (RR = 1.26) more likely 
to report ADRs than males (p ˂ 0.001). Medical specialists were more than three times (RR = 
3.16) more likely to report ADRs than their colleagues from other professional levels (p ˂ 
0.017). Across the different professions, the likelihood of pharmacists to report ADRs was 
more than double (RR = 2.84) compared to medical interns (p ˂ 0.030). Those who received 
training on ADR reporting were almost more than twice likely (RR = 1.84) to participate in 
ADR reporting than those who did not receive any training (p ˂ 0.001). Respondents with 
average knowledge on PV were 8% more likely (RR = 1.08), and those with good knowledge 







Figure 4-4: Type of facility breakdown of those who noted that the reporting form was not available 
Respondents who noted that ADR reporting forms are not available in their workplace were 
equally distributed between private-public healthcare facilities (14; 45.2%). None (0; 0%) of 
the respondents working at clinical research sites and a small portion (2; 6.5%) of those 
working at private-public healthcare facilities noted that the ADR reporting form was not 






















Figure 4-5: Professional level characteristics of those who answered that they were not aware of the reporting procedure 
Of the (65; 20%) who responded that they were not aware of the ADR reporting procedure, 
(28; 43.1%) were medical officers and (21; 32.3%) were medical specialists. None (0; %) of 
the pharmacists reported that they were not aware of the ADR reporting procedure.  
 
 
Figure 4-6: Background characteristics of those who have received training on ADR reporting.  
A slightly higher proportion of females (51; 56%) than males (40; 44%) had previously 
received training on ADR reporting. A small difference was noted between those working in 
private (38; 41.8%) and public (35; 38.5%) healthcare facilities. Most consulted less than 14 


































































higher proportion than those who serve between 25 to 34 patients a day (ranging from 4.4 – 
5.5%). There was an equal distribution (31; 34.1%) of medical officers and specialists who 
had previously received training on ADR reporting. None (0; 0%) of the respondents who 
qualified at European universities had received ADR reporting training previously. Of the 
respondents who were previously trained on ADR reporting, (4; 4.4%) had poor knowledge, 
(17;18.3%) had good knowledge (70; 77%) had average knowledge.  
4.7 Suggestions 
The method that could potentially improve ADR reporting in South Africa selected by most 
of the respondents (266; 81.8%), was the inclusion of PV training to the undergraduate 
curricula at universities. More than seventy percent (235; 72.3%) of respondents agreed that 
implementation of on-line or telephonic ADR reporting could potentially increase reporting 
rates. Other suggestions included continuous and refresher training (226; 69.5%), and 
frequent communication and feedback from national PV centres (220; 67.7%). Only (45; 
13.8%) of the respondents suggested remuneration for ADR reporting.  
 
Table 4-10: Suggestions from study participants on promoting PV 
# Suggestions N (%) 
1 Include Pharmacovigilance training to the undergraduate curricula at 
Universities. 
266 (81.8%) 
2 Provide continuous & refresher training. 226 (69.5%) 
3 Increase awareness on ADR reporting of patients, prescribers, and dispensers by 
the relevant Authorities at a National level. 
171 (52.6%) 
4 Implement a pharmacovigilance centre within each hospital. 159 (48.9%) 
5 Provide frequent communication & feedback from pharmacovigilance centres 
with updates on the benefit-risk profiles of drugs resulting from ADR reporting 
efforts.  
220 (67.7%) 
6 Have an ADR specialist in each hospital department? 50 (15.4%) 
7 Implement on-line or telephonic reporting.  235 (72.3%) 
8 Collaboration among all healthcare professionals (Doctors, Pharmacists, Nurses, 
etc.) is required in the reporting process, i.e., completing the reporting forms.  
194 (59.7%) 
9 Implement departmental meetings to discuss potential ADRs. 111 (34.2%) 
10 Implement remuneration for each reported ADR case.  45 (13.8%) 
 
4.8 Additional explorative associations 
1. An analysis of the following additional explorative associations, as stipulated in the 
study protocol (Methods Section 5.4.2, page 18 and 19) was performed; however, 
none of them were significant (data not shown).  
2. If professional level has an influence on whether the participants think it may be 
difficult to detect an ADR. 
3. Comparing the type of facility where the participants work and whether they have 




4. Comparing the number of patients served on an average day and whether the 
participants have encountered an adverse drug reaction in their patient in professional 
practice. 
5. Comparing the universities where the participants achieved their undergraduate 
degree and the total knowledge score/percentage of participants per university. 
6. Comparing those who agreed that pharmacovigilance is their professional obligation 






5.1 Introduction  
This chapter discusses the results obtained in the research study. A comparison was made 
with results obtained in similar peer reviewed studies to highlight similarities and notable 
differences. The significance and possible implications of the study results will be discussed.  
Limitations of the study which came to light upon analysing the study results will be outlined.  
5.2 Demographics 
A total of 325 completed responses were received from members the South African Medical 
Association (SAMA) and the South African Clinical Research Association (SACRA), 
equating to 85% of the target sample size. This is a higher response rate than was achieved in 
similar studies conducted in South Africa (68.9%) amongst community and hospital 
pharmacists in the North West Province (Joubert M, 2016), (78.5%) amongst nurses and 
pharmacists working in a private hospital (Bogolubova, 2018) and lower but similar to those 
achieved in other similar studies in South Africa (87.7%) amongst doctors, nurses and 
pharmacist working in a tertiary hospital in Johannesburg (Gordhon Y, 2020), (91.7%) in 
healthcare practitioners (HCPs) working in primary healthcare facilities (Haines, 2020).  
A little over half (164; 50.5%,) of the respondents were male, (298; 91.7%) were medical 
doctors, across several professional levels, ranging from medical interns to medical 
specialists; (24; 7.4%) were pharmacists. Amongst the medical doctors, most of them were 
medical specialists (133; 40.9%). Just above forty percent (137; 42.2%,) of all respondents 
consult < 14 patients per day. Most of the respondents (298; 91.7%,) obtained their 
undergraduate qualifications at local South African universities and inclusively, (308; 94.8%) 
at universities in low to middle income countries.  
5.3 Knowledge  
The primary objective of this study was to determine the knowledge on pharmacovigilance, 
among medical doctors and pharmacists in South Africa. The results indicate that there is an 
average level of knowledge on pharmacovigilance among medical doctors and pharmacists in 
South Africa. The knowledge scores achieved by participants in this study ranged between 2-
9, with a mean of 6.25 and a range of 7. Knowledge scores were categorized into good, 
average, and poor. The good category was allocated to a score of 8-10; an average category 
was allocated to a score of 5-7 and a poor category to a score of ≤ 4. Most of the study 
participants (252;77.5%) achieved an average score for knowledge, followed by a good 
knowledge score at (45; 13.8%) and a poor knowledge score at (28; 8.6%).  
Medical specialists comprised the largest proportion of those having average knowledge 
(102; 40.5%) followed by medical officers (96; 38.1%); whereas in other similar studies, with 
the same objectives, pharmacists had a higher knowledge on ADR reporting compared to 
medical doctors. This is likely due to the higher number of doctors on current study (298; 




conducted in South Africa by Haines et al. (Haines, 2020), reported higher mean knowledge 
scores for pharmacists (91.4%; p = 0.003) compared to nurses (84%; p < 0.0001) and medical 
doctors (82.8%; p = 0.017). Another South African study conducted by Gordhon and 
Padayachee in 2020 (Gordhon Y, 2020), reported that 83% of pharmacists, compared to 54% of 
doctors and 54% of nurses stated that they knew how to report ADRs.   
In similar studies from other parts of Africa, a study conducted in Nigeria by Ezeuko et al. 
(Ezeuko, 2015), with the representation of pharmacists at 22 participants, compared to 24 in this 
current study, it was reported that pharmacists were more aware of ADR reporting at 81.8% 
of the participants and the difference in awareness among the respondents was statistically 
significant (p < 0.001). In another Nigerian study by Emeka and Badger-Emeka [149] (Emeka, 
2017), in which the sample population included pharmacists only, three quarters (75%) of the 
respondents were knowledgeable (p = 0.046) and most of them (85%) were familiar with the 
signs and symptoms that could be exhibited by a patient suffering from an ADR (p = 0.006). 
These findings are further supported by Ezeuko et al. (Ezeuko, 2015) in their reporting on more 
pharmacists (90.9%) compared to nurses (85.3%) and doctors (83.5%), believing that ADR 
reporting is their professional responsibility. If pharmacists believe that it is their professional 
responsibility to report ADRs, they probably take it upon themselves to remain informed on 
how to identify and report ADRs.  
In terms of individual knowledge related questions, only (90; 27.7%) of the respondents 
selected the correct definition for pharmacovigilance, compared to 45% in a similar study 
conducted by Joubert & Naidoo in South Africa in 2016 (Joubert M, 2016). It should be noted that 
the ability to select the correct definition for pharmacovigilance may not necessarily be the 
best way to measure a respondent’s knowledge on the subject, because as new developments 
in the field of pharmacovigilance transpired, the definition and scope of pharmacovigilance 
have also evolved. It is therefore appreciated that while healthcare professionals may be 
familiar with the concept of pharmacovigilance, they may not know the correct definition 
thereof. This is evidenced by the (278; 85.5%) respondents who knew that the purpose of 
pharmacovigilance is to enhance patient care and patient safety in relation to the use of 
medicines. This also explains why (310; 95.4%) agreed that it is their professional obligation 
to report ADRs and consistent with the 89% reported by Haines et al. (Haines, 2020), who also 
reported that 92.5% of respondents in his study were aware that ADRs must be reported.  
Studies from other LMICs outside of South Africa also supported this notion. In the 2015 
study by Ezeuko and colleagues (Ezeuko, 2015) conducted across a combination of public and 
private healthcare facilities in Nigeria (Ezeuko, 2015), 85.8% of the respondents, including 
doctors, pharmacists, and nurses, agreed that ADR reporting is their professional 
responsibility. A 2017 study in India by Srinivasan et al. (Srinivasan, 2017), reported that nearly 
83.9% of the respondents felt that reporting is necessary. A 2014 study in Ghana by Sabblah 
et al. (Sabblah, 2014) found that 96.4% of medical doctors participating in the study, agreed that 
it is not only their responsibility, but that of other HCPs as well.  
Over seventy percent of respondents (232; 71.4%) knew what NADEMC stands for. This 
score is higher than those reported in a similar 2016 study by Joubert & Naidoo (Joubert M, 
2016), where about half (49%) of the participants answered this question correctly. 
Considering the time difference between the current study and the 2016 study, it is possible 
that with more studies being conducted covering the topic of pharmacovigilance, awareness 






Most respondents (320; 98.5%,) agreed that reporting of adverse drug reactions is necessary. 
A similar 2018 study by Bogolubova et al. (Bogolubova, 2018), conducted at private hospitals and 
clinics in the Gauteng Province, reported that three-quarters of the participants (76%) thought 
that reporting ADRs was particularly important. Bogolubova et al. (Bogolubova, 2018) also 
reported that in the opinion of over 80% of respondents “it is important to report ADRs to 
help establish the safety of new drugs” and “to identify new ADRs”. When asked if they have 
any concern about the risk(s) associated with medicines, almost ninety percent (287; 88.3%) 
of the respondents agreed they are concerned. This is encouraging as it indicates that the 
importance of ADR reporting is well understood by HCPs in South Africa. 
Almost 60% (193; 59.4%) of the respondents reported that they do have time to report 
suspected ADRs. From this group, a slightly higher proportion (101; 52.3%) were female. An 
almost equal number of 47.2% and 47.7% were working at private health facilities and 
consulted <14 patients a day, respectively. Medical officers and specialists were the highest 
number of HCPs who admitted to having time to report ADRs, ranging between 33.4 – 
38.9%. The majority (158; 81.9%) of HCPs within this group had average knowledge on 
ADR reporting. Medical officers and specialists were also equally distributed (31; 34.1%) as 
the highest proportion of respondents who had received training.  
Over seventy percent (231; 71.1%) of respondents admitted that it may be difficult to detect 
an ADR. Srinivasan et al. (Srinivasan, 2017), reported that a low number (35.2%) of their study 
respondents admitted that it was difficult to detect whether ADR has occurred or not.  Emeka 
et al. (Emeka, 2017) reported that 45% cited this as a barrier for ADR reporting. The same 
concern was raised by 47.5% of medical doctors in a Nigerian study by Oshikoya and 
Awobusuyi (Oshikoya, 2009).  
Most of the respondents (269; 82.8%) in the current study thought that awareness regarding 
pharmacovigilance in their professional environment is inadequate. In the 2017 study by 
Srinivasan et al. (Srinivasan, 2017), 91.3% of the participants agreed that pharmacovigilance 
should be taught in detail to healthcare professionals.  
5.5 Practices 
Of all 325 respondents, (229; 70.5%) have never received PV training and only (91; 28%) 
had received training.  From this sub-group, an equal number (34.1%) of medical officers and 
medical specialists had received training. None of the 12 study participants who completed 
their undergraduate qualifications in European universities had received training previously. 
This is contrary to the assumption that PV training is incorporated into European university 
curricula, unlike at LMIC universities. The majority (70; 77%) of the respondents who have 
been trained had average knowledge and only (17;18.7%) had good knowledge. Despite 
having received training, (4; 4.4%) had poor knowledge. The low rate of training is consistent 
with findings from similar studies across South Africa as reported on by Gordhon and 
Padayachee (Gordhon Y, 2020), Bogolubova et al. (Bogolubova, 2018) and Joubert and Naidoo (Joubert 
M, 2016). Similar findings were reported in Ghana, where Sabblah et al. (Sabblah, 2014) reported 
that only 27.4% of the medical doctors, participating in the study, had received training.  In 
the study by Srinivasan et al. (Srinivasan, 2017), 64.3% of the respondents had received training, 
in comparison to a mere 28% in the present study. Although a higher number of HCPs in the 
Srinivasan study had received training, a lower number (36.5%) had participated in ADR 




raise questions about the type of training received and whether comprehension was assessed 
during training.  
In this current study, training, gender, professional level, and level of knowledge were found 
to be associated with the likelihood of participating in ADR reporting and all observations 
reached statistical significance. This is consistent with the Sabblah et al. study (Sabblah, 2014), 
where training was found to significantly improve ADR reporting (p < 0.001) and medical 
officers and medical specialists were more likely to report (p = 0.035). Bogolubova et al. 
(Bogolubova, 2018) also concurred that those who had received training were more likely to 
understand ADR reporting procedures (p < 0.001). 
Most of the respondents (266; 81.8%,) have previously encountered an ADR in a patient. 
This finding is and improvement from other studies. In a 2020 study conducted in South 
Africa by Gordhon and Padayachee (Gordhon Y, 2020), 59% respondents reported that they had 
encountered ADRs; however, a much lower (17%) proportion had participated in ADR 
reporting. An Indian study by Srinivasan et al. (Srinivasan, 2017), and a Ghanaian study by 
Sabblah et al. (Sabblah, 2014), both reported that 59.5% of the respondents in their studies, 
previously encountered an ADR in a patient.  
In this current study, a surprisingly high number of respondents (36.6%) had never seen an 
ADR reporting form before. This is slightly higher than the 24.8% in the study by Srinivasan 
et al. (Srinivasan, 2017). Approximately half (172; 52.9%;) of the study participants have 
previously reported an ADR. A similar, but slightly lower 44.1% was reported by Joubert and 
Naidoo (Joubert M, 2016) in 2016. This is higher than the 18% in the 2018 study published by 
Bogolubova et al. (Bogolubova, 2018), 36.5% in the 2017 study by Srinivasan et al. (Srinivasan, 2017) 
and 20% in the 2014 study by Sabblah et al. (Sabblah, 2014).  
Of the (152; 46.8%) who have not previously reported an ADR, the highest reason cited was 
a lack of knowledge of the reporting procedure (65; 20.0%). This is consistent with the 
finding of 28.5% of respondents by Sabblah et al. (Sabblah, 2014). Almost 10% (31; 9.5%) cited 
that their reason for under reporting ADRs is the unavailability of the ADR reporting form in 
their place of work. This is an improvement to the reports of Sabblah et al. (Sabblah, 2014) that 
shows that 43.1% of respondents in their study cited the reason for non-reporting as being the 
unavailability of the ADR reporting form. Other barriers to reporting as reported by other 
researchers, included non-remuneration for reporting (13.9%), lack of time to report ADR 
(33.4%), a single unreported case may not affect ADR database (17.3%) (Srinivasan, 2017). In the 
study by Emeka et al. (Emeka, 2017), it was reported that factors discouraging ADR reporting 
include non-availability of forms and unavailability of a professional environment to 
encourage discussion about ADRs. Other factors included the fact that the reactions were not 
deemed serious and therefore did not appear to meet reporting requirements and a lack of 
understanding of the need to report. These are consistent with findings from other local 
studies as reported by Gordhon and Padayachee (Gordhon Y, 2020), Bogolubova et al. (Bogolubova, 
2018) and Joubert and Naidoo (Joubert M, 2016).  
5.6 Suggestions to improve ADR reporting 
The top suggestion selected by the respondents in the current study to improve ADR 
reporting in South Africa was the inclusion of PV training in the undergraduate curricula at 
universities (266; 81.8%,). More than seventy percent (235; 72.3%,) of respondents agreed 




rates. Other suggestions included continuous and refresher training (226; 69.5%,) and 
frequent communication and feedback from national PV centres (220; 67.7%,). These 
suggestions are consistent with those reported by Srinivasan et al. (Srinivasan, 2017), Sabblah et 
al. (Sabblah, 2014), Ezeuko et al. (Ezeuko, 2015) and Olsson et al. (Olsson, 2015)).  
To address the urgent need for PV training among HCPs, a PV training initiative was piloted 
by Jusot et al. (Jusot, 2020 ) between 2016 and 2018 in Malawi. As a result, an exponential 
increase in ADR reports was reported (228 in total). From these, 84.6% were reported from 
districts where training had been conducted and 98.2% contained all the minimum mandatory 
information, whereas previous reports had been found to be missing some key information. 
As suggested by Joubert and Naidoo (Joubert M, 2016), and Bogolubova et al. (Bogolubova, 2018), 
there is a willingness to participate in PV activities among HCPs and they are willing to 
receive appropriate training on an ongoing basis. Most (89.5%) of the respondents on the 
study by Srinivasan et al. (Srinivasan, 2017) agreed with this notion. 
5.7 Significance of the study 
This current study builds on previous studies conducted across LMICs and within South 
Africa with the objectives of assessing the knowledge, attitudes, and practices of 
pharmacovigilance among healthcare professionals. The results of this study, in line with 
those of previous studies, contribute to the body of evidence aimed at creating an awareness 
about PV among HCPs and inevitably, increasing ADR reporting. The results show that 
although the attitude towards PV appears to be positive and HCPs show a good understanding 
on the importance of PV, it does not necessarily translate into acceptable levels of ADR 
reporting. The findings of the current study show that HCPs who have received formal 
training are more likely to participate in ADR reporting, which suggests that adequate 
training indeed has a significant impact on the level and quality of ADR reporting. 
5.8 Limitations 
The major limitation of this study is that it does not include nurses and only includes the low 
number of responses received from pharmacists. Nurses play a pivotal role in the care of 
patients, even more so in primary healthcare facilities. It is imperative to include nurses in 
similar studies to this one and to all efforts made to promote ADR reporting. This was mainly 
due to the unequal proportions of medical doctors and pharmacists being members of the two 
professional societies, viz the South African Medical Association (SAMA) and the South 
African Clinical Research Association (SACRA), respectively. SAMA has a higher number 
of medical doctor memberships than the total number of SACRA memberships, which 
include pharmacists and doctors. Another limitation relates to the selection of questions to 
assess knowledge. When questions include definitions and acronyms, it may not be an 
accurate measure of knowledge due to the possibility that an individual may be familiar with 
a certain concept in a general sense, without knowing the exact textbook definitions. It would 
be advisable for researchers to in future, consider the use of questions which may be a better 
measure of knowledge. In this study, a balance of questions was created by including 
questions which pertain to the ADR reporting procedure; these are deemed more valuable in 





CHAPTER 6  
Conclusions and contributions 
6.1 Introduction  
This chapter provides recommendations based on the findings of this study, while aligning 
with recommendations from other researchers. It concludes the thesis by providing a 
summary of the study results in relation to the objectives.  
6.2 Summary of results  
In summary, the majority (252; 77.5%) of HCPs who participated in this study demonstrated 
an average level of knowledge o ADR reporting, despite low levels (91; 28%) of training. 
Although the majority (310; 95.4%) of respondents agreed that ADR reporting is their 
professional obligation, (119; 36.6%) had never seen a reporting form and only (172; 52.9%) 
had ever participated in ADR reporting.  
The overall aim of study was to promote ADR reporting in South Africa. To facilitate this, 
the study investigated the factors that inhibit ADR reporting. This was done by assessing the 
knowledge, attitudes and practices of medical doctors and pharmacists in SA.  The results of 
this study support findings from other studies which suggest that providing PV training which 
includes how to detect potential ADRs, with practical instructions on how to report, together 
with implementation of online ADR reporting platforms, will indeed impact ADR reporting.  
Respondents in this study also suggested that communication of signals and general feedback 
to HCPs from national PV centres on reported ADRs will create a better awareness of 
pharmacovigilance and improve future PV activities and the general knowledge, attitudes and 
practices of HCPs with regards to pharmacovigilance. 
6.3 Recommendations 
Reports received by the WHO from other parts of the world, have also shown that in addition 
to adverse events, there are also increasing incidents of medication errors as well as a surge in 
counterfeit medication. It is alarming therefore, that so few ADR reports (0.88% from 1992 
to 2015) (Ampadu, 2016)  and a mere 0,93% by 2018 (Watson, 2019) are submitted to the WHO 
VigiBase® from African countries.  
The study recommends the following actions to promote awareness, enhance reporting rates 
and increase communication among all stakeholders in South Africa: 
6.3.1. Digitalize and diversify reporting platforms (e-forms, app, telephonic 
reporting)  
To increase chances of reporting, reporting platforms must be made easily accessible and 




situations, where one option is challenging to implement, alternatives must be made 
available.  
As we enter a new age of technology, access to the internet and smart phones with apps if 
fast growing across South Africa. This is mostly still prominent in the urban areas, 
unfortunately, leaving those in remote rural areas and those in remote areas are the ones 
requiring online reporting platforms the most since they have limited access to care, due 
to long distances and on poor road infrastructure to get to the nearest healthcare facilities. 
In time for the South African national vaccine roll-out, SAHPRA on 22 April 2021 
launched the MedSafety mobile reporting app (SAHPRA, 2021). suspected ADRs and AEFIs 
by both the public and healthcare providers. The App also allows the public and 
healthcare providers to learn about medicine safety news from SAHPRA, thereby creating 
an awareness of medicines, their potential adverse effects and pharmacovigilance 
(SAHPRA, 2021).  
The limitation is that the app does require a smart phone and has specific criteria that the 
phone software must meet (system version is at the minimum, version 3.0 for Android OS 
and version 8 for iOS). Although, it should be noted that the app does allow for offline 
data entry. This is a step in the right direction; however, since the reality is that not 
everyone has access to a smartphone, a recommended strategy is making a digitalised 
format of the reporting form available to healthcare facilities; for downloading and for 
online completion on the SAHPRA website and implementing a tollfree telephonic 
reporting platform in parallel to that. This would allow reporters to call into the tollfree 
number to report an AEFI and an allocated PV healthcare worker at the facility would, in 
real time enter the data into the digitalised form; thereby also collecting any additional 
information required on the form.   
As an ultimate back-up process, where the app and e-form cannot be accessed, paper 
ADR/AEFI forms (NDoH, 2021) must be distributed to all healthcare facilities across the 
country, especially in the rural areas. Albeit with paper forms comes the challenge that 
there is a delay between the time of reporting and the delivery of the report to SAHPRA 
PV unit and even so, there is a need to still transcribe the data onto an electronic format, 
which requires human resources.  
6.3.2. Pharmacovigilance Awareness campaign  
In settings such as South Africa, where stigma and suspicion exists towards the 
pharmaceutical industry, pharmacovigilance needs to be about much more than medicine 
safety. It is about building trust between local healthcare workers and the public which 
they serve, for the public to feel confident that the health structures are put in place for the 
protection of their rights and welfare. Education, at laymen level is paramount to this 
process. It is imperative that the messaging is kept simple, provides clear instructions, and 
brings out the altruistic motivation behind ADR/AEFI reporting. As suggested by Lopez-
Gonzalez et al. (Lopez-Gonzalez, 2009) and Olsson et al. (Olsson, et al., 2015) effective methods to 
promote and achieve increased ADR reporting, will have to involve all stakeholders, 
including healthcare professionals from public and private sectors, pharmaceutical 
companies, academic institutions as well as patients themselves. It is recommended that 
SAHPRA, in collaboration with relevant stakeholders such as academia, government, 
patient advocacy groups, pharmaceutical industry, etc. implements a national PV 




patients, parents & teachers, children, HCPs and aim to reach all people across the 
country, including in remote areas. A diverse approach is required to build a safety 
culture within South Africa; however, there is a lot of groundwork that has already been 
covered by global stakeholders as such the WHO-UMC (refer to sec 2.9 global PV 
awareness). Tools provided by initiatives such as the Scope campaign (Jadeja, 2016) can 
be leveraged and adapted to suit the South African landscape. Like the WHO-UMC and 
Scope awareness activities already alluded to, social media platforms, comic books, print 
media (i.e., newspapers, where applicable), local radio stations, etc. should be used to 
widen the reach of the campaign.  
6.3.3. Develop e-learning module on ADR reporting for HCPs 
The current Covid-19 pandemic situation and vaccine roll-out programme, creates an 
urgent opportunity to educate HCPs on ADR reporting and even more so, AEFIs. The 
pandemic has also brought a challenge in terms of physical distancing regulations, thus 
limiting the amount of training sessions that can be attended physically. ADR reporting 
training of HCPs has been successfully implemented in Malawi (Jusot, 2020 ) and Nigeria 
(Tripathy, 2018)  E-learning courses on ADR reporting, such as that developed by the Scope 
campaign (Jadeja, 2016), ISoP/ASoP (ISoP, 1992), WHO-UMC (UMC-eLearning, 2021), among 
others are available as a reference; however, courses must be tailored to local PV 
reporting processes and cultural nuances.  
6.3.4. Introduce ADR reporting modules in undergraduate curriculums 
To support WHO PIDM member countries, a WHO collaborating centre has been 
established in the Netherlands with the specific task of integrating pharmacovigilance 
within the curricula for health training institutions (Olsson, et al., 2015). Such initiatives are 
good references for developing ADR reporting modules that are relevant to the South 
African requirements and processes.  
6.3.5. ADR reported added to HCPs key performance indicators (KPIs)and 
reward reporting 
To increase motivation of HCPs to attend ongoing CPD e-learning courses and to 
participate in ADR reporting, it is recommended that it should be included as part of their 
key performance indicators and the quantity and quality of reports submitted form part of 
performance appraisal processes.  
6.3.6. Further studies 
It is recommended that further studies are conducted to include a larger sample size, 
including patients, nurses, and any other healthcare workers who are suited to report 
ADRs. To better reflect a representation of healthcare workers across South Africa, it is 
recommended that future studies collect information on the geographical locations of the 
participants in terms of provinces and whether the locations is categorized as rural or 
urban.  
The results of the study only reflect the knowledge, attitudes and practices of PV during 
the time period in which the study was conducted. Future studies are recommended to 





In conclusion, this study supports the findings of other similar studies, which suggest that 
lack of knowledge on how to report ADRs is the main cause for under reporting and that 
training is the solution for this. The objectives of this study were to determine the knowledge 
on PV among medical doctors and pharmacists in South Africa. Most of the respondents 
(77.5%), were found to have average knowledge on pharmacovigilance. Another objective 
was to determine the attitude towards practicing PV among medical doctors and pharmacists 
in South Africa. It can be concluded that most respondents demonstrated a positive attitude 
towards ADR reporting. It was encouraging to note that over half (59.4%) of the respondents 
reported that they do have time to report suspected ADRs. The last objective was to 
determine the current practices of PV, among medical doctors and pharmacists in South 
Africa. Although most of the respondents (81.8%) had previously encountered an ADR in a 
patient, around half had previously reported an ADR. The most common reason for not 
reporting was lack of knowledge of the reporting procedure.  
Training and awareness campaigns are the most pressing recommendations made by this 
study. Gaps in awareness and training are emphasized by factors such as the high proportion 
71.1% of respondents agreeing that it may be difficult to accurately detect whether an adverse 
drug reaction has occurred and most of the respondents (70.5%) not having been trained on 
ADR reporting previously and 82.8% agreeing that awareness regarding pharmacovigilance 




As a continuation to this study and 
 towards the achievement of the researcher’s PhD studies,  
an e-learning course is to be developed for the training of healthcare professionals (nurses, 
doctors, and pharmacists) at any level of their career,  
across South Africa.  
 
The e-learning course will focus on the principles of Drug Safety and pharmacovigilance 
 as well the reporting processes for ADR and AEFIs.  
 
The training will be aimed at creating an awareness of pharmacovigilance among healthcare 
professionals as well as provide practical instructions  
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Appendix A – Informed Consent Form_V3.0_09 Sep 2019 
PARTICIPANT INFORMATION AND INFORMED CONSENT FORM  
 
Study Title: A cross-sectional study to investigate the knowledge, attitudes and current 
practices of pharmacovigilance, among Medical Doctors & Pharmacists in South Africa.  
Researcher: Ms Nyeleti Rikhotso [portia.rikhotso@gmail.com; 072 253 9109] 
Supervisor: Dr Carine Page, Senior Lecturer, Division of Clinical Pharmacology 
[carinepage@sun.ac.za; 082 871 5127]  
Co-Supervisor: Prof Helmuth Reuter, Head of Division of Clinical Pharmacology 
[hr@sun.ac.za; 021 938 9860] 
 
Introduction 
You are being invited to participate in a research study to investigate the knowledge, 
attitudes, and current practices of pharmacovigilance, among Medical Doctors& Pharmacists 
in South Africa.  The study is conducted by Ms Nyeleti Rikhotso, in fulfilment of the Master 
of Science Degree at the University of Stellenbosch, Division of Clinical Pharmacology. You 
were selected as a possible participant in this study because you are a Medical Doctor or 
Pharmacist in South Africa.  
 
The aim of this study is to investigate the factors influencing the low ADR reporting levels in 
South Africa, as reported by the WHO on submission of Individual Case Safety Reports 
(ICSRs) to the Vigibase database. The investigation will be conducted by investigating the 
knowledge, attitudes, and current practices of pharmacovigilance, among Medical Doctors & 
Pharmacists in South Africa.  
 
How big is this study? 
384 Medical Doctors & Pharmacists combined are required for the conduct of this study.  
 
What are the benefits of participating in the study? 
The information gathered through this study will contribute towards science in general and 
more so towards the endeavor to promote post marketing drug surveillance. You will not be 
reimbursed to participate in this study, and you will not bear any costs for participating.  
 
What are the risks associated with this study? 
There are no risks to participating in this study. The questionnaire will take 10-15 minutes to 
complete.  
 
Can I change my mind about being in the study? 
Your participation in this study is entirely voluntary and you will face no consequences 
should you choose not to participate. You have the right to withdraw participation from the 
study at any point without providing a reason.  
 
How will my information be used? 
The results of this study will be used to make recommendations on how to promote post-




made for opportunities to present the study results to relevant people within Academia, 
National Health & Tertiary Education Departments, the pharmaceutical industry, SADC, and 
BRICS member countries. The study results will also be shared with the participants of the 
study in the same manner that the questionnaire is presented to you now.  
 
What precautions will be taken to protect my privacy? 
To protect your privacy as a study participant, you will not be requested to provide your 
name or any information which may identify you as an individual. Your participation will 
remain strictly confidential.  
 
Who do I call if I have questions? 
Should you have any questions or wish to discuss any matter related to the study, you may 
contact the researcher or supervisors: 
Researcher: Ms Nyeleti Rikhotso [portia.rikhotso@gmail.com; 072 253 9109] 
Supervisor: Dr Carine Page, Senior Lecturer, Division of Clinical Pharmacology 
[carinepage@sun.ac.za; 082 871 5127]  
Co-Supervisor: Prof Helmuth Reuter, Head of Division of Clinical Pharmacology 
[hr@sun.ac.za; 021 938 9860] 
 
Declaration by Participant:  
 
Please TICK appropriate box (All information is strictly confidential) 
 


















Appendix B – Questionnaire Form_V2.0_09 Sep 2019 
A cross-sectional study to investigate the knowledge, attitudes, and current practices of 
pharmacovigilance, among Medical Doctors & Pharmacists in South Africa.   
 
Section A: Demographics 
 
Please TICK appropriate box (where applicable) 
 
What type of health institution do you work in? (i.e. private practice, public/private hospital, 







Age (Years)  
________________________________________________________________________ 
 
Average patients seen per day  
≤ 14 15 - 19 20 - 24 25 - 29 30 - 34 ≥ 35 















      
 




Section B: Knowledge 
 
1. Select a definition of Pharmacovigilance below by ticking the box next to the correct alphabet 
letter: 
 A The science and activities relating to the detection, assessment, 
understanding and prevention (mitigating) of adverse events/effects or any 
other drug related problems 
 B The science and activities relating to the detection, assessment, 
understanding, monitoring and prevention of adverse events/effects 
 C The science relating to detection, assessment, monitoring and preventing of 
adverse events and other drug related problems 
 D The science and activities relating to the detection, assessment, 








 A To enhance patient care and patient safety in relation to the use of 
medicines 
 B To identify adverse drug reactions (ADRs) 
 C To calculate the incidence of ADRs  
 D To assess the benefit-risk ratio of a marketed medicine 
 




4. Where is the Pharmacovigilance unit situated in South Africa? 
 A Clinical Evaluation and Trials Directorate of the MRA 
 B Medicines Regulatory Affairs Cluster (MRA) of the Department of Health 
 C South African Health Products Regulatory Agency (SAHPRA) Cluster of 
the Department of Health 
 D Clinical Cluster of the Department of Health 
 
5. What does NADEMC stand for? 
 A National Adverse Drug Effect Monitoring Center 
 B National Adverse Drug Event Monitoring Center 
 C National Adverse Drug Effect Manufacturing Center 
 D National Adverse Drug Event Manufacturing Center 
 
6. What is the name of the International Centre for ADR monitoring? 
 A Uppsala Monitoring Centre 
 B NADEMC 
 C Pharmacovigilance Reporting Centre 
 D Pharmacovigilance Risk Assessment Committee (PRAC) 
 
 
7. What document is used when for ADR reporting in South Africa? 
 A Case Report Form (CRF) 
 B Individual Case Safety Report (ICSR) 
 C Yellow Form  
 D Vigilance Adverse Reaction Reporting Form 
 
8. Tick all the applicable minimum information required when reporting an ADR. More than 
one option may apply. 
 
 A An identifiable source (reporter) of the information 
 B An identifiable patient 
 C Suspected medicine(s) 
 D Patient home address 
 
 




Tick appropriate option for each question below: 
# Question  Yes No Unfamiliar  
1 Do you think reporting of adverse drug reactions is necessary?    
2 Do you have any concern about the risk(s) associated with 
medicines you prescribe? 
   
3 Do you think you have time to report suspected ADRs?    
4 Do you think it may be difficult to decide whether an adverse 
drug reaction has occurred? 
   
5 Do you think there’s adequate awareness regarding 
pharmacovigilance in your professional environment? 
   
 
 
Section D: Practice 
1. Have you ever experienced an adverse drug reaction in your patient in professional practice? 
Yes No Not sure 
   
 








4. If your answer to the above question was “no”, select the most appropriate reason(s) below; 
more than one may apply: 
 A The reporting form was not available 
 B I have never been able to identify an adverse drug reaction 
 C I am/was unaware of the reporting procedure 
 D I did not know I was supposed to report 
 E Other (specify) 
 












Tick next to all the methods below that you believe may improve ADR reporting in South Africa. 
More than one may apply: 
 # Methods 
 1 Inclusion of Pharmacovigilance to undergraduate curriculums at Universities 
 2 Continuous & refresher training  
 3 Increased awareness on ADR reporting to patients, prescribers and dispensers by the 
relevant Authorities at a national level 
 4 Implementing a pharmacovigilance centre within each hospital 
 5 Frequent communication & feedback from pharmacovigilance centres with updates on 
the benefit-risk profiles of drugs resulting from ADR reporting efforts  
 6 Having an ADR specialist in each hospital department 
 7 Implementing on-line or telephonic reporting  
 8 Collaborating among all healthcare professionals (Doctors, Pharmacists, Nurses, etc.) 
in the reporting process, i.e. completing the reporting forms  
 9 Implementing department meetings to discuss potential ADRs 




Thank you for your participation! 
 
Stellenbosch University https://scholar.sun.ac.za
